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Marek’s disease virus (MDV), the causative agent of Marek’s disease in chicken, is 
an important oncogenic avian pathogen which leads to world-wide economic losses 
in the poultry industry. It targets the chicken's immune system by initially causing a 
lytic infection in B-lymphocytes in lymphoid organs (spleen, bursa of Fabricius and 
thymus), followed by a latent infection of T-lymphocytes, which may lead to tumour 
formation. Despite the presence of well-established vaccination programs against 
MDV, it is still a major concern for the poultry industry due to the emergence of 
more virulent strains. As MDV is also considered an excellent model for herpesvirus-
induced oncogenicity and immunosuppression, a better understanding of its 
pathogenesis, including the functional roles of individual MDV proteins, is of both 
biomedical as well as economical importance.  
 
All open reading frames (ORFs) of the CVI988 vaccine strain and the RB1B virulent 
strain were PCR-amplified from BAC DNA and cloned into the pDONR 207 entry 
vector by recombinatorial cloning (Gateway® system). Subsequently, all ORFs were 
subcloned into the yeast-two-hybrid (Y2H) vectors pGBKT7–DEST (bait) and 
pGADT7-DEST (prey), as well as other expression vectors. The Y2H bait and prey 
vector clone collections were transformed into the yeast strains AH109 and Y187, 
respectively. More than 140 ORFs, or ORF fragments, were analysed against each 
other in a comprehensive Y2H assay. Of > 20.000 interactions tested, 435 positive 
interactions between 115 ORFs were observed. Several of these interactions have 
previously been reported in other species of herpesvirus indicating that they may be 
conserved within the family. A subset of the positive interactions were confirmed 
using co-immunoprecipitation and LUMIER pull-down assays as a second 
independent assay.  
 
In the second part of the project all MDV proteins were tested for their ability to 
inhibit the chicken interferon-alpha (chIFN-α)-induced immune response. In 




interferon stimulated responsive element (ISRE), four MDV-encoded chIFN-α 
inhibitors were identified, including UL12, UL26, UL50, and Meq, the main MDV 
oncoprotein. Both isoforms Meq and L-Meq derived from the oncogenic and the 
non-oncogenic vaccine strain, respectively, similarly inhibited the interferon 
response in a dose-dependent way, and Meq deletion mutants revealed that the C-
terminal, proline-rich transactivating domain is not required for this inhibitory effect. 
In transient transfection experiments, Meq induced a dose-dependent proteasomal 
degradation of the chicken interferon regulatory factor 7 (chIRF7), which is required 
for chIFN-α- induced activation of ISRE. Over-expression of chIRF7 lead to a dose-
dependent degradation of Meq and its accumulation in the cytoplasm, suggesting that 
proteasomal degradation of both Meq and chIRF-7 is linked. Consistent with these 
findings, MDV deletion mutant lacking both copies of the Meq gene was more 
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TRAIL Tumour necrosis factor-related apoptosis-inducing ligand 
TRE Tetradecanoylphorbol acetate response element 
TRIF TIR-domain-containing adaptor protein inducing IFN-ß 
TRL Terminal repeat long 
TRS Terminal repeat short 
U Unit 
UAS Up-stream activation sequence 
UK United Kingdom 
UL Unique long 
US Unique short 
USA United States of America 
V Volt 
VEGF Vascular endothelial growth factor gene 
vIL8 Viral interleukin 8 
vMDV Virulent Marek's disease virus 
VP Viral protein 
vTR Viral telomerase 
vvMDV Very virulent Marek's disease virus 
VZV Varicella zoster virus 









Herpesviruses are important pathogens associated with a wide range of diseases in 
mammals and birds. The family Herpesviridae is divided into the 
Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae subfamilies. Each 
of these is further subclassified into several genera containing many species (Table 
1.1). Marek's disease virus (MDV), which is the focus of this thesis, belongs to the 
genera Mardivirus in the Alphaherpesvirinae. 
 
Table 1.1: Summary of the taxonomic structure of the family Herpesviridae 
Subfamily Genus Examples from the species 
Simplexvirus Human herpesvirus 1 
Varicellovirus Human herpesvirus 3 
Mardivirus 
 
Gallid herpesvirus 2, Gallid 
herpesvirus 3, 
Meleagrid herpesvirus 1 
Alphaherpesvirinae 
Iltovirus Gallid herpesvirus 1 
Cytomegalovirus Human herpesvirus 5 
Muromegalovirus Murid herpesvirus 1 
Betaherpesvirinae 
Roseolovirus Human herpesvirus 6 
Lymphocryptovirus Human herpesvirus 4 





Ictalurid herpes-like viruses Ictalurid herpesvirus 1 






1.2 Biology of Marek's disease virus (MDV) 
1.2.1 Discovery of MDV 
Marek's disease virus was first described by Dr Josef Marek in 1907 as a disease that 
causes paralysis in the legs and wings of adult chickens. The case was restricted to 
the nervous system so was named as polyneuritis gallinarum or neuritis interstitialis. 
Similar cases were observed and reported in the USA and the Netherlands in 1921 
and 1924 (cited in (Davison and Nair, 2004)). The disease was restricted to the 
nervous system and was named as fowl paralysis or range paralysis. Thereafter, 
Pappenheimer and colleagues observed that lesions were not only restricted to the 
nervous system, but lymphatic tumours in different visceral organs were also 
involved, and consequently the disease was renamed as neurolymphomatosis 
gallinarum (pappenheimer, 1926). By 1956 and 1957, two outbreaks of visceral 
lymphomatosis were reported in broiler age chickens in the USA (Cover, 1957). The 
gross pathology of these cases appeared on the spleens, livers, ovaries and 
musculature. This new form of Marek's disease was associated with higher mortality 
in younger age chickens. Thus, it was named acute Marek's disease while the former 
one was named classical Marek's disease. Until 1961, it was thought that the disease 
belonged to the avian leukosis complex, and then it was considered to be a separate 
disease. In 1967, an electron microscopy examination of infected tissue cultures 
revealed that the causative agent of Marek's disease is a herpesvirus (Churchill and 
Biggs, 1967). In the same study, the cell-associated nature and the cytopathic effect 
of the virus on the kidney chicken culture were identified. After a few years, the cell-
free form of the virus was found in lysed materials from the feather follicle 
epithelium of infected birds (FFE) (Calnek et al., 1970). After many years, new 
forms and syndromes of MDV started to appear around the world, such as the 
transient paralysis and the acute cytolytic form. In the USA, Witter and colleagues 
isolated variant strains from MDV called Md-5 and Md-11 (Witter et al., 1980). 
These variant strains were characterised by a higher rate of early mortality at a young 
age as a result of acute cytolytic infection. In Europe, the presence of the acute 





MDV, characterised by early mortality due to severe cytolytic infection, were 
isolated from the UK, Germany and Spain (Kross et al., 1998; Barrow and 
Venugopal, 1999). The emergence of new virulent strains of MDV has been 
explained by failure of the existing vaccines to provide the birds with adequate 
protection against MDV (vaccine breaks) (see Section 1.8.2). Currently, MDV is 
classified into 4 pathotypes (Witter, 1997), and many laboratories around the world 
are studying the development of new MDV vaccines and analysing the genomic 
contents of the virus.  
 
1.2.2 Taxonomy of MDV 
MDV belongs to the genus Mardivirus of the family Herpesviridae. Herpesvirdae, a 
class of DNA viruses, are classified into three subfamilies: Alphaherpesvirinae, 
Betaherpesvirinae and Gammaherpesvirinae. Each subfamily is further subclassified 
into several genera containing many species, causing diseases in humans and 
livestock (Table 1.1). Many species of herpesviruses can infect birds, six of these 
species are classified as alphaherpesviruses and are fully sequenced: Gallid 
herpesvirus II, Gallid herpes virus III and Meleagrid herpesvirus 1 (Genus 
Mardivirus), Gallid herpesvirus I and Psittacid herpesvirus 1 (Genus Iltovirus) and 
Duck herpesvirus 1 (Genus unassigned yet). Gallid herpesvirus II, Gallid herpes 
virus III and Meleagrid herpesvirus 1 are serologically-associated viruses and cause 
Marek's disease virus-1 (MDV-1), Marek's disease virus-2 (MDV-2) and herpesvirus 
of turkey (HVT), respectively. While Gallid herpesvirus I causes infectious 
laryngotracheitis (ILT) in chickens, and Psittacid herpesvirus 1 causes Pacheco’s 







Infectious laryngotracheitis (ILT) is an important respiratory disease in chickens. It 
was identified as a respiratory syndrome affecting chickens in 1925 by May and 
colleagues, as been reviewed in (Cover, 1996). The viral cause of the problem was 
identified in 1930 by Beach (Beach, 1930). The virus usually infects birds via the 
respiratory route. The symptoms of the disease vary according to the virulence of the 
infective strain from mild respiratory signs to haemorrhagic inflammatory lesions in 
the upper respiratory tract. Similar to other herpesviruses, ILT infection is divided 
into two phases: the acute phase and the latent phase, the latter is established only in 
the trigeminal gangalion (Bagust, 1986; Williams et al., 1992). Neither neutralising 
antibodies, nor local antibodies, are able to protect chickens from ILT infection 
(Fahey and York, 1990). Only cell-mediated immunity has this protective role. Two 
live viral vaccines are available for ILT control. The first one is a virulent strain, and 
it is applied via cloacal route. The second one is a live attenuated strain, and it is 
applied via the respiratory route. 
 
Duck enteritis virus (DEV) is an important infectious disease, occurring amongst 
duck, geese and swans. The oral and cloacal routes are considered the main route for 
virus transmission. The disease is associated with septicaemia, as well as vascular 
damage and haemorrhagic patches in the digestive tract, and annular bands in the 
small intestine. In the late stage, the lesions in the gastrointestinal tract turn to 
yellowish necrotic diphtheritic membrane (Pattison et al., 2008). A live attenuated 
vaccine is used for prevention of the disease and repeated annually. 
 
Marek’s disease virus-2 (MDV-2) is a naturally non-oncogenic virus belonging to 
Gallid herpesvirus III species. SB-1, MDV-2 strain, can induce early protection 
against MDV challenges after a few days of SB-1 inoculation (Schat and Calnek, 
1978b; Schat and Calnek, 1978a). Therefore, it was used as vaccine for MDV 





Herpesvirus of turkey (HVT) is a non-pathogenic herpesvirus isolated from turkey 
(Witter et al., 1970; Witter, 1972). It is non-pathogenic in chickens, but it can induce 
cross protection against MDV-1 infection. Because of this, HVT has been used as a 
potent vaccine against MDV, either alone or in combination with other non-virulent 




Figure 1.2.2: Phylogeny of the avian alpha-herpesviruses. The phylogenetic 
tree represents the relationship between the conserved large polymerase gene 
(UL30) of the most popular avian alpha-herpesviruses; Marek’s disease virus-1, 
Marek’s disease virus-2, herpesvirus of turkey, infectious laryngotracheitis, 
Pacheco’s disease virus and duck enteritis virus. The tree was created using the 
Phylogeny.fr web site (Dereeper et al., 2008). 
 
1.2.3 MDV morphology 
Marek's disease virus is a double stranded DNA virus. Electron microscopy has 
revealed that MDV is morphologically similar to other herpesviruses (Ahmed and 
Schidlovsky, 1968; Nazerian and Burmester, 1968; Nazerian, 1974). It is composed 
of an inner electron dense cylindrical core surrounded by the virus genome (Figure 
1.2.3), an icosahedral nucleocapsid with 256 capsomeres, and an outer envelope. In 
addition, an amorphous layer known as a tegument lies between the nucleocapsid and 
the surrounding envelope. The mature enveloped virus displays glycoprotein spikes 






A recent electron microscopy study of chicken embryo skin cells (CESCs) infected 
with eGFP-recombinant MDV revealed the following: the hexagonal MDV 
nucleocapsid has a diameter of approximately 100 nm (Denesvre et al., 2007). The 
primary enveloped virus was detected in the perinuclear space of the infected cells 
130-160 nm, and it is composed of nucleocapsid surrounded by dense envelope. The 
mature enveloped virus is 153-274 nm in diameter and contains a dense tegument 
layer beneath the envelope. The size of the mature virion was estimated in an earlier 
study on infected feather follicle epithelium (FFE) to be 273-400 nm (Calnek et al., 
1970). This variation may be attributed to the difference in the tissues examined or 











Figure 1.2.3: The morphology of herpesvirus. MDV DNA is coiled around this 
dense structure within the hexagonal capsid. An amorphous tegument layer 
separates the nucleocapsid and the envelope. The envelope carries glycoprotein 
spikes on its surface. 
 
1.3 MDV replication 
It is believed that the mechanism of herpesvirus replication is conserved throughout 
the entire family. While most of our current knowledge comes from research on 
herpes simplex virus (HSV) (Roizman and Knipe, 2001), it is believed that other 
herpesviruses follow similar pathways. Infection starts when the herpesvirus virion 
attaches to the host cell through the envelope glycoproteins (Figure 1.3). The viral 
envelope fuses to the plasma membrane in a pH-dependent manner, releasing the 
capsid into the cytoplasm. The capsid travels to the nuclear membrane where the 
viral DNA is released. The linear genome enters the nucleus and circularises. Once in 





herpesviruses, viral gene expression is tightly regulated and divided into 3 kinetic 
classes of expression. In HSV, the tegument protein VP16 transactivates 
transcription of five immediate-early (IE or alpha) genes, which generally encode 
transcriptional activators. These IE proteins then initiate transcription of the early (E 
or beta) genes. These gene products are enzymes needed to increase the pool of 
nucleotides and for viral replication. In addition to proteins directly involved in DNA 
replication, late (L or gamma) genes are transcribed for production of viral structural 
proteins. After transcription in the nucleus, all mRNA transcripts are translated into 
proteins in the cytoplasm. Subsequently, the proteins can be transported to the 
nucleus, stay in the cytoplasm, or become a part of the membrane bilayer. Capsid 
proteins assemble in the nucleus to form empty capsids. Full-length viral DNA is 
packaged into these capsids to form nucleocapsids. The progeny nucleocapsids exit 
from the nucleus by budding at the inner nuclear membrane into the perinuclear 
space. The process of virus egress and envelopment is still controversial and it could 
be through one of three probable pathways. The first pathway is the perinuclear 
enveloped virions transport inside vesicles in secretary pathway to the Golgi complex 
and exocytosis at the cell surface. The second pathway is perinuclear enveloped 
virions de-envelope at the outer leaflet of perinuclear membrane and secondary 
envelopment occurs in the trans-Golgi area, then the virions released at the cell 
surface acquiring their glycoproteins. The third pathway is depending on virus 
egression from the nucleus to the cytoplasm directly through the dilation of nuclear 
pores. 
 
Electron microscopy showed the stages of virus development in FFE at 12 to 32 dpi 
(Gilka and Spencer, 1993). The nucleocapsids were shown inside the nuclei as coiled 
threads, either naked or partially covered by a membrane. Primary vesicles, 
containing granular materials and some fibrils, were formed inside the cytoplasm. 
The nucleocapsids bud into these primary vesicles and a dense material formed 
between the naked nucleocapsid and the vesicle membrane, probably virus tegument. 
The vesicles containing the virus were named as cytoplasmic vesicular inclusions. 





During the cytolysis of the FFE, the vesicular inclusions lost their membranes due to 
its fragility, and may be fused together. This is resulted in the formation of 




Figure 1.3: Herpesvirus replication. The herpesvirus virion fuses with the cell 
membranes for the host cell through the envelope glycoproteins1. The capsid is 
released into the cytoplasm2 and travels along the cytoskeleton to the nuclear 
pores3, where the viral DNA is released4. In the nucleus, the immediate-early and 
early viral genes are transcribed to form transcriptional regulators and enzymes 
required for DNA replication5. After the formation of the new DNA progeny6, 
late (L or gamma) genes are transcribed for the production of viral structural 
proteins such as capsid proteins7. Full-length viral DNA is packaged into these 
capsids to form nucleocapsids. The progeny nucleocapsids exit from the nucleus 
by budding at the inner nuclear membrane into the perinuclear space8. Thereafter, 
the virus egresses and envelopment occurs, in order to form and release complete 









1.4 MDV classification and nomenclature  
Marek's disease has many different synonyms, such as neuritis, polyneuritis, 
neurolymphomatosis gallinarum and range paralysis. Based on its virulence in 
chickens, its ability to induce T-cell lymphomas and its antigenic properties there are 
three MDV serotypes: MDV-1 (e.g. RB-1B, Md5, GA & CVI988 strains), MDV-2 
(e.g. HPRS24 strain) and MDV-3, which is also called herpesvirus of turkeys (HVT) 
(e.g. FC126 strain). MDV-1 can be further divided into four pathotypes: (i) mild, (ii) 
virulent, (iii) very virulent and (iv) very virulent + (Witter, 1997; Calnek et al., 1998; 
Witter and Schat, 2003). According to the most recent nomenclature, MDV-1 is 
classified as Gallid herpesvirus II (GHV II), MDV-2 as Gallid herpesvirus III (GHV 
III), and HVT is classified as Meleagrid herpes virus 1. 
 
1.5 MDV pathogenesis 
1.5.1 Pathogenesis and cellular tropism of MDV 
Since MDV is mainly lymphotropic virus, the affinity of MDV for certain types of 
lymphocyte is mainly correlated with the stage of virus infection (Figure 1.5.1). 
Infection with MDV can be divided into four stages (Calnek, 1986; Calnek, 2001): 
the first stage is the lytic infection of bursa-derived B-lymphocytes between 3 and 6 
days post-infection (dpi). The second stage starts with the infection of thymus-
derived T-lymphocytes. Later, the latent infection is established between 5 and 10 
dpi in T-lymphocytes, then the virus is reactivated from the latency between 14 and 
21 dpi, and in the fourth stage lymphomas may develop in different organs of 
infected birds (Calnek, 1986; Calnek, 2001). 
a. Virus entry  
MDV infects birds through the respiratory route via inhalation of cell-free virus in 
the feather dander (Calnek et al., 1970). The macrophage cells present in the lung act 
as transporters for MDV from the respiratory tract to different organs (Calnek, 2001; 
Barrow et al., 2003). They carry MDV through the blood stream to the lymphoid 





possibility that MDV is transported from the blood to the spleen via capillaries 
located in the peri-ellipsoid lymphocyte sheath of the spleen (Jeurissen et al., 1989a; 
Jeurissen et al., 1989b). Once MDV passes through this sheath, it is transferred to the 
adjacent ellipsoid associated reticulum cells (EARCS) then to the B-lymphocytes 
(Jeurissen et al., 1989a; Jeurissen et al., 1989b). EARCS are non-lymphoid antigen 
presenting cells, located in the B-cell region of the spleen. 
 
b. Early cytolytic infection 
After MDV particles are delivered to the lymphoid organs, the virus undergoes 
cytolytic infection in these organs 4-6 dpi (Calnek, 1986; Calnek, 2001; Witter and 
Schat, 2003; Davison and Nair, 2004). B-cells derived from the bursa, thymus and 
spleen are considered the main target cells for the lytic MDV infection (Shek et al., 
1983; Baigent et al., 1996; Baigent et al., 1998; Witter and Schat, 2003). Staining of 
spleen lymphocytes isolated from infected birds during the cytolytic stage with 
monoclonal antibodies (mAbs) for both PP38 MDV specific Ag and different 
lymphocytes markers confirmed that B-cells are the main cells for MDV lytic 
infection.  
 
Additionally, these experiments showed that T-cells could also act as target cells for 
lytic infection, but to a much lesser extent than B-cells. A small population of CD4+ 
and TCRαβ1+ CD8+ T-cells were detected in PP38-positively stained spleen cells 
during the early stage of infection (Baigent et al., 1996; Baigent et al., 1998).  
 
Immunocytochemistry was also used to investigate whether MDV could infect 
macrophage cells in vivo. Surprisingly, spleen macrophages from infected birds were 
lytically infected with MDV (Barrow et al., 2003). Furthermore, confocal 
microscopy analysis of the infected macrophages showed the expression of MDV 
proteins from three kinetic classes (ICP4, PP38 and gB).  
  
Usually, lytic infection appears as a necrotic infection in the lymphoid organs, 





reticular cells which leads to an enlargement in the spleen. Thereafter, thymus and 
spleen atrophy can occur (Witter and Schat, 2003). Microarray analysis of MDV 
infected spleens showed that 79 proteins from MDV have transcriptional activity 
during lytic infection (Heidari et al., 2008b). In these 79 proteins, there were: vIL8, 
PP38, vLIPase, US3 and UL49.5, all of which play critical roles in virus 
pathogenesis.  
 
c. Latent Infection 
Herpesviruses, in general, are characterised by their ability to establish latent 
infection inside host cells. The cells harbouring latent virus contain the viral genomes 
as a closed circular molecule and only a small subset of viral genes are expressed 
(Roizman and Knipe, 2001). MDV also has this ability to remain latent inside the 
host cells. After the establishment of lytic infection in B-lymphocytes, MDV 
becomes latent inside T-lymphocytes. This mainly starts at 6-7 dpi (Witter and Schat, 
2003; Davison and Nair, 2004). The latent stage of MDV infection could be 
subclassified into 3 phases: establishment, maintenance and then reactivation from 
latency (Davison and Nair, 2004).  
 
The ability of MDV to establish latency was initially suggested by Pepose and 
colleagues. They suggested that the MDV-induced neural lesions in nerves and 
dorsal ganglia were initiated by the establishment of virus latency. Furthermore, they 
showed that latency can be established in non-neuronal mononuclear cells which 
infiltrate nerves and ganglia (Pepose et al., 1981). Later, it was revealed CD4+ 
bearing T-cells are the major cell population targeted by MDV during latent infection 
(Calnek et al., 1984; Morimura et al., 1998; Osterrieder et al., 2006). Usually, the 
MDV genome is present during latency in a methylated state. The former was 
confirmed when isolated SB-1 DNA from avian lymphoid leukosis transformed 
derived cell line had the restriction enzyme pattern of 5´ CPG 3´ methylation in 






Indeed, cell-mediated immunity is required for the establishment and maintenance of 
MDV latency. Induction of an immunosuppressed state in the infected birds by 
cyclosporine, betamethasone or thymectomy resulted in prolonged early and late 
cytolytic stages (Buscaglia et al., 1988). On the other hand, the induction of 
immunosuppression in MDV infected birds by infectious bursal disease virus 
(IBDV) and Reticuloendotheliosis virus (REV) resulted in the reduction of both 
cytolytic and latent infection (Buscaglia et al., 1989). This inconsistent result may be 
due to either IBD or REV killing MDV target cells, making the cells more resistant 
to MDV infection or by causing cytokine induction (Buscaglia et al., 1989). 
 
Reactivation from latency is associated with a significant increase in expression of 
the lytic protein PP38 (Baigent et al., 1996; Baigent et al., 1998; Parcells et al., 
2003). Parcells and colleagues presented a model for the mechanism of virus 
maintenance and reactivation from latency (Parcells et al., 2003). This model 
suggests that Meq homodimers (Meq-Meq complex formation) bind to the origin of 
replication. This binding results in the inhibition of the expression of PP38 gene 
products, and therefore maintenance of the latency state. Indefinite changes in the 
cellular environment could result in splitting of this homodimer and the formation of 
Meq heterodimer with any other (basic leucine zipper) bZIP proteins in the cells. At 
this point, the expression of PP38 gene product starts again and the infection is 
reactivated.  
 
Recently, microarray analysis of MDV gene expression in the spleen from infected 
birds has been established. Meq, 23KDa and RLORF5 proteins were the only 
proteins which showed a marked increase during the latent infection stage (Heidari et 
al., 2008b). 
 
d. Late cytolytic Infection and productive infection in feather follicles  
After the 2nd or 3rd week of infection, a restricted productive infection appears in 
different epithelial tissues (Calnek, 1986). It has been suggested that latently infected 





adrenal gland, thymus and bursa of Fabricius (Calnek, 1986; Witter and Schat, 2003; 
Davison and Nair, 2004). This infection results in necrotic-inflammatory lesions in 
the affected organ, as well as infiltration with mononuclear lymphocytes. The feather 
follicles epithelium (FFE) is also affected by the second lytic infection as virus 
particles could be detected in the skin at 12 dpi (Gilka and Spencer, 1993). 
Interestingly, the FFE is considered the only tissue which can support fully 
productive infection and disseminate complete virus particles. Earlier, electron 
microscopy of lysed material from FFE of MDV infected bird showed complete 
enveloped virus particles (Calnek et al., 1970). Moreover, skin biopsies taken from 
MDV infected birds at different time points revealed two types of lesions in the 
perifollicular area associated with MDV infection. The first one is the inflammatory-
associated lesion and the other one is the tumour-associated lesion. The 
inflammatory-associated lesion was characterised by the presence of small 
lymphocyte aggregates (LCA), distributed in the connective tissue of the 
perifollicular dermis (Cho et al., 1996).  
 
The genetic background of the birds can affect the presence of the virus in the feather 
follicles. Though the MDV genome load was lower in MDV resistant birds, 
compared with MDV susceptible birds at 21 dpi (Abdul-Careem et al., 2009b). MDV 
shedding from FFE is associated with the stimulation of the cell-mediated immune 
response at the site of virus release. The cell-mediated immune response is 
represented in increasing in the infiltration of T-cells, especially CD8+, in the feather 
pulp area. In addition, the level of interferon-gamma and interferon–alpha secretion 
increased (Abdul-Careem et al., 2008c). 
 
e. Transformation 
The transformation in MDV is defined as the neoplastic changes of the latently 
infected lymphocytes to lymphoblastoid tumour cells (Davison and Nair, 2004). 
Three to four weeks post infection, latently infected lymphocytes migrate into 
different visceral organs and peripheral nerves, where they differentiate to form 





transformation (Schat et al., 1991; Burgess and Davison, 2002). The phenotypes of 
MDV transformed cells were investigated in two groups of cell lines (Schat et al., 
1991). The first group was derived from a naturally occurring lymphoma and the 
second group was derived from local MDV-induced lesions. The former cell lines 
were CD3+, mainly CD4+ and either TCR2+ or TCR3+. While, the latter cell lines 
derived from MDV induced lesions were also CD3+ and either TCR2+ or TCR3+. 
Interestingly, the latter cell lines have only 21% CD4+ CD8- cells and the rest were 
CD4- CD8+. This confusing result could be due to the difference in the conditions of 
MDV tumour formation in each group. 
 
A feature of transformed MDV infected cells is the high expression level of AV37, 
an extracellular MDV Ag. The immunocytochemistry revealed that the transformed 
cells in MDV naturally occurring lymphoma are mainly a population of CD4+ T 
helper cells which are either TCR2+ or TCR3+, MHCIhi, MHCIIhi, PP38-, gB- and 
AV37hi (Burgess and Davison, 2002). These AV37hi cells fulfil the neoplastic 
transformation criteria as follows: they have a high proliferation rate, support latent 
MDV infection, a low death rate and are very frequent cells in MDV lymphoma. 
Also, AV37hi lymphoma cells need to escape the immune response in order to 
survive as a tumour cell. Thus, AV37hi cells escape the immune system via the 
down-regulation of CD28 at the mRNA level (Burgess and Davison, 2002). Later, 
AV37 was recognised as CD30 and the MDV Lymphoma was recognised as a 
CD30hi lymphoma (Burgess et al., 2004).  
 
AV37+ CD4+ cell (CD30+ CD4+) infiltration usually appears in genetically 
susceptible as well as genetically resistant breeds. However, after the cytolytic stage 
the fate of these cells changes according to host genetic susceptibility (Burgess et al., 
2001). Hence, cell infiltration appeared 5 dpi in the genetically susceptible breeds 
and 7 dpi in the genetically resistant breeds. Thereafter, CD4+ T lymphoid cell 
infiltration increased in the genetically susceptible lines and decreased in the 






Meq is an MDV protein which is able to transform Rat-2, NIH3T3 and DF1 cell lines 
(Liu et al., 1998; Levy et al., 2005; Ajithdoss et al., 2009). Interestingly, CD30hi 
transformed cells contain the Meq oncogene, and the presence of Meq is positively 
correlated with the expression of CD30+ (Ross et al., 1997). Furthermore, Meq forms 
heterodimers with the cellular protein c-Jun, and this is important for tumour 
formation and growth (Levy et al., 2005).  
 
MicroRNAs (miRNAs) are small RNAs that act as post-transcriptional regulators of 
protein expression, and they have been implicated in many different biological 
processes, including oncogenesis and cell regulation. Studies on the role of miRNAs 
in MDV oncogenesis and transformation have found an up-regulation of miR-221 
and miR-222 in MSB-1 cell line (Lambeth et al., 2009a). These miRNAs target the 
degradation of chicken P27kip1, a cell cycle regulatory protein. It is possible that 
MDV uses a miRNA-mediated mechanism to transform infected cells.  
 
 
Figure 1.5.1: Pathogenesis and cellular tropism of MDV. MDV infects birds 
through the respiratory route. Thereafter, the virus infects macrophages, which 
distribute the virus to the lymphoid organs. Lytic infection is established in B-
lymphocytes (3-6 dpi) followed by latent infection in T-lymphocytes (7-14 dpi). 
Later, the virus is reactivated from latency and spreads to the external 






1.5.2 MDV Transmission 
MDV is an airborne disease, transmitted by direct and indirect contact (Witter and 
Schat, 2003). Birds are usually infected at a very young age via the inhalation of cell-
free virus, which is present in the feather follicle dander, desquamated skin 
epithelium and poultry house dust (Calnek et al., 1970; Carrozza et al., 1973; Gilka 
and Spencer, 1993). In addition, the virus is highly endemic in poultry houses and 
can live at room temperature for several months (Carrozza et al., 1973; Witter and 
Schat, 2003). Therefore, early vaccination is extremely important to prevent early 
infection and subsequently leads to a reduction in virus transmission rate. Many 
studies were established to identify MDV proteins responsible for the horizontal 
transmission of the virus, and US2, UL13 and gC are considered good candidates. 
Hence, MDV lacking these genes is not able to spread from infected to susceptible 
chickens (Jarosinski et al., 2007b). However, the mechanism behind the role of these 
genes in virus transmission remains inconclusive.  
 
1.6 Clinical disease and pathology 
Marek's disease is a very important lymphotropic avian disease which causes great 
worldwide economic losses in the poultry industry. Additionally, study of Marek's 
disease virus (MDV) has contributed significantly to our understanding knowledge 
of herpesvirus-associated oncogenicity. The main host of MDV is the chicken. 
However, quails, turkey and pheasants can also be infected (Witter and Schat, 2003). 
In addition, there is evidence of its isolation from white-fronted geese in Japan and 
the Far East region of Russia (Murata et al., 2007). MDV is highly cell-associated 
and is only cell-free in the feather follicles. As described in Section 1.2.1, it was first 
described by Marek in 1907; thereafter many forms of the disease started to be 
revealed. MDV is a multi-phasic disease composed mainly of early cytolysis and late 
transformation (see Section 1.5). The disease has many forms including classical 
MDV, lymphomatosis, ocular form, skin form, early mortality syndrome, acute 
cytolytic infection, transient paralysis and atherosclerosis (Table 1.6). MDV clinical 





1.6.1 Classical MDV (Fowl paralysis) 
Fowl paralysis, the classical MDV, is the original form of MDV which is 
characterised by both neuropathy in peripheral nerves and lymphomatosis in visceral 
organs, particularly the ovaries (Biggs and Payne, 1967). The disease appears in the 
form of asymmetrical paralysis called spastic paralysis (Figure 1.6d). Thereafter, leg 
paralysis develops to complete paralysis and death. Sometimes the vagus nerve is 
involved and results in dilation of the crop (pendulous crop) and gasping (Witter and 
Schat, 2003). Paralysis is usually associated with the gross enlargement of the 
peripheral nerves, which usually appears 3-4 weeks after infection in experimentally-
challenged susceptible birds (Biggs and Payne, 1967).  
 
1.6.2 Lymphomatosis (Visceral lymphomas)  
The affected birds with MDV-induced lymphomatosis have no particular clinical 
signs. However, there are a few external clinical signs, which range from general 
depression to totally comatose. Visceral lymphomas occur in the ovaries, lung, heart, 
mesentery, kidney, liver, spleen, bursa, thymus, adrenal gland, pancreas, 
proventriculus, iris, skeletal muscle and skin in the presence or absence of gross 
nerve lesions (Payne and Rennie, 1976; Witter and Schat, 2003; Davison and Nair, 
2004). The gross pathology of MDV lymphomas is reviewed in details in (Witter and 
Schat, 2003). The general shape of an MDV lymphoma appears as an enlargement of 
the organ with diffuse or nodular white or grey discoloration (Figure 1.6b). The 
ovary has a distinct cauliflower appearance as the normal foliated shape is replaced 
with a cauliflower-shaped mass. Thickness and firmness is seen in the proventriculus 
wall plus paleness in the heart and occasionally nodular lymphomas appear on the 
myocardium. Diffuse or nodular enlargement is seen on the liver with firm texture 
and sometimes granular appearance. Histologically, interfollicular lymphomatous 
proliferation in the bursa of Fabricius, lymphomatus proliferation in the thymus 
medulla, as well as lymphoproliferative foci in the spleen are usually present in 






As described in detail in Section 1.5.1, the CD3+CD4+T-cell population is the main 
cell type in an MDV lymphoma. The histological changes of MDV visceral 
lymphomas from 1 to 9 weeks post infection (pi) have been recorded (Cho et al., 
1998). The MDV lesions of the visceral organs and nerves were infiltrated with small 
lymphocytes 1-3 weeks pi, thereafter the lesions were infiltrated with a mixture of 
lymphoblasts and small lymphocytes 4-6 weeks pi. At 7-9 weeks pi, the visceral 
organ lesions consisted mainly of lymphoblast cells with some small lymphocytes. 
Interestingly, the visceral and nerve-lymphoma-affected birds have characteristic 
cytological changes in the feather pulp lesions (FPL) compared to MDV-infected 
birds with no lymphomas. These cytological changes consisted mainly of small 
lymphocyte cells aggregates (LCA) 1-2 week pi (Cho et al., 1998). Thereafter, the 
number of the lymphoblast cells increased in the aggregates until 7-9 weeks when the 
aggregates became large lymphoid aggregates of polymorphic lymphoblast cells.  
 
1.6.3 Ocular form 
In the USA, two flocks of vaccinated replacement pullets >10 weeks old suffered 
from an outbreak of MDV. The main clinical manifestation of this outbreak was 
blindness in the infected birds (Ficken et al., 1991). Whilst ocular MDV has been 
observed in sporadic cases, this was the first outbreak in which it presented as the 
main clinical symptom. The gross pathology of the eye revealed acute uveitis and 
corneal oedema (Figure 1.6c). Microscopically, there was mononuclear cell 
infiltration in the iris, ciliary body, cornea, retina, pectin and optic nerve. 
 
1.6.4 Skin form (Skin leukosis) 
Skin leukosis is considered another lymphoproliferative form of MDV infection 
(Figure 1.6a), and lesions usually appear 4 weeks post infection (pi) (Cho et al., 
1996; Witter and Schat, 2003). Macroscopically, the lesion extends from the dermis 
to the subcutaneous layer until it reaches the skeletal muscle. A few weeks later (7-9 
weeks pi) the lesions appear as nodular skin lesions on many areas of the skin which 





of feathers is not mandatory for the development of MDV induced skin tumours 
(Heidari et al., 2007). The lesions are usually more abundant in the bird 
dorsocervical tract, followed by ventrocervical, abdominal, sternal, outer crural and 
inner crural tracts (Cho et al., 1996; Cho et al., 1997).  
 
Microscopically, MDV skin lesions have two distinct patterns in the perifollicular 
area: a tumour-associated pattern and a non-tumour-associated pattern (Cho et al., 
1996). The tumour-associated pattern is classified into two types according to the 
cellular composition of LCA: the progressive and regressive types. The progressive 
type starts with an accumulation of small LCA in the perifollicular area 1 week pi. 
These small LCA develop to large LCA containing a mixture of small lymphocytes 
and lymphoblast cells 4-6 week pi. Later on, at 7-9 weeks pi, the LCA cells 
accumulate together and the lymphoblast cells become the major cell population. The 
muscles adjacent to the skin lesions are infiltrated with proliferated fibroblasts and 
the connective tissue in between contain small LCA (Cho et al., 1996). The 
regressive type is characterised by gradual regression of the LCA after 4 weeks pi, 
which is localised to the connective tissue of the perifollicular dermis. No 
lymphoblast cells are detected in the regressive type. Cho and colleagues classified 
the MDV-induced skin leukosis into five types (A, B, C, D and E) depending on the 
size and the cellular composition of LCA, where type A contains small LCA of small 
lymphocytes. Thereafter, the lesions progress and lymphoblast cells increase until the 
small lymphocytes are completely replaced with lymphoblasts in type E (Cho et al., 
1997).  
 
1.6.5 Early mortality syndrome and acute cytolytic infection 
This form was reported earlier when Witter and colleagues isolated two variant 
strains of MDV: Md5 and Md11. The clinical disease of the early mortality 
syndrome varies according to bird susceptibility. Hence, it is characterised by acute 
cytolytic infection and high rates of early morality in the susceptible birds. However, 
it can induce lymphoma in HVT vaccinated birds and genetically resistant birds 





MDV strains (vvMDV) (Witter, 1983). The acute cytolytic infection of these strains 
is characterised by marked atrophy in the bursa and thymus and higher spleen 
necrosis than other MDV strains (Witter et al., 1980; Witter, 1983). Whilst it induces 
a high rate of visceral lymphoma in both genetically resistant and susceptible birds, it 
induces fewer neural lymphomas in the genetically resistant birds than the vMDV 
strains does (Witter, 1983). Other two vvMDV strains, MS1 and MS2, were isolated 
in Japan, and they also caused early mortality syndrome in P-2 genetically 
susceptible chickens and vaccinated with HVT (Imai et al., 1992). These two strains 
are viscerotropic and neurotropic and differ from Md5 strain, as they produced gross 
lesions in visceral organs and nerves at a similar rate. In Europe, early mortality 
syndrome was recorded when C12/130, MR36 and MR48 MDV isolates induced 
high mortality during the cytolytic stage associated with lymphoid atrophy (Barrow 
and Venugopal, 1999).  
 
1.6.6 Transient paralysis 
MDV infection of the central nervous system (CNS) usually results in cases of 
general flaccid paralysis called transient paralysis (TP). It was believed that TP is 
one form of temporary flaccid paralysis which disappears after 2-4 days (Kenzy et 
al., 1973). Then, Gimeno and colleagues classified and described 4 forms of MDV-
induced transient paralysis, which appeared in experimentally-infected birds: 
classical-transient paralysis, acute-transient paralysis, persistent neurological disease 
and late paralysis (Gimeno et al., 1999). Birds suffering from classical-transient 
paralysis (TP) have different degrees of paralysis 9-11 dpi, from which they 
completely recover by 12-14 dpi. This classical form is mainly caused by infection 
with the virulent MDV pathotype, whilst acute-TP is caused by the very virulent and 
very virulent + MDV pathotypes. Signs of acute paralysis appear 9-10 dpi, often with 
signs of flaccid paralysis in the neck and limbs, and birds die 24-48 hr. In persistent 
neurological disease (PND), birds recover from the paralysis, but other neurological 
signs, such as ataxia and torticollis, appear and persist. The late paralysis (LP) form 
is similar to the acute-TP form, but it appears later at 21 dpi. Both PND and LP occur 





strains. Brain and cerebellum lesions are usually associated with MDV transient 
paralysis signs. Such lesions appear in the brain and cerebellum 6-8 dpi with 
vasculitis, perivascular oedema, microgliosis and mononuclear perivascular cuffing 
(Gimeno et al., 1999; Witter et al., 1999). 
 
1.6.7 Atherosclerosis 
Atherosclerosis is a pathological case of thickness in the artery walls as a result of 
cholesterol and other lipid droplets deposition. Infection with MDV is sometimes 
associated with atherosclerosis in the aorta, coronary arteries and other large arteries. 
It usually appears in the arteries >1 month pi, and the virus is detected in the middle-
smooth muscle cells layer of the affected arteries (Fabricant et al., 1978; Minick et 
al., 1979; Hajjar et al., 1986; Fabricant and Fabricant, 1999). Macroscopically, 
MDV-induced atherosclerosis appears as a marked narrowing in the lumen of the 
affected artery with small focal plaques 1-2mm in diameter (Minick et al., 1979). 
Microscopically, the arterial lesions are classified into: fatty, proliferative and fatty-
proliferative (Fabricant et al., 1978; Minick et al., 1979). Fatty arterial lesions have 
intra- and extra-cellular lipid accumulation, low cellular proliferation and a small 
quantity of dense collagen deposition. The proliferative lesions have fibro-cellular 
thickening of the artery intima, fragmentation of the internal elastic lamina and low 
level of mononuclear cell infiltration, whilst fatty-proliferative lesions combine both 
the fatty arterial and proliferative arterial lesions. Hajjar and colleagues have 
suggested that the aortic deposition of cholesterol and cholesteryle ester (CE) in 
MDV infected birds is due to alterations in CE metabolism (Hajjar et al., 1986). 
Briefly, aortic cholesteryle ester synthetic activity (ACAT) was increased in MDV 
infected bird 50% and 2 folds 4 and 8 months after MDV infection, whilst aortic 
hydrolytic activity, represented by lysosomal CE hydrolase (ACEH) and neutral CE 
hydrolase (NCEH) activity, was reduced by 30 and 80% 8 months after MDV 
infection, respectively. Therefore, the reduction in CE hydrolytic activity and the 
increase in CE synthetic activity led to an accumulation of CE on the artery wall, 
which leads to development of atherosclerosis. MDV-induced atherosclerosis can be 













Table 1.6: Different disease syndromes of Marek's disease infection in chickens 
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Figure 1.6: MDV clinical disease and pathology. (a) A case of skin 
lymphoma in an MDV infected chicken. (b) A case of lung lymphoma in 
an MDV infected chicken. (c) A case of ocular lymphoma in the eye of an 
MDV infected chicken. (d) A case of spastic paralysis (leg paralysis due to 
a tumour in the sciatic nerve) in an MDV infected chickens (Witter and 





1.7 Immune responses to MDV 
MDV is a lymphotropic virus, and its infection is strictly associated with immune 
cells (B-cells and T-cells). As infection with MDV also results in an increased 
severity of subsequent secondary infections or a reduction in the post vaccinal 
immune response, it is considered a major immunosuppressive disease in chickens.  
 
In this section, the general immune response upon MDV infection and/or vaccination 
will be discussed in detail. Generally, the host immune response following the 
invasion of any micro organism is divided into the innate and adaptive immune 
responses. The innate immune response is a non-specific immediate and temporary 
immune response against a spectrum of molecular signals, whereas the adaptive 
immune response is a specific immune response developed after pathogen 
recognition by the innate immune response.  
 
1.7.1 Innate immune response 
Innate resistance is an immediate protective response, consisting of a range of 
mechanisms to inactivate the invading pathogen (Stewart, 1997). It has many 
components, such as phagocyte cells (macrophage cells & neutrophil cells), natural 
killer cells (NK cells), the complement system and cytokines. Some of these 
components are developed upon MDV infection, and they exert a role in host 
protection from the virus. 
 
a. Macrophage 
Macrophage cells respond immediately upon infection with any pathogen and 
consequently secrete a group of cytokines that attack virus particles. After infection 
with MDV, the macrophage phagocytic activity and index increase (Powell et al., 
1983). Moreover, their infiltration of the different organs in the infected birds, such 
as the bursa of Fabricius and lung parenchyma, increases (Abdul-Careem et al., 





exert a negative effect on MDV replication, as it was shown earlier that macrophage 
cells were able to restrict MDV replication in duck embryo fibroblasts (DEF) (Lee, 
1979). The negative effect on MDV replication could be a direct effect or also an 
indirect effect through the up-regulation inducible nitric oxide synthase (iNOS) 
secretion. Hence, the increasing of macrophage cells is always consistent with 
increasing of iNOS secretion (Djeraba et al., 2000; Xing and Schat, 2000b; Abdul-
Careem et al., 2008a; Abdul-Careem et al., 2009a).  
 
b. NK cells 
NK cells are a specific population of lymphocytes which represent an important part 
of the non-specific immune response at the early stage of virus infection. Once the 
cells are attacked by the pathogen, NK cells respond directly by killing virus infected 
cells. Furthermore, it responds indirectly by secreting interferon-gamma, which 
stimulates the macrophage cells to kill the phagocytosed pathogens. In case of MDV 
infection, NK cells activity may be correlated with the bird’s genetic resistance. One 
example, a genetically MDV-resistant chicken strain (N2a) has a higher NK cell 
response, than an MDV-susceptible chicken strain (P2a) upon MDV challenge 
(Sharma, 1981; Garcia-Camacho et al., 2003). Thus, MDV-genetic resistance can 
attribute to the high NK activity in the resistant breeds (Garcia-Camacho et al., 
2003). 
 
c. Cytokines response  
Cytokines are a group of glycoproteins which are secreted by the cells as a result of 
their stimulation by a stimulus (Stewart, 1997). Macrophage cells are the main 
source of cytokine production. Some cytokines act as modulators for the innate 
immune response such as interferons, tumour necrosis factor (TNF) and interleukins, 
especially interleukin-1 (IL1) and IL12 (Stewart, 1997). Whereas, there are other 
cytokines that are considered related to both innate and adaptive immune responses, 
such as interferon-gamma. Innate immunity cytokines such as TNF and IL1 are 
mainly involved in attracting phagocytic cells to infection sites, while IL12 targets 





gamma activates macrophage cytokine secretion and also mediates antibody 
production. Additionally, upon virus infection, infected cells produce type I 
interferon (interferon-alpha and interferon-Beta), which inhibits virus replication. In 
this section, the cytokine response to MDV infection will be discussed in detail. 
 
Interferon 
Interferons are a group of cytokines that contribute to the innate non-specific 
antiviral immune response. They are produced immediately upon virus infection by 
infected cells. Subsequently, the secreted interferons trigger the surrounding cells to 
establish an antiviral state. Moreover, interferons can activate the cytotoxic activity 
of NK cells, which in turn kill virus infected cells. In mammals and birds, there are 
three types of interferon: type I (e.g. interferon-alpha and Beta), type II (interferon-
gamma) and type III interferon (interferon λ). The interferon classification and mode 
of action will be discussed in more detail in Chapter 5. In this section, it will be 
focused more on the role of interferon in the regulation of MDV infection and the 
effect of MDV infection on the modulation of interferon secretion. 
 
Interferon-alpha (IFN-α) 
Herpesvirus infection is associated with the down-regulation of type 1 interferon, 
particularly IFN-α (Quere et al., 2005; Yu et al., 2005; Ambagala and Cohen, 2007; 
Wu et al., 2009b). Consistently, MDV infection also results in the down-regulation 
of IFN-α level in infected birds. Moreover, it is able to block the interferon response 
of the Newcastle disease vaccine, a potent IFN-α inducer (Quere et al., 2005). This 
effect on IFN-α is not correlated with the virulence of the MDV strain. Hence, the 
down-regulation of IFN-α mRNA was observed in genetically resistant chickens 
from 1 to 7 days post infection with either RB-1B MDV or HVT (Quere et al., 2005). 
This down-regulation or even absence of IFN-α transcripts was mainly detected in 
the spleens of MDV infected birds, particularly in the latent stage (Xing and Schat, 
2000a; Heidari et al., 2008b). This effect on IFN-α level in MDV-infected birds may 
be due to certain molecules encoded by MDV which exert a negative regulatory 





Interferon-gamma (IFN-γ)  
Interferon-γ is considered to be a cytokine of both the innate and adaptive immune 
response. Many studies have suggested that MDV infection and/or vaccination are 
associated with an up-regulation of IFN-γ mRNA level in different organs, such as 
the spleen (Xing and Schat, 2000b; Abdul-Careem et al., 2007; Heidari et al., 2008b) 
and feather follicle epithelium (Abdul-Careem et al., 2008b; Abdul-Careem et al., 
2008c; Abdul-Careem et al., 2009b). However, the up-regulation of IFN-γ level 
seems to correlate more with disease development than protection from the disease. 
For example, there was an increase in IFN-γ transcripts in spleens from MDV-
vaccinated but diseased birds than the vaccinated and protected birds (Abdul-Careem 
et al., 2007). 
 
The genetic type of the chickens is also considered a major factor contributing to the 
modulation of IFN-γ levels in different organs. After infection with oncogenic MDV 
or vaccination with HVT, the enhancement of IFN-γ transcripts was observed in the 
blood of genetically resistant chickens (Quere et al., 2005). In contrast to the blood, a 
significant increase in IFN-γ transcripts was observed in the feathers of genetically 
susceptible chickens, more than the genetically resistant line, after infection with a 
virulent MDV strain (JM-16) (Abdul-Careem et al., 2009b). 
 
Interleukin (IL) 
Interleukins are a group of proinflammtory cytokines which involved in both innate 
and adaptive immune responses. They are secreted from the immune cells such as 
macrophage and T-lymphocytes. Interleukin proteins work as immunomodulators 
through the regulation and differentiation of the immune cells. 
 
MDV disease development, rather than protection from the disease, is associated 
with the up-regulation of a group of interleukins such as IL18, IL6, IL10, IL8 and 
IL1β (Abdul-Careem et al., 2007). This up-regulation was detected in different 
organs such as spleen, bursa of Fabricius, lung and FFE (Abdul-Careem et al., 2007; 





Abdul-Careem et al., 2009a; Parvizi et al., 2009). Consistently, the genetic 
susceptibility of the bird also contributed to the increasing level of some interleukins, 
such as IL18. Hence, IL18 level was higher in genetically susceptible birds 
challenged with virulent HPRS-16 strain than genetically resistant birds challenged 
with the same strain (Kaiser et al., 2003).  
 
Inducible nitric oxide synthase (iNOS) 
iNOS is an eukaryotic enzyme that regulates some cellular-signalling molecules such 
as IRF1 and NF-kB. The expression of iNOS is not affected by MDV infection or 
vaccination (Abdul-Careem et al., 2007). Although, the previous study is not in 
agreement with other studies that showed a marked increase in the iNOS level in the 
spleens of MDV infected chicken with either serotypes 1, 2 or serotype 3 (Xing and 
Schat, 2000b; Heidari et al., 2008b). Also in more recent study, lungs of RB-1B 
infected chickens showed marked increase in the iNOS level (Abdul-Careem et al., 
2009a). 
 
1.7.2. Adaptive immune response 
a. Cell-mediated immune response. 
Upon infection with any pathogen, T-cells are activated by recognition of peptides 
presented by MHC molecule on surface of the antigen presenting cells (APCs). They 
are divided and differentiated into 5 types T helper, T cytotoxic, T regulatory, T 
memory and NK T cells. T helpers are CD4+ cells, and they mainly help the other T 
and B-cells to divide, activate and exert their immune responses. T cytotoxic are 
CD8+ cells, and their role are to destroy virus infected cells and tumour cells. T 
regulatory cells are a group of T-cells that function as a suppressor for the activated 
immune system. It can be CD8+ or CD4+ CD25+ cells. It suppresses the immune 
system after attacking pathogens and preventing it from attacking the host tissues. T 
memory subpopulation is a group of antigen specific T-cells which can be CD4+ or 
CD8+. NK T-cells are a special kind of cells that communicate the adaptive immune 





cytotoxic cells, and are mainly involved in eliminating tumour cells and herpesvirus 
infected cells. 
 
MDV is a cell-associated virus and because of this cell-mediated immunity plays a 
potential role in controlling MDV infection. Both T helper cell and T cytotoxic cell 
immune responses are developed in response to MDV infection and/or vaccination. 
 
Infection with virulent MDV strains results in a CD4+ helper lymphocyte and CD8+ 
cytotoxic lymphocyte (CTL) immune responses (Abdul-Careem et al., 2008a). The 
infiltration of both types of T-cells increased significantly at 10th dpi in the inter-
follicular areas of the bursa of Fabricius in MDV infected chickens (Abdul-Careem 
et al., 2008a). This suggested that CD8+ cells are responsible for clearing of the virus 
from the infected bursa, and CD4+ cells provide suitable cytokines media for the 
virus clearance.  
 
CD4+ helper cells are usually differentiated into a group of effector cells, such as T 
helper-1 (Th-1) and T helper-2 (Th-2). T helper-1 functions mainly as source of 
interferon-γ, whereas T helper-2 functions mainly as a cytokine source, including 
IL4, IL13 and IL10. Since the process of the naïve CD4+ cell differentiation and the 
subtype of CD4+ cells required for the immune response is determined according to 
specific cytokines excretion pattern, chickens infection with a very virulent+ MDV 
strain induced cytokine secretion pattern specific for the Th-2 cell pathway. These 
cytokines are IL4, IL10, and IL13, which were up-regulated during the MDV-
cytolytic infection stage (Heidari et al., 2008b). 
 
The cytotoxic T cell response representing in CD8+ CTLs is developed after MDV 
vaccination with either HVT, SB-1 or CVI988 vaccine, particularly CD8αhighTCR1+ 
phenotype (Omar and Schat, 1997; Morimura et al., 1998; Quere et al., 2005; Abdul-
Careem et al., 2008c; Kano et al., 2009). Development of an MDV specific cytotoxic 
immune response is induced by the MDV glycoproteins: gB, gC, gE, gH, gL (Omar 





immunised with recombinant fowl pox virus expressing MDV gB induce CD8+, 
TCRαβ1+ and CD4- CTLs, which are specific for gB (Omar et al., 1998). All of the 
previous indicate that CD8+ CTLs play a crucial role in the immune response to 
MDV, particularly after vaccination. On the other hand, the presence of CD8+ cells is 
not enough to prevent the lymphomas induced by the oncogenic MDV strain 
(Morimura et al., 1998). Thus, CTLs could have an antiviral effect, but they appear 
to have no anti-tumour effect (Morimura et al., 1998). Interestingly, genetic 
resistance to MDV is correlated with the activity of CTLs. MDV genetically-
susceptible birds challenged with the virulent strain of the virus had a lower level of 
MHC restricted CTLs than non-infected birds at 20 days post infection (Garcia-
Camacho et al., 2003). In the same study, genetically-resistant birds challenged with 
MDV had a higher MHC restricted CTLs than control birds at 4, 8, 12, 16 and 20 
dpi. Virulent strains of MDV have the ability to reduce the expression of MHC class 
I in CEF infected cells as a smart way to evade CTLs host immune response (Levy et 
al., 2003). On the other hand and in contrast to all other herpesvirus, MDV up-
regulates MHC class II expression on the surface of infected cells (Niikura et al., 
2007). This up-regulation occurs as a cellular response to MDV lytic infection. 
 
b. Humoral immune response  
The humoral immune response to MDV is either passively acquired through the 
maternal antibodies, or actively acquired through previous virus exposure. Previous 
exposure to MDV leads to the development of neutralising antibodies against the 
virus14 days post infection or vaccination (Zelnik et al., 2004; Wu et al., 2009a). 
Later on, the level of MDV-specific neutralising antibodies usually continues to 
increase (Zelnik et al., 2004; Wu et al., 2009a). Re-vaccinated birds usually have a 
higher level of neutralising antibodies than single vaccinated birds. This is because of 
the maternal antibodies neutralise some of the first day old vaccine antigenicity. 
Therefore, boosting of the immune system by a second vaccine dose could enhance 






The role of humoral antibodies in controlling MDV infection is currently uncertain. 
Hence, it is stated that the cell-mediated immune response plays the main role in the 
bird protection from MDV infection, due to the virus cell-associated nature (Sharma 
et al., 1975). On the other hand, Zelnik and colleagues noticed that the high 
seroconversion of MDV-specific antibodies was correlated with protection of birds 
challenged with a very virulent MDV strain (Zelnik et al., 2004). 
 
1.8 MDV vaccination  
Marek's disease was the first tumour which can be prevented by vaccination 
(Schierman and McBride, 1979; Calnek and Schat, 1991). MDV vaccines are either 
attenuated MDV-1 vaccine (CVI988), non-virulent MDV-2 (SB-1) or HVT (FC126). 
These vaccines are either monovalent (composed of one virus strain), bivalent 
(composed of two virus strains) or trivalent vaccines (composed of three virus 
strains). Monovalent vaccines are HVT (FC126) or CVI988; bivalent vaccines are 
HVT (FC126) + CVI988 or HVT (FC126) + SB-1, while trivalent vaccines are HVT 
(FC126) + SB-1 + CVI988 vaccine or HVT (FC126) + SB-1 + Md11/75C.  
 
1.8.1 Vaccination route and time 
HVT is inoculated either subcutaneously (s/c) at hatching or in ovo (Sharma and 
Burmester, 1982; Sharma et al., 2002; Zhang and Sharma, 2003; Tan et al., 2007). A 
comparison study of the times and routes of HVT vaccination by Tan and colleagues 
found that embryo day (ED-11) and (ED-17) vaccination times gave a higher 
survival rate than ED-6 vaccination, with survival rates of 89.5%, 94.1% and 38.5%, 
respectively (Tan et al., 2007). Thus, vaccination at later stages of embryonic 
development is better than early embryonic vaccination. However, early in ovo 
vaccination, particularly before ED-14 could lead to the development of tolerance to 
the HVT vaccine (Zhang and Sharma, 2003). The protection levels which usually 
obtained from the subcutaneous 1 day old HVT vaccination and the in ovo 
vaccination are similar. Hence, comparable levels of protection were obtained from 





MDV strain (Tan et al., 2007). This was in contrast to an earlier study, where ED-18 
HVT vaccinated chickens were more protected from MDV challenge than the 1 day 
old vaccinated chickens (Sharma and Burmester, 1982). These contrasting results 
may be due to the difference in the time of challenge in the both studies. In the 
former study, chickens were 8 days old when challenged, whereas they were 3 days 
old in the latter study. Thus, the in ovo vaccination of HVT gives better protection to 
an early challenge with MDV, while in ovo and at hatching vaccination gives similar 
protection in the case of a late challenge. In agreement with this conclusion, 
vaccination of HVT at hatching was able to protect chickens challenged with MDV 
virulent strain 5 days post vaccination. In contrast, the same vaccine was not able to 
protect the challenged chickens 2 days post vaccination (Islam et al., 2007). The 
authors suggested that 5 days is enough time for the viral vaccine replication and 
development of the host immune response.  
 
Rispens (CVI988) was characterised as mild pathogenic classical serotype 1 Marek's 
disease virus strain (Bulow, 1977). It was tested as a vaccine for the first time in 
1971 in the Netherlands (Rispens et al., 1972a; Rispens et al., 1972b). It has been 
found that this vaccine can give a high protective efficacy against MDV challenge 
and a high seroconversion. Thus, it provides a superior MDV protection rate, 
compared with the attenuated HPRS-16, HVT and R2/23 serotype-1 vaccine 
(Rispens et al., 1972a; Rispens et al., 1972b; Witter et al., 1995; Tan et al., 2007). 
The commercially available CVI988 vaccine was attenuated and turned to be 
completely avirulent by passaging in cell culture (Rispens et al., 1972a; Rispens et 
al., 1972b). However, inoculation of 10 times field dose, 10,000 plaque forming units 
(PFU), of the vaccine resulted in MDV lesions in the inoculated birds (Bulow, 1977; 
Pol et al., 1986). CVI988 vaccine is usually administrated directly subcutaneously 
(s/c) after hatching, even though previous studies proved that intramuscular (i.m) 
administration of this vaccine could give a better protection rate than the s/c route 
(Bulow, 1977). In addition, CVI988 was very effective when it was tested for the in- 





vaccination provides the birds with better protection against early MDV challenge 
more than the post hatching vaccination does (Zhang and Sharma, 2001). 
 
It has been found that the very virulent strains of MDV could break the protection 
barrier induced by an MDV monovalent vaccine. In order to provide the birds with 
adequate protection against the very virulent strain of MDV, bivalent or poly 
vaccines are used. These vaccines consist of different serotypes of MDV, either 
trivalent (combination of serotypes 1, 2 and 3) or bivalent (combination of serotypes 
1 and 3 or 2 and 3). The use of a combination of MDV serotypes is efficient and has 
no safety hazards for the inoculated birds (Witter and Lee, 1984). Interestingly, 
protective synergism was observed between HVT and SB-1 when they were 
inoculated together (Witter and Lee, 1984). In the same study, the inoculation of the 
trivalent vaccine or bivalent vaccine gave better immunity than the usage of each 
serotype alone. In addition, the combination vaccine of HVT and SB-1 was better for 
the growth rate and the general survivability of the birds when it is administrated in- 
ovo rather than post hatching (Sarma et al., 1995). Also, combination of HVT and 
CVI988 vaccines could provide the bird with adequate protection against the recently 
emerged very virulent strains of MDV (Geerligs et al., 1999). This was inconsistent 
with other data showed earlier by Witter and colleagues. Hence, there was no 
improvement in the protection or synergism when CVI988 vaccine combined with 
serotype 2 and or 3 vaccines (Witter et al., 1995). This inconsistency may be due to 
the difference in the passage level of the CVI988 strain and the virulence of the 
challenged viruses used in the two studies.  
 
1.8.2 Disadvantages of MDV vaccines 
Until now, the current vaccination strategy against MDV is successful for the 
prevention of the disease but not for control of an existing infection. There are three 
main disadvantages associated with MDV vaccination strategy (Figure 1.8) (Baigent 
et al., 2006b). Firstly, the current vaccines do not provide sterilising immunity, 
meaning the birds remain a potential source of infection even after vaccination 





the evolution of more virulent strains. Thirdly, with the exception of HVT, MDV 
vaccines are presented in a cell-associated form due to the higher efficacy of the 
system. The presence of the vaccines in this form has many drawbacks, such as the 
possible contamination of the cell line by latent vMDV or endogenous viruses such 
as Avian Leukosis virus. In addition, the cost of vaccine production is high, because 
it is prepared in primary chicken embryo cells from specific pathogen free (SPF) 
eggs. Handling of the vaccine is very difficult as it should be frozen slowly when in 
storage, transferred in liquid nitrogen and thawed rapidly to maintain the virus titre in 
the cell (Jarosinski et al., 2006).  
 
1.8.3 New vaccination strategies 
Due to the many emerging drawbacks of the current vaccination strategies, new 
strategies for the prevention and control of the disease need to be developed, for 
example new vaccines or vaccination programmes. Different vaccination 
programmes used over the world depending on the level of immunity required and 
thus mainly depends on the breeding practices used. Field trials proved that 
revaccination with either CVI988 or FC126 vaccine reduced the mortality rate from 
MDV compared to a single vaccination at 1 day old (Wu et al., 2009a). This could be 
due to an induction of vaccine immunity from the productive infection of the 
vaccines.  
 
Nowadays, using recombinant DNA technology such as bacterial artificial 
chromosome (BAC) or cosmid is considered to be a good approach to overcome the 
disadvantages of the already existing vaccines. Hence, the construction of an MDV 
BAC or overlapping cosmid will help in developing recombinant vaccines lacking 
MDV genes inducing virulence and oncogenicity. Additionally, an MDV BAC could 
be used as a recombinant vaccine for MDV and a vector for many other diseases by 
engineering in genes for avian viruses such as Newcastle disease (ND) and avian 






In recent years, many MDV strains have been cloned as BAC or overlapping cosmid 
constructs, and tested for their vaccine efficacy. For example, overlapping cosmids 
containing recombinant Md5 strain lacking vIL8 (rMd5/ΔvIL8) have been generated 
and tested as a vaccine (Cui et al., 2005a). This mutant virus decreased MDV 
incidence in the challenged birds and gave a protection index higher than that 
provided by the CVI988 vaccine. Also, a recombinant virulent MDV lacking the 
Meq oncogene (rMd5ΔMeq) was tested (Lee et al., 2008). This Meq knock-out virus 
gave protection for maternal Ab+ and maternal Ab- chickens higher than the 
protection provided by the Rispens strain (Lee et al., 2008). Virus reconstituted from 
this HVT BAC can confer 100% protection against challenge with virulent MDV 
strain (Baigent et al., 2006a). In addition, recombinant HVT encoding chicken IL2 
was tested in comparison with the parental HVT strain (Tarpey et al., 2007). There 
was no significant difference in the protection index of birds challenged with RB-1B 
strain and vaccinated with either the parental HVT or HVT/IL2. However, the level 
of neutralising Ab was higher in HVT/IL2 vaccinated birds 7 weeks post vaccination. 
Many other BACs were reconstituted from different strains such as MDV-814 and 
CVI988 and tested as MDV vaccines. Most of the engineered strains produced level 
of protection similar to that of the parental virus (Petherbridge et al., 2003; Cui et al., 
2009). 
 
Few trials have been done to study the ability of MDV BAC to be used as a DNA 
vaccine (Tischer et al., 2002a; Petherbridge et al., 2003) The DNA vaccine derived 
from CVI988 or 584Ap80C attenuated MDV strain gave a lower protection rate and 
showed higher MDV incidence than the BAC-derived or parental virus, which was 
attributed to an inefficient delivery method (Tischer et al., 2002a; Petherbridge et al., 
2003).  
 
Insertion of molecules which inhibit viral replication in the MDV genome could be 
another approach to improve MDV vaccine efficacy. For example, a double stranded 
small interfering RNA (siRNA) could be used to inhibit some viral or cellular genes 





(shRNAs) targeting MDV UL27 and UL29 were engineered on HVT BAC and 
tested as a recombinant MDV vaccine. These HVT-RNAi vaccines were able to give 
up to 50% survival rate against challenge with MDV virulent strain, comparable to 
the parental HVT vaccine, which gave a 60% survival rate (Lambeth et al., 2009b). 
 
Quantitative real time-PCR (QRT-PCR) is considered a good tool for assessing 
responses to vaccination and can contribute to design of vaccines and vaccination 
strategies. It may therefore be a good predictor of protection (Baigent et al., 2006b; 







Figure 1.8: The vaccination of MDV. Figure illustrates how the MDV 
vaccine works as it inhibits the appearance of the clinical disease in case 
of infection but the host remains a potential source of infection for the 
other susceptible birds (Baigent et al., 2006b). 
 
 
1.9 MDV genome  
1.9.1 MDV genomic organisation 
The genome of MDV is predicted to be about 174 kbp in size. The genome is 
composed of two regions of unique nucleotide sequences, each enclosed by inverted 
repeat sequences (Figure 1.9) (Cebrian et al., 1982). MDV was initially classified as 
a gamma-herpesvirus, as biologically it is similar to Epstein-Barr virus (EBV). Later, 
genetic analysis revealed its similarity to other alpha-herpesvirus such as herpes 
simplex virus-1 (HSV-1) (Cebrian et al., 1982). The UL region of the GA strain of 
MDV was analysed and found to encode 55 homologues to HSV ORFs and 12 ORFs 
unique for MDV (Lee et al., 2000a). This is in accordance with the first complete 
genomic sequence of the very virulent strain Md5 of Marek's disease virus serotype 1 
(MDV-1), which also encodes 55 HSV homologues in the UL region (Tulman et al., 
2000). However, Tulman and colleagues only predicted 6 unique MDV ORFs in the 









Figure 1.9: The genomic structure of MDV. This Figure shows the genomic 
organisation of the GA strain of MDV. MDV genome is composed of two 
regions of unique nucleotide sequences UL and US regions, each enclosed by 














1.9.2 Gene products of MDV 
Similar to the other herpesviruses, MDV genes are expressed in three kinetic classes: 
immediate-early, early and late. Except for a few, there are no available data for the 
kinetic expression of each MDV gene. In this section, MDV encoded proteins will be 
listed and discussed according to their organisation in the virus genome. As other 
herpesviruses, the MDV genome is composed of two sets of unique regions, unique 
long (UL) and unique short (US) regions. Both are flanked by two sets of repeat 
regions; repeat long and repeat short region, which are repeated twice in the genome. 
The regions are arranged as following: terminal repeat long (TRL), unique long 
(UL), internal repeat long (IRL), internal repeat short (IRS), unique short (US), and 
terminal repeat short (TRS) region (see Figure 1.9). 
 
a. Unique long region (UL) 
The unique long region of MDV-1 is composed of 113,508 bp and 113,563 bp in GA 
strain and Md5 strain, respectively (Lee et al., 2000a; Tulman et al., 2000) and 
encodes at least 67 proteins. From the sixty seven proteins, only 12 proteins are 
unique to MDV, and the rest of the ORFs have homologues in the other alpha-
herpesviruses (see Appendix A), particularly HSV-1 (Lee et al., 2000a). Since the 
alpha-herpesvirus conserved MDV-ORFs have been named according to their 
homologues in the other herpesviruses as (ULs), the unique MDV ORFs which are 
located in the unique long region have been named as LORFs (Lee et al., 2000a). An 
additional spliced gene encoded in the unique long region of MDV-1 has been named 
as Lipase gene and will be discussed later in this section. 
 
Although MDV's unique long region is fully sequenced, there are no available 
published data for the biological role of each MDV protein located in this region. For 
example, Lee and colleagues discovered that MDV's unique long region encodes 
homologues for the enzymes required for HSV-1 DNA metabolism, such as UL2, 
UL23, UL39, UL40 and UL50 (Lee et al., 2000a). However, the roles of these 









Viral Lipase is a spliced gene in the unique long region which is composed of 2 
exons. The first encodes signal peptides, whilst the second encodes lipase activity. 
The protein is produced via splicing, with a length of 756 amino acids. It is a late 
gene, as it is sensitive to the inhibition of DNA replication (Kamil et al., 2005). 
 
UL13 
UL13 encodes a 60 kDa serine/threonine protein kinase and is located in the MDV-
unique long region (Reddy et al., 1999). Studies with a virus reconstitution from a 
BAC with a frame shifted UL13 showed that it is unable to spread from one bird to 
another, suggesting that while UL13 is not required for tumour formation and feather 
follicles tropism (Blondeau et al., 2007; Spatz et al., 2007c), it may be needed for 
horizontal transmission in combination with other genes such as glycoprotein C (gC) 
and US2 (Jarosinski et al., 2007b; Spatz et al., 2007b).  
 
UL30 
UL30 is present in the unique long region and expresses a protein of a 135 kDa in 
size (Sui et al., 1995). Similar to its homologues in the other herpesviruses, it 
possesses three N-terminal domains with 3`-5` exonuclease activity and six C-
terminal domains with catalytic activity (Sui et al., 1995). As such, MDV-UL30 has 
polymerase activity, and it is the polymerase gene as in other herpesviruses. 
Interestingly, UL30 is conserved in the whole Mardivirus genera, including MDV-2. 
MDV-2 UL30 encodes ORF of 1190 amino acids and has the same nine conserved 










UL41 is a tegument protein that acts as a virion host shut-off (vhs) protein in various 
herpesviruses including MDV (Gimeno and Silva, 2008). It possesses inherent 
mRNase activity which degrades the host mRNA. Deletion of UL41 from the MDV 
genome leads to a longer lytic phase in vivo, which may be attributed to the 
regulatory role of the vhs in the organisation of gene expression (Gimeno and Silva, 
2008). It is very likely that the active form of UL41 has a negative effect on viral 
transcripts, and diminishing this form leads to an improvement in viral gene 
expression and replication. Hence, a single aa mutation in MDV-UL41 (R 337 C) 
diminishes host shut-off activity and increases MDV replication compared with wild-
type virus (Mao et al., 2008).  
 
UL45, UL46, UL47, UL48, UL49, UL49.5 and UL50 
Seven ORFs sequenced in MDV’s unique long region display a high degree of 
homology with the HSV-1 genes UL45, UL46, UL47, UL48, UL49, UL49.5 and 
UL50, some of which are functionally conserved (Yanagida et al., 1993). The growth 
of mutants lacking either UL46, UL47, UL48, UL49 gene or combination of them on 
chicken embryo skin cells (CESC) revealed that UL46, UL47 and UL48 are non-
essential genes for virus growth and spread in cell culture (Dorange et al., 2002). 
However, plaques formed by these mutants were smaller than the plaques formed by 
the parental BAC. UL48 encodes the tegument protein (VP16), which has both a 
structural and a regulatory role in the other herpesviruses. Transcripts of the VP16 
gene were detected in only one latently infected cell line (MSB-1) (Koptidesova et 
al., 1995; Ui et al., 1998). VP16 protein expression is not detected during infection of 
CESC, suggesting no clear evidence for UL48 expression during infection (Dorange 
et al., 2000). UL49 (VP22) is a tegument protein with a high degree of homology to 
its HSV-1, VZV, HVT and GaHV3 homologues which reaches to 24%, 29%, 56% 
and 59%, respectively (Yanagida et al., 1993; Dorange et al., 2000; Blondeau et al., 
2008). It is localised in the nucleus and shows marked DNA binding activity 
(Dorange et al., 2000; O'Donnell et al., 2002). Deletion of UL49 produces a virus 





al., 2002; Blondeau et al., 2008). Thus, UL49 is an essential gene and is required for 
virus growth and spread. 
 
ICP27 
ICP27 was described by Ren and colleagues as a 55 kDa protein which has great 
similarities to HSV-1-ICP27 and VZV-ORF4, particularly in the C-terminus region 
(Ren et al., 1994). In contrast, MDV-ICP27 has a limited homology with its 
equivalent in the avian infectious laryngotracheitis virus (Johnson and Tyack, 1995). 
 
Glycoproteins 
The UL region of MDV encodes six glycoproteins, which have orthologues in the 
HSV-1 genome. These glycoproteins are gL, gM, gH, gB, gC and gK, and they are 
encoded by UL1, UL10, UL22, UL27, UL44 and UL53, respectively (Lee et al., 
2000a). An additional ORF, UL49.5, also encodes a membrane protein, though to be 
gN. The glycoproteins have a high level of sequence similarity in MDV-1, MDV-2 
and HVT, and there is no consistent mutation that is associated with virulence 
(Shamblin et al., 2004). MDV gK has glycoprotein features, including an N-terminal 
signal sequence, four N-linked glycosylation sites, and four potential transmembrane 
domains (Ren et al., 1994). Unlike other glycoproteins, MDV-gK has an immediate-
early kinetic (Ren et al., 1994).  
 
Glycoprotein B or UL27 was identified in serotype 1 by Ross and colleagues, their 
identification was based on the ORF sequence homology with a gB of the other 
alpha-herpesviruses, such as HSV-1, VZV and Pseudo rabiesvirus (PRV) (Ross et 
al., 1989). Later, gB of serotypes 2 and 3 were identified by Yoshida and colleagues, 
and their identification was based on the sequence homology with a gB of serotype 1 
(Yoshida et al., 1994b). Interestingly, it was revealed that gB of MDV and MDV B 
antigen are the same, as anti-B Ag mAb and anti-gB serum cross-reacted with gB 
and MDV B Ag, respectively, and they recognised the same product on SDS-PAGE 
gel (Niikura et al., 1992). Glycoprotein B displayed a protective immunological role 





constructs expressing gB were able to protect chickens from subsequent challenges 
with different virulent MDV strains (Nazerian et al., 1992; Ross et al., 1996; Liu et 
al., 1999). MDV-1 BAC lacking gB (20ΔgB) was able to grow in a single cell only 
in CEF and QM7 cell lines, therefore the mutant was not able to spread from one cell 
to another (Schumacher et al., 2000). MDV gM, UL10, encodes a protein of 47 kDa 
(Osterrieder, 1999). MDV gL or UL1 was identified by Yoshida and colleagues 
according to the ORF genomic organisation and the similarity between it and HSV-1 
gL (Yoshida et al., 1994a). Whilst, MDV gL similarity with the orthologue is as low 
as 18%, it has a highly conserved region with VZV ORF60, equine herpesvirus 1 
(EHV1) 62 and HSV-1 gL extending from amino acids 71 to 98 in MDV gL. Similar 
to other alpha-herpesviruses, MDV gH and gL form a hetero-oligomeric complex 
together (Yoshida et al., 1994a; Wu et al., 2001a). This complex has an important 
role in virus entry into host cells and cell-to-cell infection in herpesviruses. MDV gC 
or formally known as MDV Ag A was recognised as gC of MDV when IHARA and 
colleagues found 36.2% amino acids sequence similarity between it and gC of HSV-
1 (Ihara et al., 1989). It was reported that gC expression has a negative effect on both 
virus growth and virus spread from cell to cell (Tischer et al., 2005). Hence, MDV 
lacking gC (MDVΔgC) produces wider plaque and has higher growth kinetics in 
vitro than the parental BAC. The authors attributed this result to the possibility of the 
effect of gC on the signalling cascade of interferon induction. However, the previous 
was just a suggestion and was not based on any evidence. In vivo experiments with 
MDV containing a frame shift mutation in gC revealed that it is required for the 
horizontal spread of the virus from one bird to another (Jarosinski et al., 2007b). 
However, the virus used in this experiment contains a frame shift mutation in UL13 
gene and also lacks the US2 gene. The UL49.5 gene encodes a glycosylated protein 
product termed as glycoprotein N in ILT and PrV (Jons et al., 1996; Fuchs and 
Mettenleiter, 2005). Furthermore, it is considered to be a complex partner for gM in 
many herpesviruses, such as ILT, PrV, EHV 1 and bovine herpesvirus-1 (BoHV-1) 
(Jons et al., 1998; Wu et al., 1998; Rudolph et al., 2002; Fuchs and Mettenleiter, 
2005). In MDV, virus growth in tissue culture and cell to cell spread requires both 





UL49.5 or gM were not able to spread from cell to cell in infected chicken and quail 
cells.  
 
b. Unique short region (US) 
The unique short region is composed of 10,847 bp and 11,160 in Md5 and GA 
strains, respectively and is predicted to encode around 11 proteins in MDV-1. The 
unique short region (US) encodes 7 ORFs with homologues in the other alpha-
herpesviruses (see Appendix A), namely US1, US2, US3, US6, US7, US8 and US10. 
Four additional MDV-specific ORFs have been identified in this region: SORF1, 
SORF2, SORF3 and SORF4 (Brunovskis and Velicer, 1995; Tulman et al., 2000). 
 
ICP22 
ICP22 (US1) is a regulatory protein that stimulates viral promoters in co-operation 
with other viral regulatory proteins, such as MDV ICP4. It is involved specifically in 
the transactivation of the ICP27 promoter and deletion of US1 resulted in a reduction 
in virus growth and yield (Parcells et al., 1994a; Kato et al., 2002). 
 
US2 
US2 was identified in 1991 and to date the protein has no distinct function in MDV 
biology and replication cycle. An MDV mutant containing a US2lac insertion has 
growth properties identical to the wild-type virus in cell culture (Cantello et al., 
1991; Parcells et al., 1994a). Whilst reconstituted virus from a BAC of the  RB-1B 
strain with US2 replaced by a mini F vector sequence is not transmitted horizontally 
(Jarosinski et al., 2007a). However, this BAC has frame shift mutations in other 
genes, such as UL13 and UL44 (gC) (Jarosinski et al., 2007a).  
 
US3 
US3 encodes the 44-48 kDa MDV serine threonine protein kinase (Sakaguchi et al., 
1993; Jang et al., 1998; Schumacher et al., 2005). Similar to its homologues in other 
alpha-herpesviruses, it has anti-apoptotic properties mediated by its kinase activity 





MDV phosphprotein (PP38), which acts as the US3 catalytic substrate. US3-negative 
BAC 20 MDV has a growth defect and smaller plaque size when infected in primary 
chickens cells (Schumacher et al., 2005; Schumacher et al., 2008). This defect in the 
virus replication cycle is due to the failure of the primary enveloped virus product to 
de-envelope at the outer nuclear membrane. Interestingly, the kinase site of US3 is 
responsible for the observed growth defect of the US3 MDV deletion mutant, as 
disruption of the US3 kinase lysine site resulted in growth characteristics similar to 
the full length US3 MDV deletion mutant (Schumacher et al., 2008). Additionally, 
US3 mediates the breakdown of the cellular actin cytoskeleton and stress fibres, a 
function which does not require the kinase activity of US3  (Schumacher et al., 2005; 
Schumacher et al., 2008). 
 
Glycoproteins 
Marek’s disease virus US6, US7 and US8 encode gD, gE and gI, respectively. MDV 
gD prepared by in vitro transcription translation system and is 43 kDa molecular 
weight in size (Zelnik et al., 1999; Tan et al., 2001). gD protein expression is 
undetectable in MDV infected fibroblast cells, but it is detectable at the 
transcriptional level, possibly due to the cell associated nature of virus growth in cell 
culture (Parcells et al., 1994b; Zelnik et al., 1999; Tan et al., 2001). Unlike other 
MDV glycoproteins, gD is not an important gene for virus transmission or growth in 
cell culture (Parcells et al., 1994b; Anderson et al., 1998). 
 
Unlike gD, both gI and gE are expressed in MDV infected cells as early as 24 hr post 
infection as either glycosylated or non-glycosylated forms (Schumacher et al., 2001). 
As in other herpesviruses, gE and gI form a heterodimer, and as such both are 
essential for transmission in cell culture (Dingwell et al., 1995; Mijnes et al., 1996).  
 
As mentioned above, the MDV US region encodes four MDV-specific ORFs, which 
have no orthologues in the other herpesviruses: SORF1, SORF2, SORF3 and 
SORF4. The functions of these four proteins are not well studied, and so little 





with the chicken growth hormone, and that this interaction may have a role in the 
virus genetic resistance (Liu et al., 2001). 
 
c. Repeat long regions 
The MDV genome contains two similar long repeat regions called internal repeat 
long (IRL) and terminal repeat long (TRL) regions. This region of MDV is 12,584 bp 
to 13,065 bp long, in strains GA and Md5, respectively (Lee et al., 2000a; Tulman et 
al., 2000). The ORFs encoded in this area are named RLORFs, with the exception of 
some, which are named according to their molecular weight. A recently identified 
gene, viral telomerase, is named due to its homology to cellular telomerase. The 
exact biological functions of RL region encoded ORFs are currently unknown, but it 
is believed that the virulence factors of MDV are encoded within this region. 
Furthermore, the differences in genomic composition between the virulent strains 
and the vaccinal strains are mainly located in this region (Spatz and Silva, 2007). In 
this section, some of RL region’s proteins, which play a vital role in virus 
pathogenesis and oncogenesis, will be discussed. 
 
RLORF2 (vIL8) 
vIL8 encodes a homologue to the CXC chemokine cellular IL8, and it was identified 
as a late spliced gene expressed during cytolytic infection (Parcells et al., 2001). It 
contains 134 amino acids, and it is composed of three exons. Exon I encodes the first 
21 amino acids, which contains signal peptides, and exon II and III encode the 
sequence homologue to CXC chemokines IL8. Though MDV vIL8 is similar to the 
cellular IL8 in its sequence composition, it also acts as a secreted molecule and 
serves to attract chicken peripheral blood mononuclear cells (PBMC) (Parcells et al., 
2001). Induction of lytic infection with n-butyrate in the MSB-1 cell line increases 
the level of vIL8 transcripts which suggests that it is involved in cytolytic infection 
(Parcells et al., 2001; Cui et al., 2004b). Studies using MDV mutants lacking a 
functional vIL8 (rMd5Δ vIL8 and RB-1BvIL8ΔsmGFP) showed that it is non-
essential for MDV growth in cell culture (Parcells et al., 2001; Cortes and Cardona, 





stages of infection resulted in a reduced rate of tumour formation in mutant-infected 
in comparison to wild-type-infected birds. Interestingly, rMd5Δ vIL8 used as a 
vaccine protects the birds from infection with very virulent + MDV strain (Cui et al., 
2005b). Additionally, the absence of vIL8 expression in infected birds leads to an 
impairment and delaying in PP38 and Meq proteins expression in lymphoid organs 
and FFE (Cui et al., 2005b). This suggests a relationship between the expression of 
these three proteins, and this is will be discussed in Chapter 4.  
 
14kDa (PP14) 
14kDa is a spliced serotype 1 specific gene with immediate-early kinetics (Hong and 
Coussens, 1994; Hong et al., 1995). It is a cytoplasmic protein with a high degree of 
phosphorylation, hence it is named as PP14. 14 kDa was detected in an MDV-
induced lymphoma cell line, so it is possible that it contributes to the maintenance of 
latency or transformation (Hong and Coussens, 1994).  
 
RLORF4 
RLORF4 is a 142 aa transmembrane protein, and it is considered one of the MDV 
virulence candidates based on several experiments. Firstly, deletion of RLORF4 
from MDV BAC (pRB-1BΔRLORF4) attenuates the virus, causing an increase in 
plaque size and DNA replication rate (Jarosinski et al., 2005). Secondly, pRB-
1BΔRLORF4 infection in chickens caused no MDV associated-death for up to 13 
weeks post infection, and there was marked decrease in the appearance of MDV 
tumour lesions in these birds (Jarosinski et al., 2005). Finally, some naturally 
attenuated strains of MDV (R2/23, JM-16/P71 and 584Ap80C) contain a RLORF4 
gene with deletions, generating a truncated protein (Jarosinski et al., 2003; Spatz and 
Silva, 2007). Recently, six splice-variants have been detected in vivo and in vitro 
encoding the N-terminal sequence of RLORF4 and exon II and/or III of vIL8, but it 








RLORF5a (IRL) and RLORF5b (TRL) are up-regulated in spleen tissue during latent 
infection (Heidari et al., 2008a). Taken with the observation that the deletion of 
RLORF5a has a little effect on virus replication suggests that this is a latent gene 
(Jarosinski et al., 2005). Similar to RLORF4, a splice-variant RLORF5a/vIL8b is 
detected in mRNA isolated from RB-1B chicken kidney cells and in MDV infected 
chickens (Jarosinski and Schat, 2007a). The functional difference between the wild-
type and splice-variant is unknown. 
 
RLORF7 (Meq)  
Meq, (Marek’s Eco Q) exists as two isoforms in the MDV genome (Jones et al., 
1992; Lee et al., 2000b; Jarosinski and Schat, 2007b). The virulent strains possess a 
339 amino acids (aa), whilst attenuated strains (CV1988/R6 and attenuated JM 
strains) possess a slightly longer Meq (L-Meq), which has a 180-bp sequence 
insertion (Lee et al., 2000b; Chang et al., 2005). The Meq protein contains several 
functional domains which play an important role in virus replication. It contains a 
basic leucine zipper (bZIP) domain near to its N-terminus and a proline-rich domain 
near to its C-terminus (Jones et al., 1992; Qian et al., 1995). Two additional basic 
regions, BR1 and BR2, contain nuclear and nucleolar localisation signals (NLS and 
NoLS). Meq mutants lacking both BR1 & BR2 remain localised in the cytoplasm 
(Liu et al., 1997; Lee et al., 2003). BR2 contains the nucleolar localisation signal 
(NoLS) of Meq protein, and its entire sequence is required for Meq-nucleolar 
localisation (Liu et al., 1997).  
 
The C-terminal proline-rich domain in Meq (129 to 339 aa) has transactivation 
activity, particularly in the last C-terminal 33 aa (Qian et al., 1995). Additionally, 
Meq forms a homodimer or heterodimer with c-Jun which increases the 
transactivation of the Meq promoter (Qian et al., 1995). The Meq-bZIP motif is 
similar to the Jun/Fos family of transcription factors and has DNA binding affinity, 
enabling it to bind with many DNA sequences (Qian et al., 1995; Qian et al., 1996; 





found the Meq homodimer binds to MERE I and MERE II DNA motifs (Qian et al., 
1996). MERE I represents a tetradecanoylphorbol acetate response element (TRE) 
and cyclic AMP response element (CRE) like sequences, whereas MERE II 
represents DNA sequence containing (ACACACA) sequences, which are present in 
the MDV origin of replication (Qian et al., 1996). These results indicate that the 
DNA binding properties of Meq enable control of virus infection and latency through 
binding with the MDV origin of replication. 
 
Meq is considered to be the main MDV-oncoprotein and is highly expressed in an 
MDV tumour cell line (Ross et al., 1997; Liu et al., 1998; Gimeno et al., 2005; 
Brown et al., 2006). Firstly, Meq has anti-apoptotic activity, which is important for 
the protection of transformed cells from apoptosis (cell death) (Liu et al., 1998). 
Secondly, the over expression of Meq leads to the transformation of Rat-2, NIH3T3 
and DF1 cell lines (Liu et al., 1998; Levy et al., 2005; Ajithdoss et al., 2009). Meq 
induced transformation with the same mechanism as v-Jun (avian retrovirus ASV17), 
chicken cDNA microarray on Meq-transformed cells identified an up-regulation in v-
Jun transformation-associated genes such as JTAP-1, JAC, and HB-EGF (Levy et al., 
2005). Interestingly, a Meq-c-Jun heterodimer abundantly exists in Meq-transformed 
fibroblasts, and removal of this by RNAi reduces the transformation potential of Meq 
by reducing JTAP-1, JAC, and HB-EGF levels (Levy et al., 2005). The formation of 
this heterodimer is therefore essential for tumour formation induced by MDV. 
Recombinant virulent MDV lacking the Meq oncogene (rMd5ΔMeq) was tested as 
an MDV vaccine (Lee et al., 2008). The Meq knock-out virus gave a higher level of 
protection to the vaccinated chickens than that provided by the Rispens strain (Lee et 
al., 2008). 
 
Recently, it has been found that MDV encodes 8 miRNAs: five of them flank the 
Meq oncogene (Burnside et al., 2006). The Meq sequence encodes many transcript 
variants. Meq/vIL8 is composed of the DNA binding domain of Meq and the 
receptor binding site of vIL8 (Anobile et al., 2006). Both of Meq and Meq/vIL8 are 





Meq-sp is a spliced product, composed of 212 aa, and its C-terminal encoded by the 
second and the third exons of vIL8 (Peng and Shirazi, 1996). Finally, there is a novel 
transcript called ∆Meq which encodes the N-terminal 98 aa of Meq but lacks part of 
the basic leucine zipper and the transactivation domains (Okada et al., 2007). 
However, ∆Meq can interact physically with Meq and L-Meq, but this suppresses 
their transactivation activity (Okada et al., 2007). Many viral proteins have been 
found to physically interact with Meq, and these will be discussed later in Chapter 4. 
 
RLORF6 and 23KDa 
RLORF6 and 23KDa are two ORFs that overlap with Meq gene. The vaccinal strain 
CVI988 has a 177 bp insertion which is not present in the virulent strains Md5, 
Md11, GA and RB-1B (Spatz et al., 2007b). Microarray analysis showed that 23kDa 




RLORF12 encodes a 115 aa protein in virulent MDV strains, where as it composed 
of 67aa in the IRL region of CVI988 strain (Spatz et al., 2007a). Moreover, 
RLORF12 binds with the growth-related transciptionally-related protein, TCTP 
protein, in the chicken genome (Niikura et al., 2004). 
 
PP24 and PP38 
PP24 and PP38 are two phosphoproteins encoded by MDV. PP38 is located between 
the UL and IRL regions of the MDV-1 genome, whilst PP24 is located between the 
UL and TRL regions of the MDV-1 genome (Chen et al., 1992; Zhu et al., 1994). 
PP38 encodes a 290 aa protein, present in the oncogenic MDV-1 but not in the non-
oncogenic MDV-3-infected cells (Chen et al., 1992). It is transcribed leftward from 
the viral genome, whereas PP24 gene is transcribed rightward (Zhu et al., 1994). The 
expression of PP38 is associated with the appearance of two bands of approximately 
41 and 38 KDa in the SDS PAGE, these are thought to represent the phosphorylated 





expressed during lytic infection and also during the early stages of virus reactivation 
from latency (Parcells et al., 2003). Analysis of PP38 DNA sequences in 10 virulent 
MDV strains of differing pathotypes found one consistent glutamine at aa 107 in 
comparison to the CVI988 vaccine strain which has argenine instead. This argenine 
could be responsible for the big difference in antibody responses induced by native 
CVI988 (Zhizhong et al., 2004).  
 
Induction of PP38 expression increased the metabolic activity of a quail cell line 
latently infected with MDV (QTP32). PP38 has no DNA binding domain or 
transactivating domain but it could act as a coactivator (Chen et al., 1992; Li et al., 
2006). Both PP38 and PP24 present rightward to the origin of replication and they 
share the same promoter, which also controls the transcription of the 1.8-kb mRNA 
family. Both PP38 and PP24 are essential to activate this promoter (Ding et al., 
2007), suggesting that these proteins physically bind together to form a complex, and 
this has been confirmed by co-immnuoprecipitation (Ding et al., 2008). 
 
Viral telomerase (vTR) 
MDV encodes two copies of viral telomerase (vTR), which exhibits 88% sequence 
identity to the chicken telomerase chTR. It consists of a protein subunit with reverse 
transcriptase activity and an RNA subunit (Trapp et al., 2006; Shkreli et al., 2007). It 
is expressed in both lytic and latent infection in vitro but responsible only for MDV 
induced T-cell lymphomagenesis in vivo, as a challenge with ΔvTR virus reduced 
tumour incidences by >60% (Trapp et al., 2006). 
 
d. Repeat short regions 
Two repeat short regions are present in the MDV genome internal repeat short (IRS) and 
terminal repeat short (TRS) regions. It is composed of 12,264 bp in Md5 strain and 






ICP4 was detected by in situ hybridisation of RNA extracted from MDV-infected 
CEF plus FFE, liver, kidney and peripheral nerves from MDV infected birds (Endoh 
et al., 1996). Additionally, ICP4 transcripts were also detected in latently infected 
necrotising lymphoblasts from CNS lesions (Cho et al., 1999). ICP4 is considered 
sense for a group of antisense transcripts associated with the latent stage of virus 
infection known as Latency associated transcripts (LATs) (Cantello et al., 1994; Li et 
al., 1994). As well as encoding functional proteins, the LATs also encode 3 of the 8 
miRNAs identified in MDV: miR6, miR7 and miR8 (Burnside et al., 2006). It has 
been suggested that MDV encoded miRNAs contribute to virus induced latency and 
tumour formation (Yao et al., 2009). 
 
1.10 Aims of the thesis 
As discussed earlier, MDV is a very important viral disease for two reasons. First, 
the virus causes an oncogenic avian disease that results in large economic losses to 
the poultry industry. Second, it provides a useful biomedical model for study of 
herpesvirus induced tumours such as EBV. The molecular functional analysis of the 
MDV genes will provide us with very useful data for understanding the fundamental 
basis behind MDV induced pathogenesis and oncogenesis. The aim of this study is to 
obtain a better understanding of the roles of individual MDV genes in the stages of 
virus replication and their role in the interplay between the MDV genes and the host 
innate immune response. The initial requirements are to clone the entire MDV library 
into different-suitable expression systems, allowing us to use them for different 
purposes. The first purpose is to transform the MDV genes into yeast cells and to test 
their interaction against each other. Using intraviral yeast-two-hybrid (Y2H) system, 
information about MDV replication cycles should be obtained. Additionally, it is 
hoped that the intraviral Y2H screen will provide information regarding MDV 
induced pathogenicity and transformation. The second purpose is to test the effect of 
the MDV genes on the chicken interferon signalling, using interferon-alpha as a 





can modulate the chicken interferon-alpha response after MDV infection or 
vaccination. With such candidates, the next aim is to study the cellular mechanism 
behind their down-regulation of the interferon-alpha response. Subsequently, the 
study will investigate the effect of the absence of MDV-interferon antagonists on 
virus growth after interferon-alpha treatment. Taken together, these data from the 
intraviral and viral-host interaction assays will provide vaccine companies and drug 
designers with valuable targets in the MDV genome. 
 




Materials and Methods 
2.1 Cell culture 
2.1.1 Tissue culture Media and supplements 
a. Basic Media 
DMEM: Purchased from Lonza, supplied in 500 ml sterile bottles, supplemented with 
4.5 g/L glucose and stored at 4°C. 
 
M199: Purchased from Gibco, supplied in 500 ml sterile bottles and stored at 4°C. 
 
b. Other sterile solutions and supplements 
Foetal Calf Serum (FCS): Purchased from Gibco, liquid supplied sterilised in 500 ml 
bottles. FCS was aliquoted into 50 ml sterile bottles and stored at -20°C. 
 
Glutamine: Purchased from Lonza, L-glutamine solution was available in 100 ml 
sterile bottles supplied at 29.2 mg/ml in 0.85% NaCl, pH 4.7-6.0. The stock solution 
was stored at -20°C in 5 ml aliquots. 5 ml of L-glutamine was added to 500 ml of 
media. 
 
Sodium Pyruvate: Purchased from Lonza, liquid supplied in 100 ml sterile bottles. 
The solution contains 100 mM of sodim pyruvate (Na Pyrvate). It was stored at 4°C, 
and 5 ml of Na Pyruvate was added to 500 ml media. 
 
Sodium Bicarbonate: Purchased from Lonza, liquid supplied in 100 ml sterile bottles. 
The solution contains 7.5 gm sodium bicarbonate. It was stored at 4°C, and 5 ml was 
added to 500 ml media. 
 
Non-essential Amino Acid: Purchased from Lonza, liquid supplied in 100 ml sterile 
bottles. The 100x solution was diluted with media to 1x solution and stored at 4°C.  





Penicillin/streptomycin: Purchased from Lonza, Penicillin/streptomycin solution was 
formulated to contain 20000U/ml penicillin and 20000 μg/ml streptomycin. It was 
aliquoted into 5 ml aliquots and stored at -20°C. It was used at 5 ml per 500 ml 
media. 
 
Tryptose phosphate broth: Purchased from Gibco, liquid supplied sterilised in 100 ml 
bottles. It was stored at 4°C. 50 ml of tryptose phosphate broth was added to 500 ml 
media. 
 
Phosphate-Buffered Saline (PBS): Purchased from Lonza, liquid supplied in 500 ml 
sterile bottles. PBS was formulated to contain 0.0067 M PO4.and stored at 4°C. 
 
Trypsin EDTA: Purchased from Lonza, Liquid supplied sterilised in 100 ml sterile 
bottles. Trypsin EDTA solution contains 200 mg/L EDTA and 170.000U/L trypsin. 
 
2.1.2 Maintenance of cell lines 
All cell lines were maintained in incubators at 37°C or 38.5°C supplied with 5% 
CO2. Cells were grown on a variety of tissue culture plasticware depending on the 
nature of the experiment. 
 
Cultures were grown to 90-95% confluency, washed with PBS and trypsonised from 
the flasks with trypsin solution (Lonza, Belgium). Cells were incubated at 37°C or 
38.5°C until all cells were dissociated from the flask. Cells were recovered by adding 
growth media containing 5 or 10% serum. Cells were centrifuged at 1000 rpm for 10 
minutes in a benchtop centrifuge. The cells pellets were resuspended in growth 
medium and counted by use of a haemocytometer. Cells were seeded at a density 
required by the experimental design. 
 




2.1.3 Freezing of cell lines 
Cells were resuspended in 1 ml of pre-cooled freezing media. The freezing media 
consists of 70% growth media, 20% FCS and 10% DMSO (Fluka, Germany). Cells 
were aliquoted in sterile freezing ampoules (Nunc, UK) at a density 2x106 cells/vial. 
Cells were transferred to a cryopreservation box (Mr Frosty, Nalgene) and slowly 
frozen overnight at -80°C. One day later, the cells were transferred to the liquid 
nitrogen storage tank. 
 
2.1.4 Thawing of frozen cell lines 
Frozen ampoules were thawed rapidly by warming in a 37°C water bath. Thawed 
cells were transferred into 15 ml tubes (Falcon, USA) and recovered by adding equal 
volumes of growth media slowly and then adjusted to 10 ml. Cell suspension were 
centrifuged for 1000 rpm for 10 minutes. 
 
2.1.5 Cell lines 
QM7 (Quail muscle cell line): 
QM7 cell line was used at a seeding density of 2x104 and cultured with the following 
media: 
D-MEM  500 ml 
NEAA       5 ml 
Na Pyruvate      5 ml 
FCS     50 ml 












DF-1 (Chicken immortalised fibroblast cell line): 
DF-1 cell line was used at a seeding density of 5x104 and cultured with the following 
media: 
D-MEM  500 ml 
TPB                50 ml 
Glutamin      5 ml 
FCS                50 ml 
P/S       5 ml 
 
CEF (Chicken embryo fibroblast cells): 
CEF cells were prepared from 10 days old specific-pathogen-free chicken embryos. 
The embryos were obtained from flock maintained at the Institute of Animal Health. 
CEF cells were used at a seeding density of 5 x104 and cultured with the following 
media: 
M199   500 ml 
TPB     50 ml 
7.5%NaHCO3      5 ml 
FCS     50 ml 
P/S       5 ml 
 
2.2 Transfection of plasmids into cells 
2.2.1 Effectene transfection 
Effectene reagent (Qiagen, UK) is a lipid based reagent that is suitable for the 
transfection of plasmid DNA into cultured eukaryotic cells. It is used with a special 
condensed DNA enhancer. The enhancer is used first to condense the DNA 
molecules, whilst the effectene reagent subsequently coats the condensed DNA 
molecules with cationic lipids. 
  
The following protocol was used to transfect DF-1 cells plated in 48 well formats. 
Briefly, DF-1 cells were plated out into 48 well plates at a density 5x104 cells per 




well. Cells were incubated until reached to 80% confluency that it is considered 
ready for transfection. 150 ng of total DNA was diluted in EC buffer, following by 
addition of 1.2 µl enhancer. The diluted DNA was incubated for 5 minutes to allow 
formation of condensed DNA. Then, the effectene reagent was added at 3.5 µl per 
well. The transfection mixture was left at room temperature for 10-15 minutes to 
allow formation of the DNA transfection complex. During the last incubation, 200 µl 
of complete growth media was added to the cells of each well. After the lipid-DNA 
complex formation, 150 µl of complete growth media was added to the transfection 
complex. The diluted transfection complex was added in a dropwise manner and 
mixed by gentle swirling of each plate. Plates were incubated at 37°C with 5% CO2. 
The transfection efficiency was checked after 24 hr using eGFP expression as a 
positive readout. 
 
2.2.2 Polyfect transfection 
Polyfect reagent (Qiagen, UK) is an activated-dendrimer transfection reagent. It 
assembles DNA into compact structures, optimising the entry of DNA into the cells. 
PolyFect–DNA complexes possess a net positive charge, which allows them to bind 
to negatively charged cellular receptors on the surface of eukaryotic cells.  
 
The following protocol was used to transfect DF-1 cells plated in 24 or 6 well 
formats. Briefly, DF-1 cells were plated-out into 24 or 6 well plates at a seeding 
density of 1x105 or 8x105 cells per well, respectively. Cells were incubated until 
reached to 80% confluency that it is considered ready for transfection. Total DNA 
was diluted in DMEM at 500 ng or 2 μg for 24 and 6 well formats, respectively. 
Then, the polyfect reagent was added at 3 µl per well for 24 well formats and at 10 µl 
for 6 well formats. The transfection mixture was left at room temperature for 10-15 
minutes to allow formation of the DNA transfection complex. During this incubation, 
suitable amount of growth media was added to the cells in each well, 400 µl for 24 
well formats and 1.5 ml for 6 well formats. The diluted transfection complex was 
added in a dropwise manner and mixed by gentle swirling of each plate. Plates were 




incubated at 37°C with 5% CO2. The transfection efficiency was checked after 24 hr 
using eGFP expression as a positive readout. 
 
2.2.3 Calcium phosphate transfection 
QM7 cells were grown in 10 cm dishes to 60-70% confluency. 250 µl of 2x HBS pH 
7.5 was added to 1.5 ml eppendorf tube. In another tube, 10 μg DNA was combined 
with 250 µl of 250 mM CaCl2. The tube with the 2x HBS was vortexed while the 
DNA/CaCl2 solution was added dropwise. The solution was incubated at RT for 30 
minutes to allow the formation of the Calcium-DNA complex. Subsequently, the 
suspension was mixed with 6 ml fresh medium and was added to the cells after 
removal of the old medium. The next day, the transfection efficiency was assessed by 
eGFP expression. 
 
2.3 Protein techniques 
2.3.1 Buffers used in protein techniques 
NP-40 lysis buffer: 20 mM Tris (pH 7.5), 150 mM NaCl, 5 mM MgCl2 and 1% NP40 
(IGEPAL). One tablet of cOmplete inhibitor tablets (Roche, UK) and 1 mM PMSF 
(Fluka, Germany) were added to 50 ml of NP40 buffer shortly before use. 
 
Sample extraction buffer ( 2x SEB): 90 mM Tris-Cl (pH 6.8). 20% Glycerol, 2% 
SDS, 0.02% Bromophenol blue and 10% Beta-mercaptoethanol. Stored at 4°C. 
 
Laemmli running buffer 10x: 30.3 g Tris, 144.2 g Glycine, 10 g SDS. Water was 
added up to 1 L and pH was adjusted to 8.3. 
 
Transfer buffer 10x: 29 g Tris, 144 g Glycine, 3.7 g SDS and water up to1 L. 
Transfer buffer 1x: 200 ml Transfer buffer 10x, 200 ml Methanol and water was 
added up to 1 L. 
 




TBST: 10 mM Tris-HCl (pH 7.5), 100 mM NaCl, 0.2% Tween and water up to 1 L. 
 
Blocking buffer: 5% skimmed milk powder (Fluka, Germany) dissolved in TBST 
solution 
 
2.3.2 Materials and supplements used in protein techniques 
a. Antibodies: 
1- Anti-HA high affinity, rat monoclonal antibody, purchased from Roche 
Diagnostics. It was used at 1 μg per reaction for the immunoprecipitation, 1/1000 for 
immunoblotting and 1/2000 for immunofluorescent. 
 
2- Anti-c-Myc, mouse monoclonal antibody, purchased from Santa Cruz 
Biotechnology. It was used at 1 μg per reaction for the immunoprecipitation, 1/1000 
for immunoblotting and 1/2000 for immunofluorescent. 
 
3- Anti-β-actin, rabbit monoclonal antibody, purchased from Cell Signalling. It was 
used at 1/2000 for immunoblotting. 
 
4- Goat anti-mouse peroxidase coupled, purchased from Jackson, Hamburg, 
Germany. It was used at 1/3000 for immunoblotting. 
 
5- Goat anti-rat peroxidase coupled, purchased from Jackson, Hamburg, Germany. It 
was used at 1/3000 for immunoblotting. 
 
6- Goat anti-rabbit peroxidase coupled, purchased from Jackson, Hamburg, 
Germany. It was used at 1/3000 for immunoblotting. 
 
7- Alexa fluor®488 goat anti-mouse IgG, purchased form Invitrogen. It was used at 
1/4000 for immunofluorescent.  




8- Alexa fluor®594 goat anti-rat IgG, purchased from Invitrogen. It was used at 
1/4000 for immunofluorescent. 
 
b. Protease inhibitors: 
1- cOmplete, EDTA free, protease inhibitor cocktail tablets, purchased from Roche 
Diagnostics. One tablet was used for 50 ml of lysis buffer. 
 
2- Phenylmethane sulfonyl fluoride, PMSF, purchased from Fluka. It was prepared 
as 0.1 M solution of PMSF in isopropyl alcohol and stored at -20°C. It was thawed at 
55°C shortly before used. 
 
c. Beads:  
Protein G Sepharose 4 Fast Flow, purchased from GE Healthcare. 50 μl of 50% 
beads slurry were used per one reaction. Protein G-Sepharose was washed 3 times 
and resuspended with NP-40 lysis buffer to obtain 50% slurry. 
 
d. cycloheximide: 




Proteasomal-inhibitor drug, purchased from Calbiochem. It was diluted in DMSO 
(Fluka, Germany) and used at 100 μM. 
 
f. BCA protein assay reagent: 
Protein quantification kit, purchased from Thermo Scientific. It was used according 
to manufacturer's instructions. 
 
g. Protein Ladder: 
SeeBlue® Plus2 Pre-Stained Standard, purchased from invitrogen, supplied ready to 
use. 4 µl were loaded for small gels and 8 µl for large gels. 




h. Anti-fade reagent: 
Prolong Gold Anti-fade reagent with DAPI, purchased from Invitrogen, Single drop 
was place on the cells layer before sealing with cover slip. 
 
2.3.3 Co-Immunoprecipitation 
Co-Immunoprecipitation was performed using the plasmids pGBKT7 and pGADT7 
with T7 promoter and recombinant vaccinia virus vTF-7 expressing the T7 RNA 
polymerase (NIH AIDS repository). QM7 cells were cultured on 10 cm dishes and 
infected with vTF-7 at an MOI of 10 in serum-free medium. One hour after infection, 
cells were transfected with 10 µg of each of the two destination plasmids by calcium 
phosphate transfection (Section 2.2.3). Expression was controlled using eGFP 
plasmid under the control of a T7 promoter. After 24 hr, cells were lysed by 
incubation in 1 ml of NP-40 lysis buffer for 30 minutes on ice. Lysates were 
centrifuged for 10 minutes at 1000 rpm and 4°C to remove unsolubilised material 
and pre-cleared with 50 µl of pre-equilibrated protein G-Sepharose by shaking for 1 
hr. Lysates and beads were then centrifuged and the supernatant was collected and 
kept at 4ºC. 
 
Supernatants were divided into two parts and by which proteins were precipitated 
from the supernatant by adding 1 g of the anti-HA (Roche, UK) antibodies or the 
anti-c-Myc (Santa Cruz, UK) antibodies with 50 µl of protein G-sepharose beads, 
each overnight at 4°C. Beads were washed three times with ice-cold NP-40 buffer 
and were resuspended in 2x SDS protein sample buffer. Samples were boiled for 10 
minutes and directly analysed by SDS-PAGE or stored at -20°C.  
 
2.3.4 Preparation of protein extracts for western blot analysis 
Cells were washed once with PBS before being lysed in lysis buffer containing 
protease inhibitors was applied to dishes in ice for 30 minutes. After which, cell 
lysates were harvested and centrifuged for 10 minutes at 1000 rpm and 4°C to 
remove unsolubilised material. Protein concentrations were determined using BCA 




protein assay kit (Thermo scientific, UK). Samples were quantified using a polar star 
plate reader (Polar star optima, BMG Biotech) on the absorbance setting. Samples 
were resuspended in 2x SDS protein sample buffer and were boiled for 10 minutes 
and directly analysed by SDS-PAGE or stored at -20°C. 
 
2.3.5 SDS-PAGE 
Gel electrophoresis was performed with large gels using a twin vertical 
electrophoresis system (Galileo, Bioscience) with 12% gels. The Resolving gels 12% 
was prepared with 9.9 ml H2O, 12.0 ml 30% Acrylamide mix, 7.5 ml 1.5 M Tris (pH 
8.8) and 0.3 ml 10% SDS. Prior to pouring the gel, 0.3 ml of 10% Ammonium 
persulfate (APS) and 0.012 ml of TEMED were added. The solution for generating 
the resolving gel was mixed and, after pouring, the gel was overlaid with 
isopropanol. After polymerisation, the isopropanol was removed and the stacking 
gels were prepared with 6.8 ml H2O, 1.7 ml 30% Acrylamide mix, 1.25 ml 1.0 M 
Tris (pH 6.8) and 0.1 ml 10% SDS. Prior to pouring the gel 0.1 ml 10% Ammonium 
persulfate and 0.01 ml TEMED were added. The stacking gel solution was poured on 
top of the separation gel and a comb was fixed. After polymerisation, the glass plates 
containing the gel were assembled in the gel electrophoresis apparatus. Samples were 
loaded on the gel together with a protein ladder. Separation was performed at 150 V 
constant current for 3 hr. 
 
2.3.6 Western blot 
Proteins were transferred to nitrocellulose membranes (Amersham Biosciences, UK), 
using the Trans-Blot semi dry Transfer Cell (Bio-Rad, UK). A piece of nitrocellulose 
membrane and six pieces of thin filter paper (Whatman, UK) of the same size as the 
gel were soaked with transfer buffer. Three pieces of the thin filter paper, the 
nitrocellulose membrane, the gel, and other three pieces of thin filter paper were 
packed and were placed on the platinum anode. The air bubbles were removed by 
rolling a pipette over the stack and subsequently the cathode was placed onto the 
stack followed by the safety cover. Blotting was performed with 15 V for 1 hr. 




Unspecific binding sites were blocked by incubation in blocking buffer 2 hr at RT or 
overnight (o/n) at 4°C. Then incubation with the first antibody was performed in 5-
10 ml TBST with 1/1000 antibody concentration. The membranes were washed 3 
times 10 minutes each with TBST buffer. Incubation with the secondary antibodies 
was performed for one hour with 1/3000 secondary antibody diluted in 1% skimmed 
milk dissolved in TBST buffer. The membranes were washed again for 3 times 10 
minutes each with TBST buffer. The blotted proteins were detected using the ECL 
Western blotting detection system (GE health care, UK), according to the 
manufacturer’s instructions. The membranes were exposed to Fuji Medical X-Ray 
film (Fujifilm Europe GmbH) for different time periods and films were developed 
using OPTIMAX X-Ray Film Processor. 
 
2.3.7 Immunofluorescence   
DF-1 cells were grown in 8-well culture glass slide (BD Falcon, USA) and 
transfected with either HA-tagged plasmid, Myc-tagged plasmid or both plasmids. 
After 48 hr, cells were washed with PBS and fixed with 100% methanol incubation 
at -20°C for 20 minutes. Cells were blocked by 3% BSA diluted in PBS buffer for 
1hr, then cells were stained for 1 hr with 1/2000 primary antibodies diluted in PBS. 
Cells were washed 3 times with PBS and then incubated for 1 hr with 1/4000 
secondary fluorescent antibodies diluted in PBS. Cells were washed with PBS 3 
times and mounted with Prolong Gold Anti-fade reagent with DAPI (Invitrogen, 
UK). Cells were examined using LEICA DM LB2 fluorescent microscopy. 
 
2.4 Dual luciferase reporter assay 
The dual luciferase system (Promega, UK) provides an efficient method to measure 
the response of a reporter plasmid. The system offsets problems encountered from 
low transfection efficiency and general transcription activity. It relies on the use of 
two luciferase plasmids one of which is the firefly reporter (Photinus pyralis) and the 




second is the Renilla plasmid (Renilla reniformis). Dual luciferase reporter assays 
were performed as the following. 
 
Cells were plated out onto 48 well plates at a density of 5x104 cells per well and 
incubated overnight at 37°C and 5% CO2. The following day cells were washed with 
PBS. Transfection reactions were prepared as detailed in Section 2.2.1 containing 10- 
ng Renilla, 90 ng of tested DNA (MDV gene cloned into pCR3 expression vector) 
and 50 ng of luciferase reporter plasmid (DNA fragment from chicken Mx1 promoter 
cloned in luciferase reporter vector pHIIα). After 48 hr post transfection, cells were 
washed once with PBS and the complete growth media was exchanged with serum 
free media containing only 0.5% serum and optimised amount of units of chicken 
interferon-alpha (GenWay, USA). 15 hr later the media was aspirated and drained 
completely followed by addition of 50 µl of 1x Passive lysis buffer (PLB; Promega, 
UK). Then, plates were left for 1 hr on a shaker to allow for efficient lysis of the 
cells. The total cell lysate were transferred into 96 well black plate (BD Falcon, 
USA). Analysis was performed by addition of 30 µl of LARII reagent (Promega, 
UK) to each well. The reading was performed on a polar star plate reader (Polar star 
optima, BMG Biotech) on the luminescence setting. After the plate was read, 30 µl 
of Stop and Glo (Promega, UK) was added to each well to quench the firefly 
luciferase activity and read again on the same settings to measure Renilla luciferase 
activity. Relative luciferase activity was calculated by normalising the firefly 
luciferase value to that of the Renilla luciferase. To standardise the luciferase activity 
of samples within the same experiment set, the relative luciferase values were 
divided by the control sample value. 
 
2.5 Polymerase chain reaction (PCR) 
PCR is a technology by which specific DNA sequences are amplified. It is used to 
screen diagnostic samples for a particular DNA sequence or to amplify DNA 
products for cloning purposes. In this study, PCR was used to amplify MDV genes to 
be cloned into the Gateway® cloning system. 




2.5.1 Primers  
The primers used for open reading frame amplification were purchased from 
different companies (Metabion, MWG, Sigma-Aldrich and Operon). 
 
Table 2.5.1: The forward and the reverse primers used to amplify MDV genes 
and chicken interferon regulatory factor 7 (chIRF7) gene 
See Appendix B. 
 
2.5.2 Enzymes and nucleotides mixture 
a. Expand Long Template PCR System: Purchased from Roche diagnostics. Kit 
contains Expand Long Template Enzyme mix (150U) (containing thermo stable 
DNA polymerase with proofreading activity) and 10X Expand Long Template buffer 
(1, 2 and 3 with 17.5 mM MgCl2, 27.5 mM MgCl2 and 27.5 mM MgCl2 and 
detergents, respectively). The kit was stored at -20°C and all the buffers thawed and 
equilibrated at 37°C before use.  
 
b. Deoxynucleoside triphospahte set: Purchased from Roche diagnostics, supplied as 
a clear, colorless solution of the sodium salts of dATP, dCTP, dGTP, and dTTP, each 
at a concentration of 10 mM in water for a total volume of 200 μl (pH 8.3). 
 
2.5.3 Primer designing and nested PCR 
The nucleotide sequences for all ORFs of CVI988 strain were obtained from 
(http://www.ncbi.nlm.nih.gov/) with accession number DQ530348. The full sequence 
of the RB-1B strain was kindly provided by Dr Venu Gobal Nair (Institute for 
Animal Health, Compton). The prediction of RB-1B viral ORFs was performed 
using the program Emboss (http://pollux.mpk.med.uni-muenchen.de/cgi-in/W2H). 
Each viral ORF was amplified by nested polymerase chain reaction (PCR) using 
viral BACs of the RB-1B and CVI988 strains as templates. For some RB-1B specific 
genes, cDNA generated by reverse transcription of RNA isolated from infected 
chicken embryo fibroblasts or cDNA from phage library were used as template. All 




of the templates were kindly obtained from Prof Venu Gobal Nair (Institute for 
Animal Health, Compton). Primers were designed using an oligonucleotide 
properties calculator (http: // www. basic.northwestern. edu/ biotools/ oligocalc. 
html) and adjusting the annealing temperature to be approximately 55ºC. Two primer 
pairs were designed. The first primer-pair is the gene specific primers and contains 
the internal parts of the attB1 and attB2 recombination sites. The second pair of 
primers contains the external parts of the attB1 and attB2 recombination site in 
addition to a 12 nucleotide overlap with the internal forward and reverse primers 
(Table 2.5.3). 
 
Table 2.5.3: Primer construction for nested polymerase chain reaction (PCR)  
 
1. attB1 internal for AAAAAGCAGGCTCCGCCATGXXXXXXXXXXXXXXX 
2. attB1 internal rev  AGAAAGCTGGGTCTAXXXXXXXXXXXXXXXXXXXX 
3. attB2 external for GGGGACAAGTTTGTACAAAAAAGCAGGCT 
4. attB2 external rev GGGGACCACTTTGTACAAGAAAGCTGGGT 
 
yellow box: attB1/attB2 sequence red letters: Kozak sequence 
bold letters: ATG (for) and stop (rev) codon XXXXX: homologous for and rev 
sequence (18–25 nucleotides, 3’ end G 
or C, 55°C annealing temperature)  
 
The two PCR reactions were performed as described below, with 10 l of the first 
reaction being used as a template for the second PCR reaction. Both reactions were 
performed using the same PCR-program (Figure 2.5).  
 






10x buffer I     5 l 
Internal Forward Primer 10 pmol/l 2 l 
Internal Reversed Primer 10 pmol/l 2 l 
Template   10 ng/l 2 l 
dNTP Mix   10 mM  1 l 
 Polymerase     5 U/l         0.3 l 




10x buffer I     5 l 
External Forward Primer 10 pmol/l 1 l 
External Reversed Primer 10 pmol/l 1 l 
Template (1st PCR Reaction)            10 l 
dNTP Mix   10 mM  1 l 
Polymerase     5 U/l         0.3 l 
H2O         add 50 l 
 
 




2.5.4 Purification of PCR product 
PCR products were purified either directly or by separation of the DNA fragment by 
1% TAE agarose gel electrophoresis. The DNA band of the correct size was cut out 
from the gel. Both the direct purification and the gel purification were performed 
using (GE GFX PCR DNA Purification Kit) according to the manufacturer’s 
instructions. 
 
2.6 DNA techniques 
2.6.1 Materials used in DNA techniques 
a. Molecular weight markers: 
1- Gene Ruler 100 bp DNA ladder: Purchased from MBI Fermentas. 
2- Gene Ruler DNA 1 kbp ladder: Purchased from MBI Fermentas. 
3- 1 kbp DNA ladder: Purchased from New England Biolabs. 
 
b. Kits: 
1- Plasmid DNA Purification NucleoBond Kit: Purchased from Machery –Nagel. 
2- QIAprep Spin Miniprep Kit: Purchased from Qiagen. 
3- PureYield TM Plasmid Midiprep System Kit: Purchased from Promega. 




1- Gateway® BP clonase enzyme mixture: Purchased from Invitrogen. 
2- Gateway® LR clonase enzyme mixture: Purchased from Invitrogen. 
3- Restriction enzymes: BamHI, EcoRI and BanII: Purchased from New England, 
Biolabs. 
4- Ribonuclease A: Purchased from Sigma-Aldrich. 
5- Ribonuclease H: Purchased from Sigma-Aldrich. 




2.6.2. Buffers and solutions used in DNA techniques 
1x TAE: Composed of 40 mM Tris base, 20 mM Acetic acid and 2 mM EDTA. 
Distilled water was added up to 1 litre. 
 
1x TBE: Composed of 89 mM Tris base, 89 mM Boric acid and 2 mM EDTA. 
Distilled water was added up to 1 litre. 
 
Solution I (Resuspension solution): Composed of 50 mM glucose, 25 mM Tris- Cl 
pH 8.0 and 10 mM EDTA pH 8.0. Distilled water was added up to 1 litre. 
 
Solution II (Lysis solution): Composed of 0.2 N NaOH, 1% SDS. Distilled water was 
added up to 1 litre. 
 




a. DONR vector: 
 pDONR 207 (Gateway®, Invitrogen). 
 
b. Destination vector: 
 pGADT7 and pGBKT7 (Gateway®, Invitrogen). 
 
c. Expression vector: 
1- non-tagged pCR3 expression vector (Gateway®, Invitrogen). 
2- N-terminal HA-tagged pCR3 expression vector (Gateway®, Invitrogen). 
3- N-terminal Myc-tagged pCR3 expression vector (Gateway®, Invitrogen). 
4- N-terminal protein-A-tagged pT-REx expression vector (Gateway®, Invitrogen). 
5- N-terminal Renilla-tagged pcDNA expression vector (Gateway®, Invitrogen).  
 




d. Reporter vectors: 
1- pHSIIα: reporter vector encoding chicken ISRE motif in the upstream region of 
firefly luciferase. 
2- pRLTK: reporter vector encodes Renilla luciferase. 
 
2.6.4 Purification of plasmid DNA 
The pCVI988-Bac and pRB-1B-Bac were isolated by midiprep alkaline lyses 
according to manufacturer’s instructions (NucleoBond, Machery –Nagel, Germany). 
 
pDONR 207, pGBKT7 and pGADT7 were isolated by midiprep alkaline lysis 
according to manufacturer’s instructions (PureYield TM Plasmid Midiprep System 
kit, Promega, UK).  
 
The cloned ORFs were isolated by plasmid DNA purification of QIAprep Miniprep 
Kit according to the manufacturer's instructions (Qiagen, UK) and by miniprep 
alkaline lysis method modified from (Sambrook and Russel, 2001). 
  
A single bacterial colony was selected from the LB plates containing the appropriate 
antibiotics (Gentamycin, Ampicillin or Kanamycin) and was transferred to 1200 μl of 
LB broth with the same selectivity of the agar. The culture was incubated overnight 
at 37°C in 96 deep-well block with constant shaking. The broth was centrifuged at 
3500 rpm for 10 minutes at 4°C. The supernatant was discarded and the bacterial 
pellet was resuspended in 300 µl of ice-cold solution I. For the alkaline lysis of the 
bacteria, 300 µl of solution II (lysis solution) were added and mixed thoroughly. The 
plate was incubated for 3-5 minutes then, 300 µl of ice-cold solution III 
(neutralisation solution) were added to stop the lyses. The mixtures were stored again 
on ice for 3-5 minutes and were centrifuged at 4000 rpm for 30 minutes at 4°C. 
Then, 800 µl of the supernatant was transferred in new plate and 580 µl of 
isopropanol was added to each well followed by a centrifugation at 4000 rpm for 45 
minutes at 4°C. Subsequently, the supernatant was discarded and 500 µl of absolute 




ethanol was added to each tube followed by a centrifugation at 3500 rpm for 5 
minutes at 4°C. Finally, the DNA was dissolved in 50 µl of distilled water. 
 
2.6.5 Determination of DNA concentration 
The concentration and purity of the purified DNA was determined by measuring the 
UV absorbance at 260 and 280 nm. The DNA concentration was calculated with the 
OD260nm (1 OD260nm = 50 µg/ml dsDNA or 33 µg/ml ssDNA). The purity was 
estimated with the OD260nm/OD280nm ratio, with a ratio of approximately 1.8, 
indicating a low degree of protein contamination. 
 
2.6.6 Restriction endonuclease digestion 
Restriction endonuclease reactions were performed according to the manufacturer’s 
recommendations. In general, 1.5 µg DNA was digested for 2 hr at the appropriate 
temperature with 10-20U enzyme. Efficacy of the cleavage reaction was determined 
by 1% TAE agarose gel electrophoresis stained with ethidium bromide. 
 
2.6.7 Cloning 
a. BP reaction 
Components: 
PCR- product    2-7 l 
pDONR 207(150 ng/ l)     1 l 
dH2O        1 l 
BP Clonase       1 l 
 
The reaction was incubated at 37°C overnight. 1 l of the reaction was transformed 
into 50 l of electrocompetent DH10B bacteria. Cells were recovered by adding 500 
l LB medium and incubating at 37°C for 1 hr whilst shaking. The whole volume of 




transformation reaction was spread on LB plates containing 15 g/ml gentamycin 
and incubated overnight. 
DNA was isolated from a single colony by mini prep alkaline lyses. The plasmids 
were digested with the restriction endonuclease BanII to determine the correct size of 
the inserted fragment. 
 
 b. LR reaction 
Components: 
Purified Entry Clone (150 ng/l) 1 l 
pGBKT7                                          1 l 
pGADT7                                         1 l 
dH2O                                                  1 l 
LR Clonase                                     1 l 
 
2 l of the reaction mixture were transformed into 50 l of electrocompetent DH10B 
bacteria. Cells were recovered by adding 500 l LB medium and incubating at 37°C 
for 1 hr whilst shaking. The transformation reaction was divided in two parts. One 
was spread on LB plates containing 50 g/ml kanamycin for pGBKT7 (bait vector), 
the other on ampicillin plates (50 g/ml) for pGADT7 (prey vector). The plasmids 
were digested with the restriction endonucleases EcoRI and BamHI to determine the 
correct size of the inserted fragment.  
 
2.6.8 Agarose gel electrophoresis 
Analysis of DNA fragments and plasmids was performed by agarose gel 
electrophoresis in 1x TAE. While, the analysis of the Bac restriction digest pattern 
was performed by agarose gel electrophoresis in 1x TBE. In general, the agarose 
concentration was 1% in 1x TAE or 1x TBE. The agarose was solubilised by heating 
in a microwave oven. Ethidium bromide was added to a final concentration of 0.25 
µg/ml (2.5 µl stock to 100 ml) just before pouring the gel. Probes were mixed with 




0.17x volume loading buffer. Gels were run horizontally at 80-120 V. DNA was 
detected with UV light. 
 
2.6.9 Sequencing of the genes  
The sequencing of the genes was done commercially by GATC Biotech (Konstanz, 
Germany), using pDONR 207 vector forward and reverse primers. 
2.7 Bacterial techniques 
2.7.1 Bacterial media and solutions 
LB broth: 10 g Bactotryptone, 5 g Yeast extracts, 10 g NaCl and water was added up 
to 1 L. The media was autoclaved and the kept at 4ºC. 
 
LB agar: 10 g Bactotryptone, 5 g Yeast extracts, 10 g NaCl. Water was added up to 1 
L and agar was added at 15 g per litre. The media was autoclaved and poured onto 
plastic plates (Sterilin limited, UK).  
 
2x YT media: 16 g Bactotryptone, 10 g Yeast extracts, 5 g NaCl and water was added 
up to 1 L. The media was autoclaved and the kept at 4ºC. 
 
10% Glycerol: Glycerol purchased from Sigma-Aldrich in liquid form. 100 ml of 
glycerol solution was diluted up to 1 L with distilled water to reach 10% 
concentration. The diluted solution was sterile filtrated.  
 
2.7.2 Antibiotics 
Gentamycin: Purchased from Sigma-Aldrich, liquid supplied and used at 15 µg/ml 
media. 
 
Ampicillin: Purchased from Sigma-Aldrich, powder supplied. Stock solution was 
prepared containing 50 mg ampicillin per ml of sterile distilled water. 1 ml from the 
stock solution was added to 1 litre media. 




Chloramphenicol: Purchased from Sigma-Aldrich, powder supplied. Stock solution 
was prepared containing 50 mg per ml of ethanol. The media was adjusted to contain 
20 µg of chloramphenicol per ml media. 
 
Kanamycin: Purchased from Sigma-Aldrich, powder supplied. Stock solution was 
prepared containing 50 mg kanamycin per ml of sterile distilled water. 1 ml from the 
stock solution was added to 1 litre media. 
2.7.3 Bacteria 
Electrocompetent Escherichia coli DH10B: Used for transformation of the amplified 
genes with pDONR 207, pGBKT7 and pGADT7. 
 
Electrocompetent Escherichia Coli DB 3.1: Used for transformation of the vectors 
carrying the ccdB cassette.  
 
2.7.4 Cultivation of bacteria 
E. coli bacteria were grown in LB medium or on LB agar plates. Incubation was 
performed at 37°C with constant shaking in the case of liquid media. 
 
2.7.5 Preparation of electrocompetent bacteria 
A single clone of DH10B was picked and grown overnight in 50 ml of LB at 37°C. 
Subsequently, 10 ml of the overnight culture were inoculated into 1 L of 2x YT broth 
and incubated at 37˚C. At an OD600nm of 0.5 the culture was rapidly chilled on ice 
for 20 minutes. 
 
The following process was performed at 4°C or on ice: The bacteria were transferred 
into centrifugation containers and centrifuged for 10 minutes at 6000 rpm. The 
supernatants were discarded and the bacterial pellets were resuspended in an equal 
volume of sterilised water. Then, the bacteria were centrifuged for 10 minutes at 
6000 rpm. The supernatants were discarded and the pellets were resuspended in 250 
ml of water followed by a centrifugation at 6000 rpm for 10 minutes. Then, the 




supernatants were discarded and the pellets resuspended in 125 ml of 10% Glycerol. 
The suspensions from two centrifugation tube were first combined into one container 
and then were centrifuged at 6000 rpm for 10 minutes. In the final washing step, the 
supernatant was discarded and the cells were resuspended in 125 ml of 10% glycerol, 
followed by a centrifugation at 6000 rpm for 10 minutes. The cells were resuspended 
in 10% glycerol to give a final volume of 3-6 ml and then distributed into 1.5 ml 




DNA was mixed with electrocompetent DH10B bacteria in 2 mm gap cuvettes. The 
cuvette containing the sample was placed on the shocking chamber of the gene pulser 
electroporation system and the mixture was electroporated at 2.5 V. Cells were 
recovered by adding 500 l LB medium and incubating at 37°C for 1 hr whilst 
shaking. 
 
2.8 Yeast techniques 
2.8.1 Yeast media and solutions 
YEPD broth: 10 g Yeast extracts, 20 g Peptone and 20 g Dextrose. Water was added 
up to1 L. The media was autoclaved and stored at 4°C. 
 
YEPD agar: 10 g Yeast extracts, 20 g Peptone and 20 g Dextrose. Water was added 
up to1 L and agar was added up to 14 g/L. The media was autoclaved and poured 
onto plastic plates (Sterilin limited, UK) then stored at 4°C until required. 
 
SBEG solution: 91.1 g Sorbitol, 5 ml Bicine 1 M (pH 8,35) and 15 ml Ethylenglycol 
(3%). Water was added up to 500 ml. The solution was sterile filtered and kept at 
4°C. 
 




PEG/Bicine solution: PEG 1000 (40%) and 200 mM Bicine (pH 8,35). The solution 
was sterile filtered and kept at 4°C. 
 
NB buffer: 3 ml from 5 M NaCl stock solution and 1 ml from 1 M Bicine (pH 8, 
35).Water was added up to 100 ml. The solution was sterile filtered and kept at 4°C. 
 
Dropout medium liquid medium: 1.7 g Yeast nitrogen base without amino acids 
(Clontech, France), 5 g Ammonium sulphate, 20 g Dextrose and 1.4 g Dropout 
supplements. Water was added up to 1 L. Media was autoclaved and stored at 4°C. 
 
Dropout medium liquid medium +3AT: The same ingredients as above plus 3 mM 3-
aminotriazole. 
 
Dropout medium solid medium: 1.7 g Yeast nitrogen base without amino acids 
(Clontech, France), 5 g Ammonium sulphate, 20 g Dextrose, 1.4 g Dropout 
supplements and 16 g agar. Water was added up to 1 L. Media was autoclaved and 
poured onto plastic plates (Sterilin, UK) then stored at 4°C. 
 
10x Leucine: Purchased from Sigma-Aldrich, Stock solution was prepared contains 
1000 mg Leucine per litre distilled water, (10x solutions). The working solution 
contained 100 mg per 1000 ml media. 
 
10x Tryptophan: Purchased from Sigma-Aldrich, Stock solution was prepared 
containing 200 mg Tryptophan per litre distilled water, (10x solutions). The working 
solution contained 20 mg per 1000 ml media. 
 
2.8.2 Yeast  
Two yeast strains were used AH109 and Y187 provided by (Ragnhild Eskeland, 
MRC). 
 




2.8.3 Competent yeast cells 
To produce competent yeast cells, first a preculture had to be prepared:  
10 ml YEPD-medium was inoculated by a colony of the yeast strains Y187 and 
AH109, respectively. The preculture was shaken overnight at 30°C.  
 
The next day, the preculture was added to 250 ml of fresh YEPD-medium and grown 
at 30°C until it reached a density of 0,6 at OD600.  The cells were harvested in ten 50 
ml Falcon tubes at 2000 rpm (930 x g, 5 minutes, 4°C). The supernatant was 
removed and the cells were resuspended in 12.5 ml SBEG-solution (each) and 
subsequently pelleted once again. The resulting cell pellet was resuspended in 500 l 
SBEG-solution. The 500 l cell suspension was split into 100 l aliquots for 
immediate use. 
 
2.8.4 Transformation into yeast cells 
For a transformation, the yeast was aliquoted in 96 deep wells block. Subsequently, 1 
g of the plasmid pGBKT7or pGADT7 was pipetted into the yeast cells of the 
appropriate yeast strain and mixed carefully by the pipette. Afterwards, 750 l 
PEG/Bicine-solution was added and again mixed by the pipette. This reaction was 
incubated at 30°C for 1 hr, then at 45°C for 5 minutes. The next step was to pellet the 
cells for 2 minutes at 3500 rpm (approx 2700 x g, table centrifuge). The supernatant 
was removed carefully and the pellet was resuspended in 1 ml NB-buffer by pipette. 
Again, cells were pelleted, as before, but only 800 l of the supernatant was 
removed. The pellet was resuspended in the remaining 200 l supernatant and plated 
on an appropriate yeast plate.  
 
2.8.5 Mating and selection by a robot device 
The steps involving a robotic workstation (Biomek 2000; Beckman Coulter) were 
performed in the lab of Peter Uetz in the Institute for Toxicology and Genetic in 
Karlsruhe.  
 




The prey array, consisting of 149 haploid yeast transformants, was divided into two 
96 well plates; lacking leucine (-Leu) (the transformed yeast vector pGADT7 
provides a leucine auxotrophy). The yeast-transformed bait array was treated the 
same way, apart from being placed on plates lacking tryptophan (-Trp). This 
procedure was done by hand in our lab. 
 
By robot device, each element on the prey plate was duplicated. The duplication 
assures reproducibility of screening results. Bait colonies from -Trp plates were 
picked and grown overnight in 20 ml YEPD at 30°C. The bait-medium was 
transferred into empty microtiter plates. The pins of the 384-pin replicator were 
dipped into the BD fusion-expressing culture and placed directly onto a fresh single-
well microtiter plate containing solid YEPD medium. This procedure was repeated 
for each of the 149 baits.  
 
Between transfer steps, the tool must be sterilised by sequential immersion into a 
20% bleach solution (20 sec), sterile water (1 sec), 95% ethanol (20 sec), and sterile 
water (1 sec). The level of these liquids should be 2 to 4 mm from the base of the pin 
and care must be taken that the ethanol does not evaporate.  
 
In the next step, the prey array was picked with sterilised pins and transferred 
directly onto the mating  colonies expressing a single protein as a binding domain 
(BD) fusion, so that each of the BD yeast spots per plate received different active 
domain (AD) yeast cells. The plates were incubated for 1 or 2 days at 30°C to allow 
mating. 
 
For selection, the colonies were transferred to single-well microtiter plates containing 
solid –Leu and -Trp dropout medium using the sterilised pinning tool. The colonies 
were grown for 2 days at 30°C until they were 1 mm in diameter. This was an 
essential control step because only diploid cells that contain Leu and Trp markers on 
pGADT7 and pGBKT7, respectively, will grow on this medium. This step also helps 
recovery of the colonies and increases the efficiency of the next selection step. 




For the next step the colonies were transferred to a single-well microtiter plate 
containing solid –His, -Leu and -Trp (+3AT) dropout medium using the sterilised 
pinning tool and grow at 30°C for up to 10 days (or longer if there was little or no 
background growth) to select two-hybrid positive diploids. 
 
The stringency of the screen can be varied by adding different amounts of 3AT, an 
inhibitor of the His3 gene product. In many cases (10% to 20%), the haploid strain 
expressing the BD fusion has transcriptional self-activation properties. These haploid 
strains can be titrated on plates lacking histidine and containing increasing amounts 
of 3AT (3 mM, 10 mM, 20 mM, 50 mM). The highest level of 3AT tolerated, should 
be added to the –His, -Leu and -Trp plates for selection of two-hybrid positive 
diploids. In many cases, the transcriptional activity is very strong (200 mM 3AT), 
so that not all self-activators can be eliminated. The cellular genes Myc and Max, 
cloned into pGBKT7 and pGADT7, were included as a positive control. Empty 
pGADT7 and pGBKT7 vectors were included as a negative control. The interactions 
were scored positive by looking for growing colonies that were significantly above 
the background (by size) and that were present in 2 colonies.  
 
2.9 RNA Techniques 
2.9.1 Materials used in RNA techniques 
a. Kits: 
1- RNeasy Mini Kit: Purchased from Qiagen and was used according to the 
manufacturer's instruction. 
2- QIA shredder column: Purchased from Qiagen.  
3- Verso TM SYBR® Green 1-Step QRT-PCR Low ROX Kit: Purchased from 
Thermo Scientific and was used according to the manufacturer’s instruction.  
 





1- Super Script TM III Reverse transcriptase: Purchased from Invitrogen and was used 
according to manufacturer's instruction. 
 
2.9.2 RNA isolation and purification 
RNA was isolated according to the manufacturer's instructions using (RNeasy Mini 
Kit, Qiagen). Briefly, cells were resuspended and disrupted in a high-salt denaturing 
lysis buffer containing guanidine isothiocyanate, and homogenised on a QIA 
shredder column (Qiagen, UK) by centrifuging at 13000 rpm for two minutes. 
Samples were added to the RNA-binding columns following the addition of 350 μl 
70% ethanol, to create correct resin-binding conditions, and centrifuged at 10000 
rpm for 15 seconds. Flow-though was discarded and bound to RNA was washed 
twice in buffer RW1 and twice in buffer RPE by centrifuging for 15 seconds at 
10000 rpm. RNA was eluted in 30 μl of RNase-free water.  
 
2.9.3 Reverse transcription  
RNA was reverse transcribed to cDNA using Super Script TM III Reverse 
transcriptase (Invitrogen, UK) and random dt21 oligos or gene specific oligos. The 
reverse transcription was performed according to the manufacturer’s instructions. 
The resulting cDNA was incubated with 1 l of E.coli RNase H at 37°C for 20 
minutes for removal of the RNA complementary to the cDNA. 
 
2.9.4 Quantitative real time-PCR (QRT-PCR) 
Quantitative real time-PCR is a molecular technique, used to measure relative gene 
expression levels or DNA copy number in tested samples. The previous is reached 
via measuring the cycle number at which the increase in the fluorescence becomes 
detectable. This point is termed as the cycle threshold (Ct) value and the detection 
level, which is set by user, is termed threshold level.    
 




a. Primers:  
Primers were designed using Primer3 online tool (http://biotools.umassmed.edu/ 
bioapps/primer3_www.cgi). The primers were purchased from (Metabion, 
Germany). The designed primers for interferon regulatory factor 7 (IRF7) and β-actin 
are listed in Table 2.9.4. 
 
Table 2.9.4: Primers used in QRT-PCR 






CAG TGC TTC TCC AGC ACA AA 
 
CCC CCG TGC TGT GTT CCC ATC 
TAT CG 
 
TGC ATG TGG TAT TGC TCG AT 
 
GGG TGC TCC TCA GGG GCT ACT 
CTC AG 
 
b. Optimisation of QRT-PCR:  
All amplifications were performed on a MX3000-P™ real-time PCR Strategene 
instrument. β-actin gene was used as an internal control for samples normalisation, 
then tested samples were normalised to calibrator samples. The PCR reaction was 
performed according to the description below. 
 
Components: 
Verso Enzyme Mix                                          0.25 l 
Forward Primer            1 M                           1.75 l 
Reversed Primer          1 M                            1.75 l 
Template                     15 ng/l                        2.00 l 
1-Step QPCR SYBR Low ROX Mix (2x)     12.50 l 
dH2O                                                        add 25.00 l 





A standard curve assay was performed to determine the amplification efficiency of 
the used primers. The efficiency was calculated according to the difference of Ct 
values, obtained from double fold serial dilution of RNA template. Any efficiency 
ranged from 90-120% was considered ideal. As shown in Figure 2.9.4b, the 
amplification efficiency of IRF7 and β-actin were 79.5% and 107.7%, respectively. 
 
 
Figure 2.9.4b: Standard curve of IRF7 and β-actin primers. Standard curve 
graph compares the Ct values of five different concentrations from double fold 
serial diluted RNA template. Each dilution was run in duplicate, and the 
amplification was done using Verso TM SYBR® Green 1-Step QRT-PCR Low 
ROX Kit (Thermo Scientific, UK). The efficiency of the standard curves was 
calculated using MxPro software (Strategene, UK). 
 
A dissociation curve assay was carried out for the primers at 60ºC annealing 
temperature for 1 minute to investigate if there was any non-specific amplification. 
As shown in Figure 2.9.4b, the dissociation curves of the both primers are 
representing a specific amplification. 







Figure 2.9.4c: Dissociation curve of IRF7 and β-actin primers. Dissociating 
curve graph show the specificity of the PCR amplification of five different 
concentrations from double fold serial diluted RNA template. Each dilution was 
run in duplicate, and the amplification was done using Verso TM SYBR® Green 
1-Step QRT-PCR Low ROX Kit (Thermo Scientific, UK). The dissociation 
curves were analysed using MxPro software (Strategene, UK). 
 
2.10 Virus techniques 
2.10.1 Viruses  
MDV strains pRB-1B5 (Petherbridge et al., 2004) and the Meq-deleted RB-1B5-D2 
(Brown et al., 2006) viruses have been described previously. Viruses were 
propagated in CEF cells, and cells were cultured as described in Section 2.1.5. 
 
2.10.2 Buffers used in virus staining 
 
a. Fixing solution: Ice cold 1:1 acetone:methanol. 
 
b. Wash buffer: PBS with 0.05% TWEEN 20 (PBST). 
 
c. Blocking buffer: PBS with 5% FCS. 




d. Developing solution: 0.513 ml of 0.1M sodium acetate (pH 4.8), 0.027 ml of 4 
mg/ml 3-amino-9-ethylcarbazole solution diluted in dimethylformamide and 0.009 
ml of H2O2. It was prepared shortly before use. 
2.10.3 Materials and supplements used in virus techniques 
a. Antibodies:  
1- HB3 murine anti-gB antibody, used at 1/100 and diluted in blocking buffer. 
2- Goat anti-mouse peroxidase coupled, purchased from Dako. It was used at 1/200 
and diluted in blocking buffer. 
 
b. Cytokines: 
Chicken interferon-alpha-2 recombinant protein: Purchased from Genway Biotech. 
Recombinant protein prepared from E.coli and was supplied in 50 l PBS. The 
solution containing 1x107 U/mg was aliquoted into small 0.5 ml reaction tubes and 
stored at -20°C. 
 
2.10.4 Staining CEF cells for MDV plaques 
CEF cells infected with MDV were fixed with ice cold acetone: methanol for two 
minutes at room temperature. Fixative was removed, and cells were washed twice 
with PBS. Cells were blocked by incubation with the blocking buffer at room 
temperature for one hour, and then incubated with murine HB3 monoclonal Ab 
(primary antibody) at room temperature for one hour. Thereafter, cells were washed 
with the washing buffer three times and incubated with Goat anti-mouse peroxidase 
antibody (secondary antibody). After removal of the secondary antibody, cells were 
washed three times with the washing buffer and the plaques were detected by adding 
the developing solution. Plaques appeared as red spots which were distinguishable 










Figure 2.10.4: Immunoperoxidase staining of MDV plaques. CEF cells were 
infected with RB-1B MDV. Cells were fixed 5 dpi and stained with monoclonal 
Ab against glycoprotein B (HB3). The MDV-specific plaques were visualised 


















Cloning of the MDV ORFeome 
3.1 Introduction 
MDV encodes more than 100 genes that have both structural and regulatory roles. 
Cloning some of the MDV genes and testing them at the proteomic level led to 
discovery of new facts on the biology and life cycle of the virus. For example, 
cloning of MDV-UL9 gene and expressing it by in vitro transcription-translation 
system was the reason for discovering that it is the MDV origin binding protein 
(OBP) (Wu et al., 2001b). Another example is the Meq gene, MDV bZIP, in murine 
retroviral vector helped in discovering Meq transformation and anti-apoptotic 
properties (Liu et al., 1998). However, previous studies were performed to study 
individual or a small number of MDV genes. With the emergence of more virulent 
strains of MDV, it becomes a necessity to undertake functional analysis of MDV 
proteins on a genome-wide scale.  
 
3.1.1 Gateway® cloning technology 
Gateway® recombinatorial cloning provides the opportunity to clone large number of 
genes in a high-throughput manner. Caenorhabditis elegans ORFeome was the first 
to be cloned by using the Gateway® technology on a genome-wide scale (Walhout et 
al., 2000). Thereafter, many libraries were constructed for many organisms including 
many members of herpesvirus (Fossum et al., 2009).  
 
Gateway® technology depends on att recombination sites, which are used by the 
lambda bacteriophage for excision and integration from the bacterial chromosome 
(Figure 3.1.1). Briefly, the insert is flanked by attB sites allowing the recombination 
into the entry vector which contains attP sites. After the first cloning step (BP 
recombination) the entry clone becomes flanked by attL sites, and the DNA can be 
easily subcloned into multiple destination vectors, which are flanked by attR sites 
(LR recombination). The formed expression clones, which are flanked by attB sites, 
can be used further for different purposes and expressed in different systems. 






Figure 3.1.1: Gateway® cloning. Gateway® cloning is based on a 
recombination derived from the λ bacteriophage. First, the gene of interest 
(PCR product) is inserted into a DONR vector to create the entry clone via BP 
recombination reaction. Subsequently, the gene of interest can be subcloned 
into different destination-expression vectors by a second recombination reaction 
(LR recombination reaction).  





Marek’s disease virus has been completely sequenced and is fully annotated (Lee et 
al., 2000a; Tulman et al., 2000; Spatz et al., 2007b; Spatz et al., 2007c). The aim of 
the work presented in this chapter was to clone all predicted MDV genes into the 
entry vector pDONR 207 using Gateway® technology. Moreover, to subclone the 
entry clone collection into different destination and expression vectors to perform 
various functional assays. These functional assays will help in understanding the role 
played by each of the MDV genes and determining the essential genes for the MDV 
infection and pathogenicity.  
 
3.2 Results 
3.2.1 Amplification of MDV genes 
To functionally analyse Marek’s disease virus proteins, MDV genes were first 
amplified by polymerase chain reaction (PCR). In total, 122 genes were amplified as 
full-length genes (Figure 3.2.1b) or as fragments. In addition, 25 extra- or 
intracellular domains were amplified from the genes which were predicted to have 
transmembrane regions (Appendix C). The templates used for the amplification of 
MDV genes were two bacterial artificial chromosome (BAC) clones of the MDV 
CVI988 and RB-1B strains (Figure 3.2.1a), RB-1B RNA isolated from MDV-
infected CEF and a RB-1B cDNA phage library. The primers were designed based 
on alignments of the RB-1B sequence with the published sequence of the CVI988, 
Md5 and Md11 strains with the accession number DQ530348, NC_002229 and 
AY510475, respectively. PCR conditions were first the same for all ORFs. Some 
ORFs, which could not be amplified under the standard conditions, were successfully 
amplified with touch-down PCR by lowering the annealing temperature 1ºC every 
cycle (from 60 to 50ºC). This was the case for RLORF9, PP38, SORF4, US8, the 
cytoplasmic domain of US6, the cytoplasmic domain of US8, the cytoplasmic 
domain of US7 and the cytoplasmic domain of UL34. The four spliced genes 14kDa, 
14KDb, Lipase and vIL8 were amplified from cDNA generated by reverse 




transcription of RB-1B RNA isolated from CEF infected with RB-1B strain. The 
reverse transcription was done using dt21 primers with the exception of the Lipase 
gene, in which the RNA was reverse transcribed using gene specific primers. The 
fifth spliced gene, UL15, could not be amplified from the RNA and the cDNA 
library as well. For UL15, two internal overlapping primers were designed. The first 
primer is the 3′ terminus for the first exon, including 11 bases from the 5′ terminus of 
the second exon and the second primers is the 5′ terminus of the second exon plus 11 
bases from the 3′ terminus of the first exon. The two exons were amplified in 
separate reactions from the RB-1B BAC construct. Then, the two fragments were 
purified and used together in the second reaction as a template. US2 gene (the area of 
BAC insertion) and another version of viral Lipase were amplified from cDNA 
phage library of RB-1B strain. The very long ORFs like ICP4 (6000 bp), UL29 
(3576) and UL36 (10047 bp) were amplified as domains. With all the displayed 
efforts, we were unable to amplify RLORF1, LORF1 or vTR. However, very short 





















Figure 3.2.1a: EcoRI digests of CVI988 BAC and RB-1B BAC DNA. After 
DNA isolation using an alkaline lysis-based protocol and restriction digest with 
EcoRI, the digests were separated on a 1 % TBE agarose gel. After 
electrophoresis, the gel was stained with ethidium bromide. Lane 3 represents 
digested CVI BAC DNA, while lane 4 and 5 represent two different digested 













Figure 3.2.1b: PCR products of MDV ORFs from the repeat long region. 
Lane 1 1 kbp DNA ladder (Fermentas), lane 2 vIL8, lane 3 RLORF3, lane 4 
RLORF4, lane 5 RLORF5, lane 6 RLORF6, lane 7 LMeq, lane 8 Meq, lane 9 
RlORF8, lane 10 RLORF9, lane 11 RLORF10, lane 13 RLORF12, lane 14 
RLORF13b and lane 15 RLORF14a (PP38).  
 
3.2.2 Cloning of MDV genes into the pDONR 207 vector 
Each PCR product was cloned into pDONR 207 by recombinatorial cloning. 119 
genes have been cloned (Appendix C) as a full-length or as fragments, plus 25 
domains for genes which were predicted to have transmembrane region(s). These 
clones represent the MDV entry clone library which can be subcloned into different 
destination and expression vectors to be used for different purposes. The cloning into 
the pDONR 207 vector was initially confirmed by restriction digest with BanII 
enzyme (Figures 3.2.2). The US7 gene could not be cloned as a full length ORF for 
unknown reason, but it was cloned as both extracellular and intracellular domains. 
Three genes were amplified by PCR but could not be cloned into pDONR 207 vector 
UL28, UL39 and LORF11. 
 





Figure 3.2.2: BanII digests of UL49 clones in the entry vector pDONR 207. 
Scanned image of ethidium bromide stained 1% TAE agarose gel which shows 
UL49 cloned into pDONR 207, and digested with BanII enzyme. Lane 1 
contains 1 kbp DNA ladder (Fermentas), while lane 2-5 represent DNA isolated 
from four different clones. 
 
3.2.3 Sequencing of the cloned entry vectors 
All cloned ORFs in pDONR 207 were sequence-verified from both ends using 
forward and reverse primers (GATC Biotech, Konstanz, Germany). Clones with 
frame shift mutations were disposed, but not clones with silent (mutations not 
leading to an amino acid exchange) or missense mutations. A total of 118 full-length 
cDNA clones and 25 clones encoding protein domains of membrane-associated 
proteins were generated and sequence-verified (Figure 3.2.3). The sequencing results 
are listed in Table 3.2 in Appendix C. 






Figure 3.2.3: Total 149 clones were verified by sequencing. 149 constructs 
from MDV genome were cloned in pDONR 207 and were verified by 
sequencing using both the forward and the reverse primers of the pDONR 207. 
They represent 114 genes cloned as a full length, 4 genes cloned as fragments 
(10 fragments) and 25 transmembrane domains. 
 
3.2.4 Cloning of the MDV entry clones into multiple destination vectors 
a. Plasmids for Y2H and Co-IP  
In order to use the Y2H system to investigate interactions between MDV proteins, 
the MDV entry clones were subcloned into the Y2H bait and prey vectors pGBKT7-
DEST and pGADT7-DEST. Both vectors are destination vectors with different 
resistance genes, ampicillin in case of the prey vector and kanamycin in the bait 
vector. The prey and bait clones were confirmed by a double restriction digest using 
EcoRI and BamHI restriction enzymes (Figure 3.2.4a). All genes which had been 
cloned in the pDONR 207 vector, were successfully subcloned into both bait and 
prey vectors.  
 




b. Plasmids for LUMIER pull-down assay 
In order to use LUMIER pull-down assays for validation, a subset of MDV entry 
clones (27 genes) were subcloned into the LUMIER Renilla and protein A-tagged 
vectors pcDNA-Renilla and pT-REx-A. Both vectors are expression vectors with an 
ampicillin resistance. The Renilla-tagged clones were confirmed by a double 
restriction digest using XhoI and XbaI restriction enzymes, and the protein A-tagged 
clones were confirmed by a double restriction digest using XhoI and NheI restriction 
enzymes (Figure 3.2.4b).  
 
c. Plasmids for eukaryotic transient-expression  
In order to identify MDV protein(s) which inhibit interferon-alpha signalling, the 
MDV entry clones were subcloned into the non-tagged mammalian expression vector 
pCR3. pCR3 expression vector has two selective marker cassettes, ampicillin and 
kanamycin resistant cassettes. The expression clones were confirmed by a double 
restriction digest using XbaI and HindIII restriction enzymes (Figure 3.2.4c). All of 
the genes, which were subcloned into the pDONR 207 vector as a full length, were 
successfully cloned into pCR3 vector. Additionally, to investigate the expression of 
some MDV genes by immunoblotting, five MDV entry clones were successfully 
subcloned into HA N-terminal tagged pCR3 expression vector. These genes were 
Meq, LMeq, UL50, UL26 and UL12. 







Figure 3.2.4a: EcoRI and BamHI digests of different ORF clones in the prey 
vector. Scanned image of an ethidium bromide stained 1% TAE agarose gel 
showing a subset of cloned genes in pGADT7-DEST digested with EcoRI and 
BamHI. Lane 1 1 Kbp DNA ladder (Fermentas), lane 2 and 3 the extra cellular 
domain of US7, lane 4 and 5 UL9, lane6 and 7 SORF4, lane 8 and 9 RLORF5, 
lane 10 and 11 UL44, lane 12 and 13 UL40 and lane14 UL37. 
 
 







Figure 3.2.4b: XhoI and XbaI digests of different ORF clones in the pcDNA-
Renilla vector. Scanned image of ethidium bromide stained 1% TAE agarose gel 
shows the cloned MDV genes in pcDNA-Renilla digested with XhoI and XbaI, 










Figure 3.2.4c: XbaI and HindIII digests of different ORF clones in the 
pCR3 vector. This scanned image of an agarose gel stained with ethidium 
bromide shows the cloned MDV genes in pCR3 digested with XbaI and 
HindIII, Lane 1 1kbp DNA ladder (Fermantus), lane 2 RLORF8, lane 3 UL15, 
lane 4 UL3, lane 6 LORF9, lane 7 US8, lane 8 UL40 and lane 9 UL9. 
 





3.3.1 The importance of a functional analysis of MDV proteins 
To achieve a better understanding of the biological role of individual viral proteins, 
the general objective of this thesis was to functionally characterise all MDV proteins 
by intraviral protein interactions and by their ability to suppress innate immune 
responses.  
 
3.3.2 Choice of MDV genes, domains and templates 
In order to study the function of each of the MDV genes, all ORFs in the viral 
genome had to be amplified and subcloned first. Two different MDV strains were 
used as templates for amplifying the viral ORFs. The first template was derived from 
the non-virulent, low-oncogenic and vaccine CVI988 strain, and the second from the 
very virulent and highly oncogenic RB-1B strain (both templates were kindly 
provided by Dr Venu Gobal Nair). Both strains belong to MDV serotype1 and share 
>90% sequence similarity. While previous studies have predicted MDV to encode 
more than 330 ORFs (Tulman et al., 2000; Spatz et al., 2007b), only 109 of these 
seem to be functional genes and of significance for genomic comparison between the 
pathotype (Spatz et al., 2007b). To avoid analysing short ORFs which may not 
expressed during MDV infection it has been decided to focus on the 109 functional 
genes. Comparative sequence analysis between the two strains revealed that most of 
the ORFs are identical in sequence composition. However, a small number of ORFs 
differed between the two strains. One example is RLORF7 (called Meq in the RB-1B 
strain and Long Meq in the CVI988 strain), which in the CVI988 contains an 
additional insertion of about 180 nucleotides. Moreover, some genes seem to be 
frame-shifted in the RB-1B strain due to deletion or insertion of one nucleotide, 
which subsequently changes the frame of the protein. This was observed for LORF1, 
UL13, UL44, US6, RLORF5a and SORF1. All the genes, which were identical 
between the two strains (identity> 98%), were cloned only from one of the strains. 
The genes that differed in sequence composition were cloned from the both the 
CVI988 and the RB-1B strains.  




In the yeast-two-hybrid system both the bait and prey proteins have to be transported 
into the nucleus in order to transactivate the GAL4 promoter. However, proteins 
containing transmembrane domains may prevent the prey or bait proteins from 
reaching the nucleus, giving a higher degree of false negative results (Van Criekinge 
and Beyaert, 1999). To overcome this problem, all full length open reading frames 
were analysed for the presence of transmembrane domains using the TMHMM 
Server v. 2.0. Open reading frames predicted to contain a transmembrane domain 
were cloned both as full length protein and as fragments. Although the specificity 
and sensitivity of the prediction software are not 100%, it was still able to identify all 
known MDV glycoproteins with the exception of (UL1) or gL. Moreover, the server 
predicted some ORFs with unknown function to have transmembrane domains, i.e. 
RLORF3 and LORF6. This could be attributed to wrong prediction from the server. 
On the other hand, these ORFs function could be involved in the signalling process 
or act as glycoproteins.  
 
3.3.3 Gene amplification and cloning 
From the 125 functional genes from both strains, a total of 122 functional genes and 
25 fragments from membrane-associated genes, were amplified from the viral 
templates. All gene products were amplified by nested PCR and analysed by gel 
electrophoresis on a 1% TAE agarose gel to verify the correct size of the gene 
product. Proof reading polymerase was used in the amplification process to 
overcome the problem of mutations associated with using the ordinary Taq 
polymerase. The annealing temperature was initially set to be 55˚C, since lower 
temperatures could increase the chance of unspecific binding of the primers to the 
template resulting in non-specific PCR product. On the other hand, much higher 
annealing temperatures could prevent the hybridisation between the primers and the 
template. For the genes which were not amplified with the initial setup, other 
annealing temperatures, templates and PCR conditions were tested until a specific 
gene product could be obtained. However, three genes were not amplified, despite 
experimenting with a variety of different conditions (RLORF1, LORF1, vTR). As 
the primers of these genes contain a high ratio of G+C nucleotides, it is possible that 




the primers form secondary structure that resist the denaturation, and subsequently 
inhibit the annealing of the primers.  
 
Most of the 122 functional MDV genes were cloned as full-length proteins or at least 
as fragments into pDONR 207 with the exception of UL28, UL39 and LORF11. 
Although the amplification of these three genes resulted in good PCR products, no 
positive colonies were received. The lengths of these ORFs (>2500 bp) suggests that 
the length of the gene to be cloned is one of the restrictive factors in recombinatorial 
cloning. On the other hand, several other genes which are longer have been 
successfully cloned into pDONR 207 such as UL19 (4182 bp). Also, the composition 
of the ORF (internal sequences with homology to att sites) could play a role when 
ORFs cannot be cloned. 
 
3.3.4 Gene sequencing 
All cloned ORFs were sequenced from the both ends using pDONR 207 forward and 
reverse primers. The sequencing result revealed that about 90% of the clones had the 
correct sequence and the correct reading frame. The remaining 10% of the clones had 
mutations in different regions. Some of the genes contained insertion or deletion 
mutation in the primer region resulting in frame shifts. The mutated genes were 
recloned and sequenced until the complete library was correct. Moreover, the 
sequencing revealed that the spliced Lipase gene (amplified from cDNA) still 
contained its intron. To solve this problem, the Lipase ORF was reamplified from a 
cDNA phage library and was subsequently cloned in the DONR vector. 
Unfortunately, the sequencing result was the same. This problem could be due to a 
DNA contamination of the template or due to the Lipase gene not being spliced in 
RB-1B strain. The later explanation is less likely due to the fact that the Lipase gene 
is highly conserved among the three serotypes of MDV (Tulman et al., 2000; Afonso 
et al., 2001; Izumiya et al., 2001). In total, 118 MDV genes from both CVI988 and 
RB-1B strains were cloned using the Gateway® system. This clone collection can 
now be used for a variety of purposes, including recombinant protein expression and 
functional assays. 




Genome-wide analysis for intraviral protein-protein 
interactions of MDV 
4.1 Introduction 
Herpesviruses have a complex structure, composed of nucleocapsid, tegument and 
outer envelope. Because of this complex structure, the process of herpesvirus 
replication is divided into several steps. Production of new viral particles starts with 
nucleic acid replication in the nucleus and nucleocapsid formation, followed by the 
egress of the capsid from the nucleus to the cytoplasm. There, tegument formation 
takes place with subsequent secondary envelopment, transport through secretary 
vesicles, virus budding and release. These processes depend mainly on a group of 
conserved interactions between different virion proteins. Genome-wide analysis for 
intraviral protein-protein interaction of herpesviruses had been investigated before 
for many mammalian herpesviruses such as herpes simplex virus-1 (HSV-1), 
Epstein-Barr virus (EBV), murine cytomegalovirus (mCMV) and Kaposi's sarcoma 
associated herpesvirus (KSHV) (Uetz et al., 2006a; Calderwood et al., 2007; Rozen 
et al., 2008; Fossum et al., 2009). However, there is very little information available 
on intraviral protein-protein interactions of avian herpesviruses. This chapter 
presents the results of a Y2H screen for intraviral protein interactions in MDV. The 
interactions detected will be discussed in terms of their role in MDV replication and 
biology. Particularly interactions conserved between MDV and other members of 
herpesviridae will be analysed and discussed in more detail. 
 
4.1.1 Role of protein-protein interactions during herpesvirus replication 
a. Role of protein-protein interactions in DNA replication 
Herpesviruses encode two distinct polymerase subunits which are termed UL30 and 
UL42 in HSV-1. The two polymerase subunits bind together and form a complex 
which is required for viral DNA replication (Gottlieb and Challberg, 1994; Loregian 
et al., 2006). The biological relevance of this interaction has been studied in HSV-1 




and equine herpesvirus (Gottlieb and Challberg, 1994; Loregian et al., 2006). In 
these viruses the interaction with UL42 increases the affinity of UL30 to nucleic acid 
and enhances its processivity.  
 
b. Role of protein-protein interactions in capsid egress from the 
nucleus 
Once the production of new progeny viral genomes is completed by rolling circle 
replication, the formation of nucleocapsid starts. Subsequently, the assembled 
nucleocapsid is released from the nucleus to the cytoplasm (nuclear egress), where 
the tegumentation process occurs. UL31 encodes a nuclear and UL34 a membrane-
associated phosphoprotein. The two proteins form a complex at the nuclear 
membrane of herpesvirus infected cells (Reynolds et al., 2001; Yamauchi et al., 
2001; Fuchs et al., 2002c). This interaction has been identified in several members of 
herpesviridae, including Herpes simplex virus type I (HSV-1), Epstein-Barr virus 
(EBV), pseudorabies virus (PrV) and murine cytomegalovirus (CMV) (Ye and 
Roizman, 2000; Fuchs et al., 2002b; Reynolds et al., 2002; Lake and Hutt-Fletcher, 
2004; Liang and Baines, 2005; Lotzerich et al., 2006). The interaction between UL31 
and UL34 is thought to play a role in the egress of primary nucleocapsids from the 
nucleus to the cytoplasm. The amino acids 137 to 181 of HSV-1 UL34 are essential 
for its interaction with HSV-1 UL31 (Liang and Baines, 2005), whereas the amino 
acids 56 and 57 of M50, the UL34 homologue of mCMV, are considered responsible 
for its interaction with M53 (Bubeck et al., 2004). Orthologs of UL31 in the 
herpesviridae have an N-terminal variable region and four conserved regions (CR1-
4). A protein complementation assay study revealed that the conserved region-1 (CR-
1) of UL31 in various herpesviruses contains the specific binding site for UL34 
proteins (Lotzerich et al., 2006; Schnee et al., 2006). 
 
c. Role of protein-protein interactions in tegumentation 
Once the nucleocapsid has been transported to the cytoplasm, the tegument proteins 
start assembling around the nucleocapsids in a process called tegumentation. Until 
now the complete mechanism of herpesvirus tegumentation has not been determined, 




but it mainly happens in the cytoplasm of virus-infected cells (Miranda-Saksena et 
al., 2002). However, several studies focusing on intraviral protein interaction 
identified a number of interactions occurring between different tegument proteins, in 
addition to interactions between tegument and capsid proteins or glycoproteins. For 
instance, the major and minor tegument protein of herpesviridae, UL36 and UL37 in 
HSV-1, physically bind together (Klupp et al., 2002; Vittone et al., 2005; Desai et al., 
2008). This interaction is functionally relevant, as it contributes to virus assembly. 
For example, in PrV the UL36-UL37 interaction is considered important for early 
capsid tegumentation and secondary envelopment, although it is not essential for the 
latter (Klupp et al., 2002; Fuchs et al., 2004). Additionally, in HSV-1 localisation of 
UL37 at the cytoplasmic budding sites of Golgi complex depends mainly on its 
binding to UL36 (Desai et al., 2008). 
 
UL11 is a membrane-associated tegument protein conserved in many different 
herpesviruses (Kopp et al., 2003). This protein is important for tegumentation and 
secondary envelopment. UL11 protein interacts with another tegument protein, 
UL16, during nucleocapsid tegumentation. Interestingly, UL11 of MDV, PrV and 
HSV-1 have been shown to interact with HSV-UL16, expressed from infected Vero 
cells, indicating that this interaction is conserved (Loomis et al., 2003; Vittone et al., 
2005).  
 
UL46, UL47, UL48 and UL49 are tegument proteins, which encode VP11/12, 
VP13/14, VP16 and VP22, respectively, in HSV-1 and other herpesviruses (McLean 
et al., 1990; Zhang and McKnight, 1993; Elliott et al., 1995). VP11/12 was recently 
was shown to be associated with both cellular membranes and viral capsids (Murphy 
et al., 2008). This association provides a very helpful model for the dynamic 
processes of nucleocapsid tegumentation and secondary envelopment (Murphy et al., 
2008). It can co-localize with VP16 and VP22 in the cytoplasm, particularly at 
perinuclear regions (Kato et al., 2000; Murphy et al., 2008). This co-localisation 
suggests that both proteins together participate in tegumentation (Kato et al., 2000). 
VP16 (UL48) is a tegument protein, which has both a structural role and a 




transregulatory role. The structural role is the involvement in the assembly of virion 
tegument; whereas the regulatory is the transcriptional activation of the other 
immediate early genes (see Section 1.3). Interestingly, both roles of VP16 are 
regulated by its interaction with other tegument proteins. The interaction of VP16 
with VP13/14 (UL47) is required for transcriptional activation, as VP13/14 targets 
VP16 to the nucleus at an early stage of virus infection where VP16 starts the 
transregulation (Donnelly and Elliott, 2001). In addition, VP16 physically binds to 
VP22, which is required for virion tegumentation and the packaging of VP22 into the 
tegument (Elliott et al., 1995; Miranda-Saksena et al., 2002; Hafezi et al., 2005; 
Vittone et al., 2005; O'Regan et al., 2007; Taddeo et al., 2007).  
 
Not only interactions between tegument proteins are required for tegumentation, but 
also interactions between tegument and glycoproteins. The first evidence for the 
presence of an interaction between glycoproteins and tegument proteins was 
published by Zhu and Courtney, who found by chemical crosslinking that gB, gD 
and gH of HSV-1 bind to the tegument complex VP16, VP11/12, VP13/14 and VP22 
(Zhu and Courtney, 1994). Later, many other interactions have been discovered 
between tegument proteins and glycoproteins in other herpesviruses, such as bovine 
herpesvirus -1 (BoHV-1) and PrV (Fuchs et al., 2002a; Chi et al., 2005; Farnsworth 
et al., 2007; O'Regan et al., 2007; Kalthoff et al., 2008). Interestingly, PrV mutants 
lacking both glycoproteins E and M failed to incorporate UL49 into the tegument, 
highlighting the significance of glycoproteins for tegumentation (Fuchs et al., 
2002a).  
 
d. Role of protein-protein interactions in secondary envelopment 
The secondary envelopment is the process by which virus particles acquire their final 
lipoprotein layer by budding through a cellular membrane in the Golgi or trans-Golgi 
network (TGN) compartments (Miranda-Saksena et al., 2002). Several interactions 
between different glycoproteins and tegument proteins contribute significally to the 
secondary envelopment process, and many of them have been studied in more detail.  
 




For example, the interactions of UL11 with different glycoproteins, such as gM, gE 
and gD, are considered to be important for the secondary envelopment of 
herpesviruses. These interactions mainly exist in alpha-herpesviruses, such as HSV-1 
and PrV (Kopp et al., 2003; Kopp et al., 2004; Farnsworth et al., 2007; Leege et al., 
2009). However, there is also some evidence that PP28, the UL11 homologue in 
human cytomegalovirus (beta-herpesvirus), is involved in secondary envelopment 
(Seo and Britt, 2007). By electron microscopy it has been shown that in cells infected 
with PrV lacking UL11, a large number of tegumented nucleocapsid can be found in 
the cytoplasm (Kopp et al., 2003). PrV and HSV-1 double deletion mutants lacking 
both UL11 and gM have lower virus titres than the wild-type virus and also show a 
marked decrease of the plaque size (Kopp et al., 2003; Leege et al., 2009). 
Furthermore, infection with these mutants results in cells with a large number of 
tegumented nucleocapsids accumulated in the cytoplasm indicating that the presence 
of both UL11 and gM is essential for the final virion envelopment (Kopp et al., 2003; 
Kopp et al., 2004; Leege et al., 2009).  
 
e. Role of protein-protein interactions in virus cell-to-cell spread 
Interactions between herpesviral glycoproteins are not only crucial for the secondary 
envelopment process, but also for virus entry and cell-to-cell spread (syncytium 
formation). The four glycoproteins gD, gB, gH, gL form a complex together, which 
is essential for HSV-1 and HSV-2 entry and virus-envelope cell-membrane fusion 
(Muggeridge, 2000; Browne et al., 2001; Atanasiu et al., 2007; Gianni et al., 2007). 
Interestingly, the presence of these 4 glycoproteins in the same cell membrane is 
enough to produce cell fusion and syncythium formation in both viruses (Turner et 
al., 1998; Muggeridge, 2000; Browne et al., 2001; Atanasiu et al., 2007).  
 
In several members of the alpha-herpesvirinae, glycoproteins E and I form a 
heterodimer complex. The presence of this complex is essential for cell-to-cell 
spread of the virus between host cells. For example, gE of Feline herpesvirus (FHV) 
can only act as a fusion protein in the presence of gI (Mijnes et al., 1996). In 
addition, a gE/gI negative mutant of HSV-1 can not spread efficiently from neuron to 




neuron in rat retina, indicating the importance of this interaction for cell-to-cell 
spread (Dingwell et al., 1995).  
 
4.1.2 Role of protein-protein interactions in the life cycle of MDV 
There is not much information available on intraviral protein-protein interactions 
between MDV proteins. Only a few reports have identified a limited number of 
interactions between MDV viral proteins or with cellular proteins. One such example 
is the interaction between glycoproteins H and L of MDV which can form a hetero-
oligomer complex. The presence of both glycoproteins is required for their 
expression and translocation from the endoplasmic reticulum (ER) lumen to the cell 
surface (Wu et al., 2001a). Therefore, the formation of this complex may be essential 
for MDV entry into cells and virus spread from cell to cell. In addition, UL11 of 
MDV is able to interact with HSV-1 UL16 (Loomis et al., 2003). Thus, it is possible 
that both UL11 and UL16 are structurally important in the process of tegumentation. 
PP38 and PP24, the two unique phosphoproteins of MDV, form a complex together 
(Ding et al., 2007; Ding et al., 2008). The presence of both proteins is important for 
the transactivation of the bidirectional promoter which is located between the 
PP24/PP38 gene and the 1.8 kb mRNA transcripts (Ding et al., 2007).  
 
Meq, the major oncoprotein of MDV, is composed of an N-terminal basic leucine 
zipper domain and a C-terminal proline-rich transactivation and transrepression 
domain. The Meq gene encodes many different transcripts, such as Meq, Meq/vIL8 
and ∆Meq (Peng and Shirazi, 1996; Anobile et al., 2006; Okada et al., 2007). Meq 
either forms a homodimer with itself or a heterodimer with the transcriptional factor 
c-Jun (Qian et al., 1995). The Meq/c-Jun heterodimer leads to an increased 
transactional activation of the Meq promoter in comparison to Meq homodimers 
(Qian et al., 1995). The transcriptional activation of the Meq promoter is mediated 
through the binding of these dimers to a AP-1-like motif present in the Meq promoter 
(Qian et al., 1995). Furthermore, transcriptional activation by the Meq/c-jun 
heterodimer is required for MDV replication and/or establishment and reactivation of 
the virus from the latency.  




Meq can also interact with the 70 kilodalton heat shock protein (hsp70), however 
there is no well-defined role for this interaction yet (Zhao et al., 2009). It is possible 
that the Meq/hsp70 complex acts as a regulator of the cell cycle. Additionally, Meq 
interacts with the C-terminal binding protein (CtBp), and this interaction is 
functionally relevant (Brown et al., 2006). The interaction between Meq and CtBp is 
strongly correlated with Meq transrepression activity, and the inhibition of this 
interaction results in diminishing its inhibitory activity (Brown et al., 2006). 
Abolishing the interaction between Meq and CtBp in the RB-1B MDV virus results 
in a complete loss of oncogenicity and the ability to induce lymphoma in birds 
(Brown et al., 2006). 
FRET studies have shown that Meq/vIL8 homodimers form in the nucleolus, 
nucleoplasm and cajal bodies of transfected CEF cells (Anobile et al., 2006). 
However, the definite role of this homodimer complex has not been elucidated yet. 
Meq and Meq/vIL8 can also form a heterodimeric complexes in vitro, which could 
have an effect on its regulatory function or its binding partners (Peng and Shirazi, 
1996). Similar to Meq, Meq/vIL8 is able to interact with c-Jun (Peng and Shirazi, 
1996). By gel shift assays it has been shown that the presence of Meq/vIL8 enhanced 
the DNA binding activity for the AP-1 recognition sequence of c-jun (Peng and 
Shirazi, 1996). However, the presence of Meq and Meq/vIL8 together does not have 
any effect on the AP-1 binding activity. These data suggest that Meq/vIL8 acts as a 
competitor for its dimerisation partners.  
 
∆Meq is another transcript derived from the Meq genomic sequence and composed 
of the N-terminal 98 amino acids of Meq and 30 aa derived from a different reading 
frame (Okada et al., 2007). ∆Meq inhibits the transactivation of the Meq and IL-2 
promoters, which is induced by Meq and L-Meq. This negative regulatory effect of 
∆Meq is through its direct physical binding with both Meq and L-Meq (Okada et al., 
2007). 
 




4.1.3 The Yeast-two-hybrid system (Y2H) 
The yeast-two-hybrid system is an important method for studying protein-protein 
interactions, particularly for screening large number of interactions. It was first 
described by Fields and Songs as a novel system for studying protein-protein 
interactions by taking advantage of the properties of the GAL4 transactivator of the 
yeast Saccharomyces cerevisiae. This protein is a transcriptional activator, composed 
of two domains: an N-terminal domain which binds to specific DNA sequences and a 
C-terminal domain which is necessary to activate transcription. Fields and Songs 
generated a system of two hybrid proteins containing parts of GAL4: the GAL4 
DNA-binding domain fused to a protein 'X' and a GAL4 activating region fused to a 
protein 'Y'. If X and Y interact, they will reconstitute a transcriptional activator and 
initiate transcription of an auxotrophy gene (Fields and Song, 1989) (Figure 4.1.3). 
Several Y2H screens in the recent years have identified very important interactions 
which have been crucial in understanding virus pathogenesis. For example, in IBDV 
(infectious bursal disease virus) the structural capsid protein (VP3) was observed to 
be the key organizer of Birnavirus structure, as it maintains critical interactions with 
all components of the viral particles: itself, VP2, VP1, and the two genomic dsRNAs 
(Tacken et al., 2002). Moreover, the crucial role of Nsp8 in the replication of the Sars 
coronavirus was shown using the Y2H system (von Brunn et al., 2007). Using the 
Y2H system, 123 intraviral protein interactions have been identified in KSHV, and 
173 in VZV (Uetz et al., 2006b). The Y2H assay has previously been used to identify 
some interactions between MDV proteins and their cellular counterpart, such as the 
interaction between the chicken growth hormone and SORF2 (Liu et al., 2001), 
between US10 and stem cell antigen (LY6E) (Liu et al., 2003), between RLORF8 
and CIQ binding protein, RLORF10 and MHC class II invariant chain, RLORF12 
and growth related transciptionally related protein, RLORF13 and CIQ binding 
protein and LORF4 with MHC class II chain (Niikura et al., 2004).  
 






Figure 4.1.3: The yeast-two-hybrid system. The GAL4 DNA-binding domain 
(DB) fused to a protein of interest 'X' (named as bait protein) and a GAL4 
activating domain (AD) fused to a protein of interest 'Y' (prey protein). If X and 
Y can interact together, they will reconstitute the GAL4 domain and initiate 
transcription of a gene under regulation of the up-stream activation sequence 
(UAS) (Fields and Song, 1989). 
 
4.1.4 Aim  
MDV causes an immunosuppressive lymphotropic disease in poultry, which severely 
affects health and welfare and causes great economic devastation in lifestock 
industry. It encodes more than 100 ORFs, a large percentage of which are only 
poorly characterised. The objective of this study was to provide a clearer and better 
understanding of the role of individual MDV proteins in virus replication and 
pathogenicity by studying their interactions with other MDV proteins. Based on the 
Y2H data, a MDV interactome map should be generated and positive Y2H 
interactions verified by a secondary biochemical assay. 





4.2.1 Identification of intraviral protein-protein interactions in MDV  
In order to analyse physical interactions occurring between MDV proteins, MDV 
bait and prey clones (see Chapter 3) were transformed into yeast. Two different yeast 
strains were used to generate Y2H prey and bait arrays, AH109 (a mating type) for 
the preys and Y187 (α mating type) for the baits. The MDV clones collection was 
composed of 149 DNA constructs from MDV genes cloned as both pGADT7 (prey) 
and pGBKT7 (bait). This clone collection contains MDV genes which have been 
cloned as full-length proteins, fragments and extra- and intracellular domains for 
membrane-associated proteins. The transformed prey clones were grown on plates of 
single drop-out media lacking leucine and the transformed bait clones were grown on 
plates of single drop-out media lacking tryptophan. As both vectors have the 
appropriate cassettes of selectivity which make the transformed yeast grow on the 
selective plate lacking suitable amino acid. The transformed yeast clones were tested 
in collaboration with Dr. Peter Uetz and Thorsten Stellberger at the Institute of 
Toxicology and Genetics, Karlsruhe, Germany, in a robot-assisted Y2H assay in 96-
well plate format. In a matrix analysis, all proteins were tested against each other. 
Since the Y2H assay can generate a number of false positive interactions, each 
pairwise interaction was tested in duplicates. Interactions in the Y2H screen were 
scored positive, if two of the two mating were positive. If only one replicate was 
positive, the interaction was scored non-reproducible and negative. The positive 
results from the Y2H array were visualised and analysed using the Cytoscape 
bioinformatics software.  
 
From the list of positives, the interactions with 5 preys (UL33, UL35, UL37 of 
CVI988 strain, UL37 of RB-1B strain, SORF4 and the extracellular domain of B68) 
were removed due to their high prey count (above 30 interactions) which suggests 
that these preys are sticky and the interactions false positive. Of more than 20.000 
tested interactions between the MDV proteins, 435 interactions were identified by 




the Y2H screen (Figure 4.2.1). The full lists of positive interactions are listed in 
Appendix D. 






Figure 4.2.1: MDV protein-protein interaction network. MDV 
proteins, indicated as nodes, were tested against each other, using Y2H 
system. The MDV Y2H screen identified 435 interactions, indicated as 
edges, between MDV proteins. The results were analysed and visualised 
using Cytoscape, in order to construct an intraviral MDV interactome.  
Protein 




4.2.2 Network analysis of MDV protein-protein interaction interactome 
The MDV network consists of 115 nodes (proteins) and 435 edges (interactions) and 
has a short characteristic path length of 2.68 (the characteristic path length is defined 
as the average number of edges between 2 random nodes in a network) and a small 
network diameter of 6 (Table 4.2.2).  
Network Parameters MDV 
Protein 115 
Interactions 435 
Interactions (without self-interactions) 413 
Average degree 7.57 
Average degree (without self-interactions) 7.18 
Power coefficient -0.94 
R2 0.80 
Characteristic path length 2.68 
Diameter 6 
Clustering coefficient 0.25 
Enrichment over ER 3.73 
Enrichment over ES 1.34 
 
Table 4.2.2: Statistical analysis for the intraviral MDV interactome 
Average degree is the average number of interactions between two proteins in the 
network. The degree of a node in a network represents the number of edges 
connecting to that node. Nodes with the highest degrees are usually termed hubs. 
The diameter of a network is the maximum distance between any two nodes. 
Cellular protein-protein interaction network is a scale-free network with a degree 
distribution follows power-law decay:  
P (k) ~ k-γ 
P (k) describes the number of proteins in the network which has a given degree 
(number of interactions), while γ indicates a coefficient which describes the decline 
of the graph. Since the MDV network is considered a small network, it can not be 
conclusively determined whether it follows the power-law distribution or not. The 
clustering coefficient was calculated according to the Watts and Strogatz model 
(Watts and Strogatz, 1998). For each protein, it is calculated as the number of 
interactions between neighbours of this protein divided by the number of possible 
interactions between these neighbours. The clustering coefficient of this network is 
calculated as the average clustering coefficient of proteins with at least two 
neighbours. The statistical network analysis was done by Caroline Friedel, Institute 
of Informatics, University of Munich, Germany. 




4.2.3 Validation of MDV protein interactions by biochemical assays 
a. Co-immunoprecipitation (Co-IP)  
To further confirm the reliability of the MDV interactome, a subset of 37 interactions 
between MDV proteins were selected to be tested by co-immunoprecipitation (Co-
IP). The Y2H bait and prey vectors were used to express the selected ORFs as Myc 
or HA N-terminal fusion protein under control of the T7 bacteriophage promoter. 
The bait and prey vectors of interacting proteins were transfected into quail muscle-7 
(QM7) cells. Simultaneously, cells were infected with recombinant Vaccinia virus 
expressing T7 polymerase. Cell lysates were split into two parts and precipitated with 
either anti-c-Myc or anti-HA antibody. Each precipitate was separated on two 
polyacrylamide gels. On the left side of each gel the precipitating proteins and on the 
right side the co-precipitating proteins are indicated (Figure 4.2.3a). The direct 
precipitations were performed to control the expression levels and the correct size of 
the tested proteins. Out of the 37 viral protein-protein interactions identified with the 
Y2H-system, 27 interactions were also detected by Co-IP, which represent 
approximately 73% of Y2H positive (Figure 4.2.3b).  





Figure 4.2.3a: Validation of MDV protein interactions by Co-IP. QM7 cells 
were infected with Vaccinia virus expressing T7 polymerase. One hour later, 
the cells were co-transfected with pGBKT7-LORF10 and pGADT7-LMeq, 
pGBKT7-US10 and pGADT7-LMeq, pGBKT7-US1 and pGADT7-UL13, 
pGBKT7-US1 and pGADT7-US10, pGBKT7-vIL8 and pGADT7-Meq, 
pGBKT7-US10 and pGADT7-US10 or pGBKT7-US10 and pGADT7-UL9. 
Twenty four hours post transfection, the whole- cell extracts were lysed and 
precipitated with either anti-c-Myc or anti-HA antibody. The precipitated 
samples separated on two polyacrylamide gels. On the left side of each gel the 
precipitating proteins and on the right side the co-precipitating proteins. 
pGBKT7 and pGADT7 Plasmids encoding cellular Myc and Max were used as 
a positive control. Empty pGBKT7 and pGADT7 vectors were used as a 
negative control. This experiment shows positive physical binding between 
LMeq with US10 or LORF10 and between Meq with vIL8. 
 
 




b. LUMIER pull-down assay 
To further confirm Y2H and Co-IP results, the same subset of interactions, which 
was tested by Co-IP, was sent to German Cancer Research Centre, Heidelberg, 
Germany to be assessed by LUMIER pull-down assay as another independent 
biochemical assay. This work has been done in collaboration with Dr. Manfred 
Koegl, German Cancer Research Centre, Heidelberg, Germany. The LUMIER pull-
down assay is a biochemical assay for investigating protein-protein interactions 
which is based on an N-terminal Renilla luciferase fusion protein (pcDNA-Renilla), 
and an N-terminal protein A fusion protein (pT-REx-A). The protein A-tagged and 
the Renilla-tagged plasmids were transfected in 293T cells. Cells were lysed and the 
cellular lysates were split into two aliquots. The total luciferase activity was 
measured for the first aliquot, while the other aliquot were allowed to precipitate 
with IgG coated magnetic beads. The precipitated protein complexes were measured 
for luciferase activity, and the bound luciferase activity was calculated relative to the 
total luciferase activity: log (bound luciferase) / log (10% of total luciferase). Out of 
the thirty seven interacting partners detected by Y2H, twenty three were validated by 
LUMIER pull-down assay (approximately 60%) (Table 4.2.3). Of the positive Y2H 
interactions tested by Co-IP and LUMIER, 20 of 37 interactions were confirmed 





















Protein 1 Protein 2 
Co-IP LUMIER Overlapping 
UL9 LORF10 - - - 
UL9 US10 + - - 
UL9 UL25 - + - 
UL25 UL17 + + + 
UL54 UL54 + + + 
LMeq LORF10 + - - 
LMeq US10 + + + 
US1 UL13 - - - 
US1 US10 - - - 
US10 US10 - - - 
UL13 US10 - + - 
UL54 UL25 + + + 
UL17 US10 + - - 
vIL8 UL34 + + + 
vIL8 UL20 + + + 
RlORF3 Md57.4 + + + 
RlORF3 vIL8 - + - 
RLORF3 RLORF5b + - - 
PP24 vIL8 + + + 
PP38 UL44 + + + 
PP38 UL34 + + + 
Meq RLORF5b + - - 
Meq PP24 + + + 
Meq PP38 + + + 
Meq RLORF3 + + + 
Meq UL20 - - - 
Meq UL53 - - - 
Meq 14kDa - - - 
Meq vIL8 + + + 
UL50 UL12 + - - 
UL50 UL50 + + + 
UL44 UL25 + + + 
UL44 Md57.4 + + + 
UL34 Md57.4 + + + 
UL30 UL42 + - - 
UL42 Meq + + + 
UL11 UL16 + + + 
  27 23 20 





Figure 4.2.3b: Confirmation of 81% of the Y2H interactions by either Co-
IP or LUMIER. Thirty seven interactions between protein pairs were analysed 
by two biochemical assays; LUMIER-pull down assay and co-
immunoprecipitation. 27 interactions were positive by Co-IP (73%), and 23 
interactions were positive by LUMIER (62%). From the 37 interactions, 20 
interactions were positive by the both assays (54%), 30 interactions were 
positive by either of the two assays (81%), and 7 interactions were negative by 
the both assays (19%). 
 
4.2.4 Extraction of biological data from the MDV interactome 
a. Interactions among structural proteins. 
Interactions among structural proteins may help elucidate the details of different 
steps during MDV replication and morphogenesis, such as DNA replication, capsid 
formation, DNA packaging, primary envelopment, tegumentation and secondary 
envelopment. Several of these interactions were observed in the Y2H analysis of 
MDV. For instance, UL33 (DNA packaging & cleavage protein and capsid-
associated protein) was observed to interact with the minor capsid scaffold protein 
UL26. Three interactions were identified by the Y2H among the minor capsid 
scaffold protein (UL26) and different tegument proteins such as VP16 (UL48), minor 
tegument protein (UL37) and tegument protein (UL3.5). Two interactions were 
identified among minor capsid protein (UL6) and two tegument proteins UL3.5 and 







Total Number Tested 37 




protein) interacted with UL14, and finally the minor capsid protein UL38 was 
observed to interact with the major tegument protein UL36. Thirteen interactions 
were detected in the Y2H screen between the different tegument proteins. VP16 
(UL48) was found to interact with UL3.5 and VP22 (UL49). Furthermore, the major 
and the minor tegument proteins (UL36 and UL37) were observed to interact 
together. In addition, the major tegument protein also interacted with itself. 
Moreover, both of the major and minor tegument proteins interacted with UL51 and 
UL25. UL7 interacted with UL51. Many more interactions between the tegument 
proteins were detected by Y2H as the following; UL11 and UL16, UL51 and UL14, 
UL17 and UL25, and UL46 and UL47. 
 
Eleven interactions were detected in the Y2H screen between tegument proteins and 
glycoproteins or membrane-associated proteins. The major tegument protein (UL36) 
has been found to interact with glycoprotein H (gH) (UL22) and the two membrane-
associated proteins UL34 and UL43. The minor tegument protein UL37 was found to 
interact with gB (UL27). Also, the tegument or the capsid-associated protein UL25 
was found to interact with gC (UL44) and gM (UL10). The tegument protein UL3.5 
was found to interact with the two membrane-associated proteins UL34 and UL43. 
The tegument proteins UL14, UL41 and UL51 interacted with gM (UL10), the 
membrane virus egress protein (UL20) and gC (UL44), respectively. Thirteen 
interactions were identified by Y2H assay between MDV glycoproteins with each 
other or with membrane-associated proteins. The glycoprotein B (UL27) interacted 
with itself, gC of the RB-1B strain, gK (UL53), gE (US8), gL (UL1) and gH (UL22). 
MDV gE (US8) was found to interact with the two membrane-associated proteins, 
UL34 and UL43. In addition to interacting with itself, the viral egress protein (UL20) 
was found to interact with gN (UL49.5) and gK (UL53). Glycoprotein C (UL44) of 
the CVI988 strain interacted with gI (US7) and gM (UL10) interacted with gH 
(UL22). 







Figure 4.2.4a: Interactions between MDV structural proteins. Model 
illustrates the role of the MDV protein-protein interaction in the virion 
assembly. This figure illustrates the interaction between capsid or capsid-
associated proteins with each other or with other tegument proteins (the 
tegument labelled by yellow colour). In addition, it indicates the interactions 
between tegument proteins with each other or with the tegument proteins and 
membrane-associated proteins (the envelope labelled by faint blue colour) and 
the interactions between glycoproteins or the membrane-associated proteins 
with each other. 




b. Protein interactions conserved between MDV and other members of 
herpesvirus subfamilies 
Previous reports have detected a number of conserved interactions between 
herpesvirus core proteins, using the Y2H system and other assays (Calderwood et al., 
2007; Fossum et al., 2009). The fact that MDV encodes 40 core proteins, which have 
homologues in the 3 subfamilies of herpesviridae, suggests that the MDV 
interactome could contain several conserved interactions. To assess this, a 
comparison was carried out between MDV intraviral protein interactions and the 
intraviral protein interactions of five viruses HSV-1, VZV, mCMV, EBV and KSHV. 
Those five viruses have been selected because they represent the three herpesviridae 
subfamilies (α, β and γ) and their intraviral protein interactions were detected using a 
similar Y2H assay setup as used for the MDV interaction network (Fossum et al., 
2009). The intraviral MDV protein-protein interactions were compared to previously 
published interactions. In this analysis, 22 interactions identified between MDV core 
proteins were found to be conserved in HSV-1, VZV, mCMV, EBV and KSHV. The 
highest similarity was between MDV and VZV, with 14 intraviral protein-protein 
interactions conserved between the two viruses. The biologically more similar virus 
EBV had 8 conserved interactions with MDV, HSV-1 and mCMV had 5 conserved 
interactions with MDV, while KSHV only showed 2 conserved interactions (Table 
4.2.4b). In comparison to previously published interactions, 16 MDV intraviral 
protein-protein interactions were overlapping with HSV-1, VZV, mCMV, EBV and 




             Table 4.2.4b: Comparison of proteins interactions between core proteins 
 
 Yeast-two-hybrid Literature 
Protein1 Protein2 HSV-1 VZV mCMV EBV KSHV HSV-1 VZV mCMV EBV KSHV 
UL42 UL42 - + - - - - - + + + 
UL42 UL30 - - - - - + - + - + 
UL42 UL12 - - - - - - - - + - 
UL38 UL36 - - - - - - - - - + 
UL37 UL27 - - - + - - - - - - 
UL37 UL36 - + - + - + - - - + 
UL37 UL26 - + - - - - - - - - 
UL36 UL36 - - - + - - - - + + 
UL36 UL25 - + + - - - - - - - 
UL36 UL22 - - - - - - - - - + 
UL33 UL31 - + + + + - - - - - 
UL33 UL16 + + - - - - - - - - 
UL33 UL26 - + - - - - - - - - 
UL32 UL32 - + - + - - - - - - 
UL32 UL14 - + - - - - - - - - 
UL27 UL27 - - - - - + - - - - 
UL54 UL54 + - + - + + - - + + 
UL53 UL26 + - - - - - - - - - 
UL52 UL5 - - - - - + - + + - 
UL52 UL8 - - - - - + - + - - 
UL51 UL7 - + - + - - - - - - 
UL51 UL12 - - - + - - - - - - 
UL51 UL51 - + - - - - - - - - 
UL51 UL6 - - - - - - - - + - 
UL49 UL48 - - - - - + - - - - 
UL23 UL23 - + - - - - - - - + 
UL25 UL17 - - + - - - - - - - 
UL25 UL25 - + - - - - - - - - 
UL20 UL20 - + - - - - - - - - 
UL16 UL11 + - + + - + - - - - 
UL14 US10 + - - - - - - - - - 
US8 US8 - - - - - - + - - - 
  5 14 5 8 2 8 1 4 6 8 




c. Meq protein interactions suggest a potential role in virus replication 
and pathogenesis 
Meq is the MDV oncoprotein which is responsible for the transformation of infected 
cells and which is mainly expressed during latency. vIL8 is a chemokine homologue, 
and may be responsible for switching the MDV infection from B lymphocytes, in 
which the lytic replication is established, to T lymphocytes, where the latent 
infection and transformation occur. PP38 is mainly expressed during lytic infection, 
and it is suggested that it is responsible for virus reactivation from latency. In this 
Y2H study, it has been found that these genes, which are responsible for different 
stages of virus infection, interacted with each other and formed a dense network 
(Figure 4.2.4c). Meq interacted with itself, PP38, PP24 and vIL8 protein. In addition, 
vIL8 protein interacted with Meq and PP24. PP38 interacted with itself and its 
homologues PP24 and Meq. Interestingly, there was also an interaction detected 
between Meq and the small polymerase subunit UL42 of MDV. 
 
 
Figure 4.2.4c: Meq protein interactions suggest a potential role in virus 
replication and pathogenesis. Dense network formed between Meq, vIL8, 
PP38 and PP24 proteins. 
 





4.3.1 The significance of the identification of intraviral protein 
interactions in MDV 
The main objective of this project has been to evaluate protein-protein interactions 
between all viral proteins of MDV. By cloning all the MDV ORFs and analysing 
them against each other in a Y2H assay, a better understanding of the biological role 
of the individual viral proteins should be obtained. Since most published studies in 
MDV focused on interactions between viral and cellular proteins (Liu et al., 2001; 
Liu et al., 2003; Niikura et al., 2004), not much has been known about intraviral 
interactions. However, several important intraviral interactions have been observed 
between orthologs in other herpesviral species. For example, the interaction between 
the two components of the nuclear egress complex, UL31 and UL34, had already 
been reported in Herpes simplex virus type 1 (HSV-1) (Reynolds et al., 2001), 
pseudorabies virus (PrV) (Fuchs et al., 2002), murine cytomegalovirus (mCMV) 
(Lotzerich et al., 2006), equine Herpesvirus 1 (EHV-1) (Neubauer et al., 2002) and 
Epstein-Barr virus (EBV) (Gonnella et al., 2005).  
 
4.3.2 Genome-wide analysis of intraviral protein-protein interactions 
and identification of conserved interactions within Herpesviridae 
Several studies examined intraviral protein-protein interactions as well as their 
biological and evolutionary roles in herpesviruses, for example in HSV-1, KSHV, 
EBV, mCMV and VZV (Rozen et al., 2008; Fossum et al., 2009). In this study, 435 
interactions between 115 MDV proteins have been identified using the Y2H system. 
These 115 proteins were represented by 149 DNA constructs and amplified from two 
MDV strains, the virulent RB-1B and the CVI988 vaccine strain. In the comparison 
of the MDV interactome with the other herpesviral interactomes, a few conserved 
interactions were identified. The VZV interactome showed the highest similarity 
with the MDV interactome, which is consistent with the fact that both VZV and 
MDV are alpha-Herpesvirinae. Interestingly, the two viruses also share biological 




characteristics, as both are strictly cell-associated. In the literature, only one of the 
MDV interactions had been reported for orthologs in VZV, which could be due to the 
low number of published interactions for both viruses (Olson et al., 1997). 
Interestingly, many of the conserved interactions between the core proteins have 
been identified before and showed biological roles in other herpesviruses, 
particularly HSV-1. For instance, the interaction between the two tegument proteins, 
UL11 and UL16, was detected in MDV, HSV-1, mCMV and EBV (Loomis et al., 
2003; Vittone et al., 2005; Fossum et al., 2009). In HSV-1, this interaction was 
shown to be required for nucleocapsid tegumentation  in the TGN (Loomis et al., 
2003). HSV-1 UL16 was also able to interact with MDV UL11, PrV UL11 and HSV 
UL11 (Loomis et al., 2003). This is consistent with our data, suggesting that the 
UL11-UL16 interaction is conserved throughout the Herpesviridae, despite the low 
homology between the orthologs.  
 
Another example is the interaction between the nuclear egress protein UL31 and 
UL33, which is conserved in the four viruses VZV, mCMV, EBV, KSHV (Fossum et 
al., 2009). Immunofluorescence studies done by Fossum and colleagues showed that 
M51, the UL33 homolog in mCMV, colocalizes with the nuclear egress complex 
M53 and M50, the UL31 and UL34 homologs in mCMV, in the nuclear membrane, 
suggesting that M51 may be a part of the nuclear egress complex (NEC). The Y2H 
interaction between UL33 and UL31 in MDV suggests that UL31 could have a 
similar role in MDV. Finally, the homodimer formation of the immediate early 
protein UL54 in MDV, has also been reported for HSV-1, mCMV, EBV and KSHV 
(Zhi et al., 1999; Malik and Clements, 2004; Fossum et al., 2009). This self- 
interacting property of UL54 could help its transregulatory function for early and late 
viral genes. In summary, several MDV core proteins showed interactions which have 
been shown before in other herpesviridae, suggesting that these interactions have a 
conserved role throughout the entire family. 
 




4.3.3 Assessment of the reliability and the limitations of the Y2H system 
The Y2H system can result in false positive and as well as in false negative results. 
False negative interactions are interactions which could not be identified by the Y2H 
system but are present in vivo and can be caused by a variety of reasons. First, the 
Y2H system only detects binary interactions which do not require additional binding 
partners as usually the case in protein complexes. Some interactions depend on post-
translational modifications that may not occur in yeast such as the formation of 
disulphide bridges, glycosylation and phosphorylation. Moreover, the failure of the 
protein to reach the yeast nucleus due to the presence of localisation sequences (e.g. 
transmembrane regions) can cause false negative results (Van Criekinge and Beyaert, 
1999). Finally, the addition of the DNA-binding domain in the bait fusion protein 
and the activation domain in the prey fusion protein can lead to incorrect folding 
which prevents protein interactions. False positive interactions do not occur in vivo 
and can be caused by the presence of protein domains with activation or DNA-
binding properties in bait or prey proteins or by proteins which are particularly sticky 
(e.g. hydrophobic proteins). Whereas false negative Y2H interactions are difficult to 
avoid due to their systematic nature, false positives Y2H interactions can be much 
better controlled and reduced. Non-surprisingly, it is estimated that with the Y2H 
protocols used here the rate of false negatives is up to 80 or 90%, whereas the 
number of false positives only about 30%. Nonetheless, crucial Y2H interactions 
should always be confirmed by other techniques such as pull-down assays or co-
immunoprecipitation (Co-IP). 
 
In order to validate the MDV Y2H interaction results, two biochemical assays, Co-IP 
and LUMIER pull-down assays, were used. Thirty seven interactions between 
protein pairs were selected randomly and tested by both techniques. Among the thirty 
seven tested interactions, 30 interactions (81%) were confirmed by the both methods. 
Based on these results, it can be concluded that the MDV interactome data presented 
here have a very high reliability. The confirmation rate was higher than in the study 
on the mCMV, EBV, HSV, KSHV networks (Fossum et al., 2009), but comparable 
to a previous study on KSHV virion protein-protein interactions (Rozen et al., 2008).  




4.3.4 A model for MDV virion assembly based on the MDV interactome  
Herpesvirus replication and morphogenesis is a complicated process including 
nucleic acid replication, nucleocapsid formation, nuclear egress, tegumentation, 
secondary envelopment and virus release. Indeed, much information is lacking 
regarding the tegumentation and the secondary envelopment processes. Most of these 
steps of virus replication are based on interactions between different virion proteins, 
but until now no study has analysed the interactions between structural MDV 
proteins. The MDV interactome data generated in this study provide the opportunity 
to create models for each of the steps mentioned above.  
 
The MDV interactome includes a large number of interactions between virion 
proteins. Unfortunately, several structural proteins including UL37 (small tegument 
protein), UL35 (capsid protein) and UL33 (capsid-associated protein) had a high 
prey count (number of baits interacting with a specific prey protein) and were thus 
excluded from the analysis. However, even after the removal of these interactions, 
there were still 46 interactions between MDV-structural virion proteins. These 
interactions could help elucidate the process of MDV virion assembly, starting from 
encapsidation, tegumentation and secondary envelopment. For instance, the MDV 
interactome revealed a physical interaction between UL33 and UL26, the minor 
capsid scaffold protein. UL33 is the DNA cleavage and packaging protein required 
for the encapsidation of HSV-1 virions (al-Kobaisi et al., 1991). In accordance with 
the MDV results, the VZV interactome also contained an interaction between ORF25 
and ORF33, the orthologs for UL33 and UL26 (Fossum et al., 2009). Furthermore, 
there were 8 interactions between capsid proteins or capsid-associated tegument 
proteins with tegument proteins, representing the early stage of the nucleocapsid 
tegumentation. The tegument protein UL16, known to be associated with the mature 
capsid HSV-1 (Meckes and Wills, 2007), interacted with the DNA cleavage and 
packaging protein UL33. This interaction also has been detected in HSV-1 and VZV 
(Fossum et al., 2009). Another interesting finding from the MDV network involves 
the major tegument protein UL36. The observation that UL36 interacts with a capsid 
protein (UL38), several tegument proteins (UL37, UL25, UL5 and itself) and several 




membrane-associated proteins (UL34, UL43 and gH) suggests that UL36 may have a 
central role in collecting these virion proteins during assembly. Again, this 
observation is consistent with findings reported for the KSHV large tegument protein 
ORF64 (Rozen et al., 2008; Fossum et al., 2009).  
 
Moreover, the MDV Y2H analysis revealed thirteen interactions between different 
tegument proteins. Many of these interactions are conserved, and have been 
thoroughly studied among herpesviridae, such as the interactions between the small 
and the large tegument proteins UL37 and UL36. It has been reported that this 
interaction is required for the early capsid tegumentation in PrV and HSV-1 (Klupp 
et al., 2002; Fuchs et al., 2004; Vittone et al., 2005; Desai et al., 2008). Furthermore, 
UL36 recruits UL37 to the cytoplasmic budding sites of the Golgi complex, where 
the secondary envelopment happens (Desai et al., 2008). Another example is the 
UL48-UL49 interaction in MDV. This interaction was not detected in any previously 
published herpesvirus networks, but it was detected in other studies for HSV-1 
protein-protein interactions (Elliott et al., 1995; Hafezi et al., 2005; Vittone et al., 
2005; O'Regan et al., 2007; Taddeo et al., 2007). These studies discovered that the 
UL48-UL49 interaction is required for tegument assembly, and that VP16 is 
responsible for recruiting VP22 inside the virion tegument. Many other interactions 
between tegument proteins were also identified which are know to have a role in 
tegument assembly, such as UL11 with UL16, UL46 with UL47 and UL17 with 
UL25 (Loomis et al., 2003; Vittone et al., 2005; Thurlow et al., 2006; Fossum et al., 
2009).  
 
After the virion tegument has assembled around the nucleocapsid, the tegumented 
nucleocapsids are recruited to the TGN. The process of secondary envelopment 
occurs at TGN, mainly through the binding of tegument protein with glycoproteins. 
Since membrane proteins have an increased chance of false negative results due to 
their transmembrane regions (see Section 4.3.3), all glycoproteins were tested both as 
full-length proteins as well as domain fragments in our Y2H analysis to minimize 
this risk. Eleven interactions between tegument proteins and membrane or 




glycoproteins could thus be detected in this study. Most of the identified interactions 
between MDV tegument proteins and glycoproteins had not been detected before in 
any other herpesvirus, and only the interaction between UL36 and gH had been 
published for KSHV (Rozen et al., 2008).  
 
In summary, it is evident from the data mentioned above that the MDV interactome 
contains a series of interactions between the virion proteins which may represent 
different stages of virion assembly. Many of these interactions have been detected 
before in other members of the herpesviridae, particularly those involved in 
encapsidation and tegumentation. 
 
4.3.5 Meq interactors suggest a potential role in virus pathogenesis 
Meq is the main MDV protein responsible for oncogenesis and is expressed during 
latency. Because it contains a N-terminal basic leucine zipper domain, it has been 
suggested that it may form homodimers (Qian et al., 1995). In support of this, our 
Y2H screen identified an interaction between Meq bait and prey. PP38 and PP24 are 
two phosphoproteins which are mainly expressed during MDV lytic infection 
(Parcells et al., 2003). Ding and colleagues observed that PP38 and PP24 bind to 
each other and form a heterodimeric complex (Ding et al., 2008). Consistent with 
this observation, in the Y2H analysis PP24 and PP38 interacted with each other in 
both directions. PP24 also interacted with itself, suggesting that it dimerizes. Several 
papers are published on the relation between Meq and PP38. It has been suggested 
that PP38 can act as co-activator for Meq (Chen et al., 1992; Jarosinski et al., 2006). 
However, only limited scientific evidence exists supporting this hypothesis. The 
MDV interactome revealed an interaction between Meq and PP38, and this 
interaction was confirmed by Co-IP. Another interesting observation is that Meq and 
PP38 have many of the same interactors in the Y2H screen. Thus, the question arises 
if Meq and PP38 are co-workers or competitors? Another interesting finding was the 
interactions between vIL8, PP24 and Meq. While an interaction between vIL8 and 
PP38 was not detected in the Y2H system, an independent biochemical assay was 
used to re-examine the possibility that this interaction also occurs. In fact, by Co-IP it 




was detected that both proteins interact with each other. This suggests that the vIL8-
PP38 interaction was a false negative result in the Y2H screen, possibly for steric 
reasons. In accordance with these results, Cui and colleagues found that the absence 
of vIL8 expression in infected birds causes an impairment and delayed PP38 and 
Meq expression in infected organs (Cui et al., 2005b). This in vivo result indicates 
the importance of this interaction, and also suggests that there may be other 
important MDV protein-protein interactions not yet detected.  
 
In summary, 435 interactions between MDV viral proteins were identified with the 
Y2H system in this study. Almost 80% of the Y2H interactions could be confirmed 
indicating that most of the observed interactions are indeed reproducible in 
biochemical assays. The MDV interactome contains many conserved interactions 
present in other members of the herpesviridae, confirming previous findings that core 
interactions are conserved to a large degree. While the MDV interactome contains a 
vast amount of biological useful data, further studies will need to address the 
biological importance and function of these interactions. In any case the MDV 
interactome will represent a valuable resource for future research into the 
pathogenesis of MDV. 




Identification of MDV proteins inhibiting chicken 
interferon-alpha signalling pathway 
 
5.1 Introduction 
Having the advantage of the MDV clone library, it was decided to study one side of 
the MDV-chicken interplay. This chapter focuses on the inhibitory effect of MDV 
proteins on the chicken interferon-alpha response. The reasons for this selection were 
as follows: firstly, many viruses, particularly herpesviridae members, encode 
proteins that are able to antagonise the induction of interferon-alpha. These proteins 
interfere with interferon-alpha signalling pathway at different levels, to date; no such 
proteins have been described for MDV. Secondly, the availability of the chicken 
ISRE reporter construct, which is known to respond by interferon-alpha treatment, 
makes a genome-wide study more feasible. In the next section, a brief introduction to 
the avian interferon system will be provided and also the effect of different viruses 
on the interferon-alpha signalling pathway. 
 
5.1.1 Avian interferon background 
Interferons are a family of cytokines, which are considered as a part of the non-
specific, innate immune response. These cytokines are produced at early stages of 
viral infection, in order to induce an antiviral state in the host. In mammalian 
systems, interferons are classified into three types: type I, type II and the recently 
identified type III interferons. Type I interferons include IFN-α, IFN-β, IFN-δ, IFN-ω 
and IFN-τ, while type II interferons include IFN-γ, as a sole member. Type III 
interferons (IFN-λ), previously known as IL28/29, include three members IL28A, 
IL28B and IL29 (Sheppard et al., 2003). 
 
Following the classification of interferons in mammals, avian interferons are also 
classified into three biologically distinct subtypes: type I, type II and type III 




interferons (Sick et al., 1996; Lowenthal et al., 2001; Qi et al., 2010). Type I 
interferons encode two serologically distinct subtypes, formally known as ChIFN1 
and ChIFN2. ChIFN1 is encoded by a family of 10 or more genes, whereas ChIFN2 
is encoded by only one gene (Sick et al., 1998). Based on some sequence homology 
with mammalian interferon and the inducibility of their promoters in response to 
different stimuli, both of ChIFN1 and ChIFN2 were characterised as chicken 
interferon-alpha (chIFN-α) & chicken interferon-beta (chIFN-β), respectively (Sick 
et al., 1998). Briefly, the 5’-up stream region of ChIFN2 contains NF-KB and IRF1 
binding sites and is strongly induced by virus infection (Sick et al., 1998; Lowenthal 
et al., 2001). On the other hand, the 5’-up stream region of ChIFN1 contains no NF-
KB binding site, and this promoter has poor inducibility following virus stimulation 
(Sick et al., 1998). Both of chIFN-α and chIFN-β transcripts are induced by different 
stimuli such as virus infection and/or treatment with poly (I:C) (an artificial double 
stranded RNA). In vitro, chIFN-α and chIFN-β transcripts were detected in primary 
chicken macrophages stimulated with UV-inactivated Newcastle disease virus 
(NDV) (Sick et al., 1998). Furthermore, CEF cells strongly produce type I interferon 
in response to viral infections; such as NDV and yellow fever virus (YF 17DD) (Sick 
et al., 1996; Caride et al., 2008). Moreover, treatment of chicken leukocytes with 
poly (I:C) leads to up-regulation of chIFN-α and chIFN-β (Karpala et al., 2008).  
 
Chicken interferon-alpha (chIFN-α) DNA is approximately 582 bp long, and encodes 
a protein of approximately 193 amino acids in length (Sick et al., 1996; Xia et al., 
2004). The recombinant chIFN-α expresses a protein of 21 kDa in size (Xia et al., 
2004). It induces antiviral effects in many chicken viral diseases, such as influenza, 
Marek’s disease virus, Newcastle disease virus, infectious bronchitis virus and 
infectious bursal disease virus (Levy et al., 1999; Marcus et al., 1999; Browne et al., 
2001; Pei et al., 2001; Xia et al., 2004). On the other hand, many avian viruses have 
evolved mechanisms to evade the effects of the endogenous interferon-alpha, 
secreted inside the bird’s body (see Section 5.1.3). These mechanisms are mainly 
exerted via expression of viral proteins that have the ability to interrupt the 




interferon-alpha signalling (Huang et al., 2003; Eldaghayes et al., 2006; Xing et al., 
2008). 
 
Chicken interferon-beta (chIFN-β) up-regulation plays a crucial role in the antiviral 
innate immune response. In chickens, infection with highly pathogenic avian 
influenza (HPAI) leads to the up-regulation of both TLR3 and chIFN-β mRNA 
(Karpala et al., 2008). This up-regulation was detected in the brains, lungs and 
spleens of infected birds 24 hr after infection (Karpala et al., 2008). In mammals, the 
up-regulation in IFN-β expression is associated with Toll-like receptor-3 (chTLR-3). 
Consistently, knock-down of chicken Toll-Like Receptor-3 (chTLR-3) from the DF-
1 cell line leads to down-regulation of both TLR3 and chIFN-β at the transcriptional 
level (Karpala et al., 2008). 
 
The chicken interferon-gamma (chIFN-γ) gene has 30-35% sequence homology with 
its mammalian counterpart (Schultz et al., 2004). The molecular weight of native and 
recombinant chIFN-γ protein varies from 17 to 27 kDa. This difference in molecular 
weight is attributed to differences in the expression systems used in the various 
studies; E. coli, chicken embryo cells or CD4+ IFN-γ high hybridoma culture 
supernatant (Song et al., 1997).  
 
Recombinant chIFN-γ was originally cloned from a chicken T-cell hybridoma and 
the chicken T cell line “855”, and the clones were used for studying its biological 
activity (Weining et al., 1996; Song et al., 1997). The result of these studies showed 
that chIFN-γ has antiviral properties, including the ability to induce activation of 
macrophages resulting in up-regulation of both MHC class I and class II expression 
and nitric oxide secretion (Weining et al., 1996; Song et al., 1997). Additionally, it 
up-regulates the guanylate binding protein (GBP) and IRF-1 in chicken T-cell lines 
and chick embryo cells (Weining et al., 1996).  
 
The chicken interferon lambda (chIFN-λ) is poorly characterised in birds. In 
mammals, it has common biological properties with type I interferon such as the 




signalling pathway and involvement in the antiviral response evoked by TLRs 
stimulation (Zhou et al., 2007; Ank et al., 2008).  
 
5.1.2 Avian interferon pathway 
Until now, there has been no direct evidence that the avian interferon-alpha pathway 
is similar to its mammalian counterpart. In mammalians, the interferon pathway 
initiates when IFN-α binds to its specific receptor, interferon-alpha receptor 
(IFNAR). Once binding is established on the surface of the target cells, the induction 
of the interferon stimulated genes (ISGs) are enhanced. Interferon stimulated genes 
factor 3 (ISGF3) translocates from the cytoplasm into the nucleus and binds to the 
IFN-stimulated regulatory element sequence (ISRE). This binding promotes the 
induction of a variety of IFN-α inducible genes including; antiviral proteins such as 
2'5'oligoadenylate synthetase (2'5'OAS), protein kinase RNA (PKR), Mx1 proteins 
and transcriptional regulators such as IRF7. Interferon regulatory factor 7 is induced 
upon interferon treatment and is activated and phosphorylated as a part of the innate 
immune response to virus pathogen associated molecular patterns (PAMPs) such as 
double stranded RNA (dsRNA) or single stranded RNA (ssRNA). IRF7 forms a 
homodimer with itself and binds to the interferon promoter to induce the production 
of interferon-alpha. The later binds with IFNAR and initiates the pathway again in 
positive feedback mechanism between IRF7 and IFN-α (Figure 5.1) (Haller et al., 
2007). 
 
The interferon-inducible chicken Mx1 gene contains an interferon-inducible motif 
(ISRE) in its promoter. This motif is functionally active in chicken and monkey cells 
(Schumacher et al., 1994). The activation of the ISRE motif can be induced by 
various stimuli, such as exogenous interferon, poly (I:C) or NDV stimulation of 
chicken cells (Schumacher et al., 1994). Another defined DNA sequence motif that 
confers interferon inducibility, is known as the interferon consensus sequence (ICS). 
The chicken ICS motif is present in the sequence from 174 to 194 of the MHC class I 
gene BF-IV and can function as an interferon-inducible promoter (Zoller et al., 
1992). In murine models, comparison between ICS motif and ISRE motif revealed 




that ICS confers lesser interferon inducibility than the ISRE motif of the mammalian 




Figure 5.1: IFN-α induced mammalian antiviral pathway. Figure illustrates 
an IFN-α induced antiviral pathway, in which IFN-α binds to its specific 
receptor, interferon-alpha receptor (IFNAR). This binding results in activation 
of the JAK-STAT pathway, as interferon stimulated genes factor 3 (ISGF3) 
translocates from the cytoplasm into the nucleus. ISGF3 binds to IFN-
stimulated regulatory element sequence (ISRE), and this binding promotes the 
induction of a variety of IFN-α inducible genes and transcriptional regulators 
such as IRF7. Interferon regulatory factor 7 binds to the interferon promoter to 
induce the production of interferon-alpha. The later binds IFNAR and initiates 
the pathway again in positive feedback mechanism between IRF7 and IFN-α 
(Haller et al., 2007). 
 
5.1.3 Avian viruses and chIFN-α down-regulation 
NS1, non structural 1 protein, from influenza virus, is a potent example of an 
interferon-alpha antagonist. Hence, infection of chicken macrophages with H9N2, a 
low pathogenic avian influenza strain, caused marginal down-regulation of the 
antiviral Mx1 protein. However, both the Mx1 and 2'5'oligoadenylate synthetase 
(2'5'OAS) genes were down-regulated in the lungs of infected chickens after 




infection with the same strain (Xing et al., 2008). Differences in the cytokine levels 
produced by wild-type H9N2 virus or the NS1 deletion virus were analysed in the 
chicken macrophage cell line HTC (Xing et al., 2009). Interestingly, the level of 
interferon up-regulation was higher in the case of the deletion mutant than that of the 
wild-type virus (Xing et al., 2009). Furthermore, vaccination of chickens with H5N1 
influenza strain possessing a truncated NS1 gene induced a protection against further 
challenges with a virulent wild-type H5N1 strain (Steel et al., 2009).  
 
Newcastle disease virus (NDV) is an avian paramyxovirus and a negative stranded 
RNA virus. NDV RNA encodes 6 proteins; NP, P, M, F, HN and L, as well as two 
proteins resulting from alternative RNA editing of P protein. These two proteins 
were named V protein and W protein. The V protein directly contributes to virus 
virulence through its inhibitory effect on chIFN-α (Huang et al., 2003; Alamares et 
al., 2010). The carboxyl terminal part of the V protein was found to be responsible 
for this inhibition through the degradation of STAT1 (Huang et al., 2003). 
Interestingly, the V protein derived from mesogenic NDV (moderate virulence) 
exhibits greater antagonistic effects on interferon, compared with the V protein 
derived from lentogenic NDV (low virulence) (Alamares et al., 2010). 
 
Avian reovirus is a double stranded RNA virus belonging to the reoviridae family. It 
causes many illnesses in chickens such as runting-stunting syndrome and viral 
arthritis syndrome. It is an immunosuppressive virus, and is also able to resist the 
antiviral effect of chicken interferon. The antiviral inhibitory effect of this virus is 
mainly due to one of the viral encoded proteins called σ A protein (Gonzalez-Lopez 
et al., 2003). This protein appears to have an essential role in the down-regulation of 
interferon-inducible genes through binding to double stranded RNA and negatively 
regulating the activity of PKR kinase. As a result of this, the presence of σ A protein 
in CEF cells confers protection of vaccinia virus from the antiviral effect following 
interferon treatment. 
 




Infectious bursal disease (IBDV), another double stranded RNA virus, infects 
chickens and causes immunosuppression due to depletion of B lymphocytes. There 
are different hypotheses regarding the role of IBDV in the modulation of the 
interferon response, in terms of being down-regulator or up-regulator. However, a 
few studies have concluded that different strains of IBDV have different mechanisms 
to block the host chIFN-α response (Ragland et al., 2002; Eldaghayes et al., 2006; Li 
et al., 2007). Comparisons of the ability of the virulent and very virulent strains of 
IBDV, F52/70 and UK661 to modulate chIFN-α response was undertaken; the 
virulent strain was found to be a non-inducer of type I interferon, whereas the very 
virulent strain can be considered as a negative regulator of the type I interferon 
responses (Eldaghayes et al., 2006). On the contrary, type I interferon was up-
regulated in spleen macrophages isolated from virulent IBDV infected chickens, 
particularly during the acute stage of infection (Kim et al., 1998). Chicken embryo 
cells infected with different MOI of Bursine-2, IBDV vaccine strain, has little or no 
induction of chIFN-α (Li et al., 2007). However, cytokine down-regulation in 
response to IBDV infection or vaccination requires further study. The IBDV protein 
or protiens responsible for modulation of the chicken cytokine response has yet to be 
identified. 
 
5.1.4 Herpesviruses and interferon-alpha down-regulation 
Herpesviruses usually have several strategies to protect themselves from the host 
immune response, especially the innate immune response. Many studies have 
reported herpesvirus encoded proteins that interfere at different levels of interferon 
signalling pathways, and few examples from them will be mentioned. 
 
UL41 or virus host shutoff protein (vhs) is considered one example of a herpesvirus 
encoded protein, which affects the innate immune response. Orthologs of UL41 acts 
as a virus host shutoff protein in many herpesviruses, such as HSV-1, PrV, HSV-2 
and herpesvirus papio 2 (HVP-2) (Fenwick and Owen, 1988; Kwong and Frenkel, 
1989; Bigger and Martin, 2002; Murphy et al., 2003). UL41 is a tegument protein 
and functions as an RNase that accelerates RNA degradation of cellular mRNAs 




(Elgadi et al., 1999). HSV-1 ∆vhs was more sensitive to recombinant interferon-
alpha (rIFN-α) and showed marked reduction in growth curves, compared with the 
wild-type virus (Pasieka et al., 2008). Similar results were also observed for HSV-1 
ICP0, where an ICP0 deletion mutant was hypersensitive to IFN-α treatment 
(Mossman et al., 2000). As a result, the treatment with IFN-α caused marked 
reduction in the virus titre which equated to an overall 1000 fold reduction 
(Mossman et al., 2000).  
  
VZV ORF63 plays a major role in the ability of VZV to suppress the host innate 
immune response (Ambagala and Cohen, 2007). One function of ORF63 is to inhibit 
the phosphorylation of the eukaryotic initiation factor-2α (eIF-2α), which is an 
essential process for inhibiting virus protein translation inside the cell. 
 
EBV LF2 is a tegument protein that can evade the host immune response, through 
blocking IFN-α production (Wu et al., 2009b). LF2 protein binds directly to the C-
terminal transactivation domain of IRF7, which is responsible for formation of IRF7 
homodimers. Therefore, the binding of LF2 to IRF7 inhibits the formation of IRF7 
homodimers and subsequently interferes with the transcriptional role of this dimer in 
initiating the innate immune response (Wu et al., 2009b). BZLF-1, an immediate 
early EBV protein, down-regulates IRF7 activity and as such the virus is able to 
tolerate the antiviral host response during lytic infection (Hahn et al., 2005). This 
down-regulation of IRF7 activity is as a result of the direct binding between the two 
proteins and the formation of IRF7/ BZLF-1 complex. 
 
To better understand the MDV pathogenesis, it is necessary to carry out functional 
assays. These assays should aim to study how MDV proteins are involved in 
modulating the host immune response. While the mechanism of immune evasion is 
not yet understood, it is likely that MDV, similar to other herpesviruses, evades host 
immune responses by encoding viral protein(s), which interact with the host 
interferon pathway. 
 




As mentioned previously (see Section 1.7.1c), there is some evidence for the down-
regulation of interferon-alpha during the course of MDV infection. Thus, it was 
decided to study host pathogen interactions between MDV proteins and interferon-
alpha signalling pathway.  
 
5.1.5 Aim 
The aim of the work presented in this chapter was to screen MDV proteins for 
inhibition of chIFN-α signalling. Potential antagonists of the chIFN-α signalling 
pathway will be studied in more detail, with an aim to describe the mechanisms 
behind chIFN-α inhibition. These candidates may later be considered as targets for 
vaccine development companies and the drug designer, in order to control the 
problem of MDV infections. 
 
5.2 Results 
5.2.1 The optimisation of the chIFN-α dose required to initiate IFN-α 
signalling  
As mentioned in Section 5.1, the interferon-alpha signalling pathway is interferon-
alpha-dependent pathway. In order to optimise the proper concentration of chIFN-α 
required for priming the interferon-alpha signalling pathway, a dose titration 
experiment was performed. Briefly, DF-1 cells were seeded in 48 well plates with 
5x104 cells per well 24 hr before transfection. When the cells reached 70-80% 
confluency, they were transfected with 90 ng of eGFP_pCR3 expression vector, 10- 
ng of Renilla luciferase and 50 ng of a reporter construct containing the chicken 
ISRE motif in the upstream region of firefly luciferase. The transfection reaction was 
prepared as detailed in Section 2.2.1. After 48 hr, the cells were stimulated with 
conditioned media containing different amounts of chIFN-α: 100U, 500U and 
1000U. The experiment was carried out in triplicate for each dose concentration and 
3 transfected wells were left as control without any interferon-alpha treatment. After 
15 hr of chIFN-α treatment, the cells were harvested and lysed. The luciferase signal 




was measured using the dual luciferase assay system (Promega) and the relative 
luciferase units (RLU) were calculated. All the luciferase values were normalised to 
the non-interferon treated samples, which represent basal interferon activity and is 
arbitrarily given a value of one. As shown in Figure 5.2.1, the amount of 1000U of 
chIFN-α induced the highest level of ISRE activation, which was around an 18 fold 





Figure 5.2.1: Dose-dependent induction of the chicken Mx1 promoter. 
Luciferase reporter assay was performed using the ISRE promoter reporter 
construct. DF-1 cells were seeded and transiently co-transfected with 
eGFP_pCR3 vector, Renilla luciferase vector and ISRE reporter vector. 
Transfected cells were grown for 48 hr prior to stimulation with different 
concentrations of chIFN-α (1000U, 500U, 100U and 0U), in triplicate. Cells 
were lysed after 15 hr following interferon treatment. Dual luciferase assay was 
performed. Values expressed as a fold difference relative to the eGFP non-
interferon treated samples value which is given an arbitrary value of 1. 




5.2.2 Effect of transient expression of individual MDV proteins on the 
inducibility of the ISRE motif of the chicken Mx1 promoter following 
chIFN-α treatment 
To identify possible interferon-alpha antagonists encoded by the MDV genome, a 
reporter assay screen was carried out. The screen aimed to identify the effect of the 
expression of MDV proteins on the inducibility of the chicken ISRE motif after 
chIFN-α treatment. DF-1 cells grown in 48 well plates were transfected with chicken 
ISRE pHIIα firefly luciferase as a reporter construct and Renilla luciferase construct 
(pRLTK) as an internal transfection control, together with the individual MDV genes 
cloned into pCR3 expression vector (see Chapter 3). DF-1 cells were seeded in thirty 
six 48 well plates 24 hr before transfection. From each plate the internal 24 wells 
were used only to avoid an edge effect. The cells were transfected with the DNA 
transfection complex, composed of 90 ng DNA of the expression clone, 50 ng DNA 
of the ISRE reporter construct and 10 ng DNA of Renilla luciferase (pRLTK) 
plasmid per well. The transfection reaction was prepared as detailed in Section 2.2.1. 
Each of MDV genes was transfected in six wells. Forty eight hours post transfection, 
three wells were treated with conditioned media containing 1000U of recombinant 
chIFN-α. The other three wells were left without interferon treatment as a non-
stimulated control.  
 
Fifteen hours after the addition of chIFN-α, the cells were harvested and lysed. The 
firefly luciferase and Renilla signals were measured using the dual luciferase system. 
Transfection of the eGFP plasmid was used as a control for the normal basal level of 
interferon-alpha response.  
 
All of the obtained luciferase values were normalised to the average of the eGFP 
interferon-treated samples value, which represents the normal activity and is 
arbitrarily given a value of one (see Appendix E). As shown in Figure 5.2.2, the 
results of the screen were plotted collectively, and the statistical analysis showed 11 
MDV genes with significant down-regulation of the ISRE reporter. However, the 
cut-off level was placed below 0.5 fold of inhibition to minimise the number of the 




hits. This screen discovered that from 106 tested genes; only 6 genes from the both 
MDV strains showed a decrease in ISRE interferon inducibility and that these genes 
gave values lower than the cut-off level. These genes were Meq, LMeq, UL50CVI, 
UL50RB-1B, UL12 and UL26. Both Meq and LMeq are considered homologues but 
with different reading frames in RB-1B virulent strain and CVI988 vaccinal strain, 
respectively. UL50, UL12 and UL26 encoded the dUTPas, deoxyribonuclease and 













Figure 5.2.2: Identification of MDV proteins blocking interferon-alpha induced activation of the chicken Mx1 promoter. DF-1 cells were 
seeded and transiently co-transfected with the individual MDV genes or eGFP_pCR3 vector, plus ISRE reporter constructs and Renilla luciferase as 
an internal control. Transfected cells were grown for 48 hr prior to stimulation with 1000U of chIFN-α for each well. Cells were lysed and dual 
luciferase assay was performed. Values were normalised to Renilla luciferase and then expressed as a fold difference relative to the eGFP interferon-
treated samples value, which is given an arbitrary value of 1. The white bars represent the non-interferon treated samples while the grey bars 
represent the interferon-treated samples. The red line represents the cut-off level 0.5. The statistical analysis was done using Welch’s T test 
(*P<0.05). 




5.2.3 Confirmation of the chIFN-α antagonists 
To confirm the ISRE reporter assay screen results (see Section 5.2.2), the positive 
hits from the screen were retested in an independent experiment. DF-1 cells were 
seeded in 48 well plate with 5x104 cells per well, 24 hr before the transfection. When 
the cells reach to 70-80% confluency, the five MDV genes, UL26, UL50, Meq, 
LMeq and UL12, were transfected in combination with firefly ISRE reporter and 
Renilla reporter. Forty eight hour later, the cells were treated with conditioning 
media containing 1000U of chIFN-α for each well. For each gene, three wells were 
left without interferon treatment as a non-stimulated control. The cells were lysed 
after 15 hr and the luciferase signal was measured using dual luciferase assay system. 
 
As shown in Figure 5.2.3, the result of this independent reporter assay confirmed that 
all of the hits were reproducible and showed reduction in the response of the ISRE 
motif. The down-regulation was below or around the 0.5 cut-off level for all. Both 
Meq and LMeq seemed to be the most inhibitory interferon antagonists for the 





















Figure 5.2.3: Confirmation of the chIFN-α antagonists. Luciferase reporter 
assay was performed using the ISRE promoter reporter construct. DF-1 cells 
were transiently co-transfected with UL50_pCR3, Meq_pCR3, LMeq_pCR3, 
UL26_pCR3, UL12_pCR3 or eGFP_pCR3 vector, plus ISRE reporter 
constructs and Renilla luciferase as an internal control. Transfected cells were 
grown for 48 hr prior to stimulation with 1000U of chIFN-α for each well. Cells 
were lysed and dual luciferase assay was performed. Values were normalised to 
Renilla luciferase and then expressed as a fold difference relative to the eGFP 
interferon-treated samples value, which is given an arbitrary value of 1. 
 
5.2.4 Investigation of the expression of the MDV-interferon antagonists 
in DF-1 cell line 
The findings outlined in Section 5.2.2 and Section 5.2.3 demonstrated that Meq, 
LMeq, UL26, UL50 and UL12 act as negative regulators for type I interferon 
signalling transduction. To study this finding in more detail, it was neccessary to 
confirm if these genes are truly expressed in the DF-1 cell line or not. To assess this, 
the entry clones of the seven genes were sub-cloned into an HA N-terminal-tagged 
pCR3 expression vector using Gateway® technology (as described in Section 3.2.4c). 
DF-1 cells were seeded in 24 well plates at a seeding density 1x105 cells per well. 
After 24 hr, the cells were transfected with 500 ng of the expression vector of each 
gene. The transfection reaction was prepared as detailed in Section 2.2.2. Forty eight 
hours later the cells were lysed. Total cell lysates were harvested and subjected to 
SDS-PAGE, and immunoblotting using anti-HA primary antibody followed by HRP-




conjugated goat anti-rat secondary antibody. All the indicated genes were 
successfully expressed at the expected sizes (Figure 5.2.4). Meq and LMeq expressed 
protein products at or above 64 kDa in size, respectively. UL50 expressed a protein 
product of 50 kDa in size, and UL12 expressed a protein product of 55 kDa 
approximately. Finally, UL26 expressed a cleaved protein product of 36 kDa in size.  
 
 
Figure 5.2.4: Transient expression of MDV interferon-alpha antagonists in 
DF-1 cell line. DF-1 cells were seeded and transiently transfected with 
MDV_Meq, MDV_LMeq, MDV_UL50, MDV_UL12 and MDV_UL26 cloned 
in HA tagged N-terminal pCR3 expression vector. Cells were grown for 48 hr, 
and then harvested and lysed. The cell lysates were subjected to SDS-PAGE 
and immunoblotting using anti-HA primary antibody followed by HRP-
conjugated goat anti-rat secondary antibody. 
 
5.2.5 Meq and LMeq reduce interferon inducibility of the ISRE motif in a 
dose-dependent manner 
As shown in Sections 5.2.2 and 5.2.3, Meq and LMeq were able to repress the 
interferon responsiveness of the chicken ISRE motif. In order to assess whether 
Meq’s and LMeq's ability to repress the interferon responsiveness of chicken ISRE 
motif was specific, another reporter assay was carried out. In this experiment, DF-1 
cells were seeded in 48 well plates at a cell density of 5x104 cells per well 24 hr 
before transfection. Thereafter, the cells were transfected with different 
concentrations of Meq and LMeq (90 ng, 45 ng, and 22.5 ng), in addition to ISRE 
firefly reporter construct (50 ng) and Renilla luciferase (10 ng) as an internal control. 
The transfection reaction was prepared as described in Section 2.2.1. eGFP pCR3 
was used as a control plasmid and serves to normalise the total amount of DNA in 




the transfection complex. Forty eight hours later, cells were treated with 1000U of 
chIFN-α and the luciferase signal was measured after 15 hours. All of the luciferase 
values were normalised to the eGFP transfected and interferon-treated samples, 
which represent the normal activity and is arbitrarily given a value of one.  
 
As shown in Figures 5.2.5a, b, both Meq and LMeq expression robustly antagonise 
interferon-alpha inducibility of the ISRE motif in a dosage-dependent manner.  







Figure 5.2.5a, b: Meq (RB-1B) and LMeq (CVI988) inhibit the induction of 
ISRE by chIFN-α in dose dependent manner. DF-1 cells were transfected 
with firefly ISRE reporter and Renilla pRLTK plasmids together with different 
concentrations of either Meq (a) or LMeq (b). At 48 hours post transfection, 
cells were treated with 1000 U of chIFN-α. Cells were harvested and lysed 15 
hr later and luciferase activity was measured by a dual-luciferase reporter assay. 
All the data were normalised to Renilla luciferase activity. Results are the 
average of 3 samples. The white bars represent the non-interferon-treated 
samples while the grey bars represent the interferon-treated samples. 




5.2.6 UL50 (dUTPase), UL26 (capsid scaffold) and UL12 (DNAse) 
proteins do not block activity of the ISRE response element in a dose-
dependent manner. 
As shown in Sections 5.2.2 and 5.2.3, MDV encoded dUTPase (UL50), DNAse 
(UL12) and capsid scaffold (UL26) proteins were able to repress the interferon 
responsiveness of chicken ISRE motif. In order to assess if these results were 
specific, a second and independent reporter assay was performed. In this experiment, 
DF-1 cells were seeded at a cell density of 5x104 in two 48 well plates 24 hr before 
transfection. Thereafter, cells were transfected with different concentrations of 
UL50, UL12 or UL26 (90 ng, 45 ng and 22.5 ng), with constant concentration of the 
ISRE firefly reporter construct and Renilla luciferase as an internal control. The 
transfection reaction was prepared as described in Section 2.2.1. 48 hr post 
transfection, cells were treated with 1000U of chIFN-α per well and the luciferase 
signal was measured after 15 hr. The different concentrations of DNA were 
transfected in six wells of a 24 well plate and tested in triplicates with or without 
interferon-alpha treatment. All of the luciferase values were normalised to the eGFP 
transfected and interferon-treated samples, which represent the normal activity and is 
arbitrarily given a value of one. These three reporter assays failed to show interferon 
signalling inhibition in a dosage-dependent manner for the three proteins UL50, 
UL12 or UL26 (Figure 5.2.6a, b and c). 
 






Figure 5.2.6a: Transient expression of UL50 down-regulates ISRE 
responsiveness in non-dose dependent manner. DF-1 cells were transfected 
with firefly ISRE reporter and Renilla pRLTK plasmids together with different 
concentrations of UL50 (90 ng, 45 ng and 22.5 ng). At 48hours post 
transfection, cells were treated with 1000U of chIFN-α. Cells were harvested 
and lysed 15 hr later and luciferase activity was measured by a dual-luciferase 
reporter assay. All the data were normalised to Renilla luciferase activity. 
Results are an average of 3 samples. The white bars represent the non-interferon 
treated samples while the grey bars represent the interferon-treated samples. 
 






Figure 5.2.6b: Transient expression of UL26 down-regulates ISRE 
responsiveness in non-dose dependent manner. DF-1 cells were transfected 
with firefly ISRE reporter and Renilla pRLTK plasmids together with different 
concentrations of UL26 (90 ng, 45 ng and 22.5 ng). At 48hours post 
transfection, cells were treated with 1000U of chIFN-α. Cells were harvested 
and lysed 15 hr later and luciferase activity was measured by a dual-luciferase 
reporter assay. All the data were normalised to Renilla luciferase activity. 
Results are an average of 3 samples. The white bars represent the non-interferon 






















Figure 5.2.6c: Transient expression of UL12 down-regulates ISRE 
responsiveness in non-dose dependent manner. DF-1 cells were transfected 
with firefly ISRE reporter and Renilla pRLTK plasmids together with different 
concentrations of UL12 (90 ng, 45 ng and 22.5 ng). At 48hours post 
transfection, cells were treated with 1000U of chIFN-α. Cells were harvested 
and lysed 15 hr later and luciferase activity was measured by a dual-luciferase 
reporter assay. All the data were normalised to Renilla luciferase activity. 
Results are an average of 3 samples. The white bars represent the non-interferon 
treated samples while the grey bars represent the interferon-treated samples. 
 
 
5.2.7 Meq N-terminal DNA binding and nuclear localisation domain 
responsible for down-regulation of chIFN-α response 
From the above mentioned results, Meq and LMeq were the only MDV protein 
candidates which functioned as interferon-alpha antagonists in a dosage-dependent 
manner (see Section 5.2.5). The Meq protein is composed of 339 amino acids in the 
virulent strains. It contains a basic leucine zipper (bZIP) domain near its N-terminus 
and a proline-rich domain near its C-terminus (Jones et al., 1992; Qian et al., 1995). 
Moreover, Meq contains two additional basic regions (BR1 and BR2) near the N-




terminus, which also contain the nuclear localisation signals (Lee et al., 2003). In 
CV1988 and the attenuated JM strain, Meq is a slightly longer and termed LMeq, in 
which a 180-bp sequence is inserted in the proline rich region. 
 
To identify the Meq domain responsible for the down-regulation of the chIFN-α 
response, a further reporter assay was carried out. In this reporter assay, three Meq 
mutants were used (kindly supplied as a gift from Dr Yoshihiro Izumiya, UC Davis 
cancer centre, USA). These mutants encode different parts of the Meq structure, and 
they were named N-151, C-151 and C-25. N-151 encodes the 151 N–terminus amino 
acids, C-151 encodes 189 C–Terminus amino acids, while C-25 encodes 315 C-
terminus amino acids. DF-1 cells were transfectd with chicken ISRE pHIIα firefly 
luciferase plasmid as a reporter construct and the Renilla PRLTK plasmid as an 
internal transfection control together with the each of the mutants. DF-1 cells were 
seeded in 48 well plates and transfected with the DNA transfection complex after 24 
hr. The DNA transfection complex was composed of 90 ng DNA of Meq mutant, 50 
ng DNA of reporter construct and 10 ng DNA of pRLTK plasmid per well. The 
transfection reaction was prepared as detailed in Section 2.2.1. At 48 hours post 
transfection, the interferon-alpha pathway was primed with 1000U of chIFN-α per 
well. Fifteen hours later, the firefly luciferase and Renilla signals were measured 
using dual luciferase system. eGFP plasmid was used as a control open reading 
frame for the normal level of interferon-alpha response. The results were shown as 
the following; all the luciferase values were normalised to the average of eGFP 
interferon-treated samples value, which represents the normal activity and is 
arbitrarily given a value of one. 
 
As shown in Figure 5.2.7, C-25 gave the same degree of down-regulation as the 
wild- type Meq. N-151 mutant gave some degree of down-regulation, but it was not 
equal to the wild-type, whereas C-151 did not retain any function as an interferon-
alpha antagonist and gave a response equal to the control. From this data, it is clear 
that the last 189 C–Terminus amino acids and the first 25 N-terminal amino acids 
have no role in blocking interferon-alpha pathway. The sequence, which has a role in 




down-regulation of interferon-alpha pathway, was identified as being located 
between amino acids 25 and amino acids 151. 






Figure 5.2.7: Meq N-terminal domain is mandatory for down-regulation of 
chIFN-α. DF-1 cells were transfected with firefly ISRE reporter and Renilla 
pRLTK plasmids together with different structural mutants of Meq DNA. Cells 
were grown for 48 hr prior to stimulation with 1000U of chIFN-α per well. 
After 15 hr of treatment, cells were lysed and dual luciferase assay was 
performed. All the data were normalised to Renilla luciferase activity. The 
white bar represents the non-interferon treated control while the grey bars 
represent the interferon-treated control and samples. 





Previous studies examining the function of MDV proteins have focused on knocking-
out virus genes from the MDV genome, using BAC technology (Cui et al., 2005a; 
Jarosinski et al., 2007b; Lee et al., 2008; Cui et al., 2009). The constructed knock-out 
mutants were then tested in vitro and in vivo for their ability to induce lytic and latent 
infection. This study tested the ability of individual MDV genes to repress the 
interferon-alpha pathway in a single gene setting. By setting up a screen based on the 
dual luciferase reporter assay system, it was possible to identify MDV proteins that 
were able to down-regulate innate immune response, represented in chIFN-α 
signalling in DF-1 cells in vitro. 
 
5.3.1 MDV and interferon-alpha response  
MDV is an oncogenic disease which affects chickens. It is characterised by multiple 
stages of infection starting from lytic infection, latent infection through to tumour 
formation. To maintain a latent inside host cells, it has been suggested that MDV 
employs a mechanism that down-regulates innate and cell-mediated immune 
responses. 
 
Interestingly, previous studies have revealed a reduction or absence in chIFN-α 
transcripts in spleen tissue from MDV infected birds (Xing and Schat, 2000a; Heidari 
et al., 2008b). Additionally, a blockage in the chIFN-α response to Newcastle disease 
vaccine has also been observed after infection with oncogenic MDV (Quere et al., 
2005).  
 
Most of herpesviridae members encode proteins that act as repressors of the innate 
immune response (Mossman et al., 2000; Pasieka et al., 2008; Wu et al., 2009b). 
Until now there have been no studies which show evidence of interactions between 
MDV encoded genes and the innate immune response. This study investigated the 
effects of MDV proteins on interferon-alpha signalling. A chicken fibroblast cell line 
was used as a model for the host interferon response, since it has been previously 




tested for interferon-alpha inducibility by Schumacher and colleagues (Schumacher 
et al., 1994). The same reporter used in their study, identified five potential genes 
that can down-regulate the interferon responsiveness in our screens. These genes 
were Meq, LMeq, UL50, UL12 and UL26.  
 
5.3.2 Meq and LMeq are inhibitors of the interferon-alpha pathway 
Meq is the main MDV-oncoprotein (Liu et al., 1998; Gimeno et al., 2005; Brown et 
al., 2006), and is highly expressed in MDV-transformed T cells (Ross et al., 1997; 
Liu et al., 1998). It can independently transform Rat-2, NIH3T3 and DF-1 cell lines 
(Liu et al., 1998; Levy et al., 2005; Ajithdoss et al., 2009). Recombinant virulent 
MDV lacking Meq (rMdV5ΔMeq) provides birds with protection higher than the 
protection provided by the rispens vaccine strain (Lee et al., 2008). 
 
In the MDV chIFN-α screen, Meq and its homologue in the vaccinal strain LMeq 
were the most potent down-regulators of the interferon response of the chicken ISRE 
promoter. This effect occurred in a dose-dependent manner, indicating the specificity 
and reproducibility of the result. The Meq transactivation domain exists in the C-
terminal proline rich domain, located between 129 to 339 amino acids (Qian et al., 
1995). This C-terminal domain contains two and a half repeats of proline rich 
sequences, located between 146 to 251 amino acids (Qian et al., 1995). The N-
terminal region contains 2 basic regions (BR1 and BR2) and a leucine zipper 
domain. This domain of Meq is mainly responsible for the nuclear and nucleolar 
localisation of the protein (Liu et al., 1997; Lee et al., 2003), in addition to its DNA 
binding affinity (Qian et al., 1996; Ajithdoss et al., 2009). This study found that the 
sequence required for down-regulation of the chIFN-α pathway is located between 
amino acids 25 to 151. Furthermore, the C-terminal transregulatory domain, 
encoding the proline rich repeat, has no down-regulatory effect when it is transfected 
alone. Additionally, the first N-terminal 25 amino acids were not required for the 
down-regulation. Based on these findings it is more likely that the interferon 
antagonistic function requires either a Meq nuclear localisation signal, DNA binding 
activity or that this region contains a novel function responsible for the down-




regulation. Interestingly, another leucine zipper encoded protein in the herpesvirus 
family down-regulates interferon-alpha response (Hahn et al., 2005). BZLF-1, an 
EBV lytic protein, down-regulates the interferon-alpha pathway. This effect is 
exerted through interfering with IRF7 function. Although, BZLF-1 is a lytic protein, 
compared to Meq which is predominately latent, both are structurally related to one 
another.  
 
5.3.3 UL50 encoded protein is a negative regulator of the interferon-
alpha pathway in the virulent and the vaccinal strains 
UL50 from the two strains, CVI988 and RB-1B, are almost identical, with the only 
differences located in the amino acids 2, 74 and 391. Hence, the aspartic acid, lysine 
and arginine in the CVI988 mutated to asparagine, arginine and glycine in RB-1B. 
MDV-UL50 encoded protein contains a dUTPase like domain, which is an important 
enzyme for DNA replication and repair. Although, dUTPase encoded proteins are 
present in many mammalian and avian herpesviruses (Fuchs et al., 2000; Zhao et al., 
2008), they may play different roles in the different viruses. An ortholog of UL50 is 
an early gene in duck enteritis virus (DEV), and it is expressed in both the nucleus 
and cytoplasm (Zhao et al., 2008). In infectious laryngeotracheitis, it is a non-
essential gene, and therefore not required for virus replication (Fuchs et al., 2000). 
Since there are no published data on the role of UL50 in MDV, this study provides 
the first evidence for the role of this gene in MDV. It was observed that the two 
genes cloned from the both strains were able to down-regulate the interferon-alpha 
responsiveness of the ISRE motif. However, this effect was not dose-dependent; 
indicating that even low expression levels of this protein is enough to induce the 
repression seen. Interestingly, the dUTPase encoded LF2 gene in EBV has been 
reported to have a similar effect on the interferon-alpha pathway (Wu et al., 2009b). 
LF2 is able to exert this effect through binding to IRF7 and interfering with the 
formation of IRF7-IRF7 homodimer complex (Wu et al., 2009b). Thus, it is very 
likely that both viruses use the dUTPase encoded proteins in order to evade the 
innate immune response during virus infection and latency. The mechanism behind 
this in MDV remains to be determined.  




5.3.4 UL26 and UL12 encoded protein are negative regulators of the 
interferon-alpha pathway  
UL26 is a capsid cleavage protein in many avian and mammalian herpesviruses 
(Weinheimer et al., 1993; Haanes et al., 1995; Dezelee et al., 1996; Kut and 
Rasschaert, 2004). It contains a protease domain near its N-terminal, which has 
proteolytic activity. The UL26 sequence also encodes another ORF at its C-terminal, 
named UL26.5, which has no protease domain. UL26.5 protein also exerts down-
regulation, although slightly above the cut-off level. This indicates that the effect of 
UL26 in the screen has no relation to its proteolytic activity and that it is most likely 
due to activities within its C-terminal sequence. However, UL26 down-regulation of 
ISRE responsiveness was not dose-dependent, although these results could indicate 
that this effect needs only low level of the protein. There is no previous evidence of 
involvement of UL26 in the host immune response against herpesviridae, except in 
case of HSV-1, where mutant virus lacking UL26 was attenuated and produced 
efficient immune response in inoculated mice (Hippenmeyer et al., 1997).  
 
The UL12 protein product has deoxyribounclease activity. It is an early gene in 
HSV-1 and PrV, although it has been defined as a late gene in BoHV-1 (Desloges 
and Simard, 2001). In the experiment reported here, UL12 induces down-regulation 
of the ISRE responsiveness. There is no recorded evidence for UL12 having a role in 
herpesvirus immune modulation. However, this could be the initial evidence for the 
role of this gene in modulation of the interferon response for MDV. 
 
More than one MDV gene has been shown to interact with the interferon-alpha 
signalling pathway and is mainly immediate early or early kinetics. Expression of 
immune suppressors at an early stage may facilitate cell infection of the virus. 
Another interesting finding is that most of the identified proteins function as 
enzymes for DNA repair and metabolism. Although, it is not clear whether this is a 
coincidence or the fact that the integrity of the viral DNA is required for interferon 
blockage function. Finally, the only proteins exerting a dose-dependent chIFN-α 
down-regulation were Meq and its homologue in the vaccinal strain LMeq. 




Therefore, it was decided to focus on Meq protein to investigate the mechanism 
behind this down-regulation.  





Elucidation of the role of Meq in the down-regulation 
of the interferon-alpha response  
6.1 Introduction 
Stimulation of the JAK-STAT interferon-alpha-dependent pathway results mainly in 
the production of two groups of antiviral factors. The first group act directly against 
viral infections. A classic example is Mx1 protein, which has an antiviral effect 
against Influenza virus, especially the strains of avian origin (Dittmann et al., 2008). 
The second group of the antiviral factors consists of transcriptional regulators such as 
interferon regulatory factors (IRFs), which regulate multiple aspects of the cell 
physiology including interferon production.  
 
Many viruses encode inhibitors of JAK-STAT signalling pathway. These inhibitors 
can hinder the pathway either up- or down-stream level of ISRE promoter activation. 
An up-stream effect could be through interference with any stage of the pathway 
preceding ISRE activation such as the IFN-α receptor or one of the STAT proteins. 
One example is the paramyxovirus family V protein which targets the STAT proteins 
for proteasomal degradation by forming a STAT-ubiquitin ligase complex (Nishio et 
al., 2005; Ulane et al., 2005). Down-stream effects occur either via hindering the 
antiviral cytokines or the interferon regulatory factors. For example, the NS protein 
of the Rift Valley fever virus which is capable of inducing degradation of the PKR 
protein in a proteasome-dependent manner (Ikegami et al., 2009). Moreover, many 
viruses, particularly herpesviruses, negatively regulate IFN-α response through direct 
down-regulation of IRF7 at different levels. 
 
6.1.1 Interferon regulatory factors (IRFs) 
Up to now, only nine IRFs (IRF1, IRF2, IRF3, IRF4, IRF5, IRF6, IRF7, IRF8 and 
IRF9) have been identified in mammals. Their DNA structure is characterised by the 
presence of a conserved N-terminal DNA binding domain and a C-terminal IRF-




association domain. They are considered a group of transcription factors which 
mainly regulate immune signalling pathways, particularly interferon, chemokine, and 
proinflammatory cytokine signalling pathways. Their role in the signalling processes 
is exerted via binding with themselves and/or different adaptor molecules, which are 
important for the signalling pathways, such as TRIF, TRAF6 and MyD88 (Honda et 
al., 2004b; Takaoka et al., 2005; Honda and Taniguchi, 2006). Once binding occurs, 
the complex translocates from the cytoplasm to the nucleus and binds with IRF 
recognition sequences in the promoters of the interferon or interferon-inducible 
genes. For example, IRF9 binds to the STAT1 and the STAT2 proteins forming the 
interferon stimulated gene factor- 3 (ISGF3) complex. ISGF3 then binds to the ISRE 
sequence in the promoter of the interferon-inducible genes, thus inducing their 
transcription. However, not all of the IRFs are considered positive regulatory factors 
for  immune signalling, as IRF7 and IRF3 are (Lin et al., 2000). IRF2, for example, 
is considered a negative regulator via suppression of the expression of many 
immunomodulatory molecules such as IL4 and TR2. This suppression is exerted via 
directly binding to their promoter sites (Elser et al., 2002; Honda et al., 2004a; Sul et 
al., 2008). 
 
In addition, many IRFs play a direct or indirect role in other cellular regulatory 
processes, as reviewed in (Taniguchi et al., 2001; Savitsky et al., 2010). These 
regulatory functions include immune cell development and differentiation, cell cycle 
regulation, apoptosis and anti-oncogenesis (Taniguchi et al., 2001; Solis et al., 2006; 
Savitsky et al., 2010). 
 
6.1.2 Interferon regulatory factor 7 (IRF7) and its interaction with viral 
proteins 
Interferon regulatory factor 7 (IRF7) is considered as a key regulator for type 1 
interferons signalling, particularly IFN-α (Au et al., 1998; Lin et al., 2000; Ning et al., 
2005). It was initially described as a negative regulator for the Q promoter (QP) of 
EBV nuclear antigen-1 (EBNA-1) (Zhang and Pagano, 1997). Thereafter, the IRF7 
transactivating activity of IFN-α, particularly after virus infection, was confirmed 




(Au et al., 1998). It forms a heterodimeric complex with IRF3 or a homodimeric 
complex with itself, through its C-terminal domains, and binds with type 1 interferon 
promoters, particularly IFN-α promoter (Lin et al., 2000). Therefore, there is a 
positive feedback mechanism between IRF7 and type 1 interferon secretion, 
particularly IFN-α. Beside its role in interferon regulation, IRF7 exerts many other 
regulatory functions inside the cell. Recently, it has been suggested that IRF7 protein 
can contribute to the anti-tumour effector functions of macrophages (Solis et al., 
2006). The latter can be via down-regulation of the pro-angiogenic genes such as 
vascular endothelial growth factor gene (VEGF) and up-regulation of apoptotic 
genes such as tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), 
resulting in an increase in death of  tumour cells (Solis et al., 2006).                          
 
Due to the close relationship between type 1 interferons and IRF7, viruses can 
interfere with the innate immune response, particularly interferon response, via IRF7 
down-regulation. Many RNA and DNA viruses express proteins that modulate IRF7 
levels in order to escape the innate immunity. This modulation can happen at the 
RNA level via the negative regulation of IRF7 mRNA levels, as the LF2 protein of 
EBV (Wu et al., 2009b). Also, it could be at the protein level via negative regulation 
of IRF7 protein stability, as KSHV-RTA (Yu et al., 2005). Finally, it could be at the 
post translational level via affecting on IRF7 phosphorylation status, such as KSHV-
ORF45 (Zhu et al., 2002).  
 
6.1.3 Chicken interferon regulatory factor 7 (chIRF7)  
Chicken interferon regulatory factor 7 (chIRF7) was identified by Grant and 
colleagues as the first example of non-mammalian interferon regulatory factors 
(Grant et al., 1995). It was initially named chicken interferon regulatory factor 3 
(chIRF3), but higher DNA sequence homology with human IRF7 (33% to IRF3, but 
42% to IRF7) led to being renamed chIRF7 (Grant et al., 2000). Like human IRF7, it 
has an N-terminal DNA binding domain (DBD) and a C-terminal IRF association 
domain (IAD). The N-terminal DNA binding domain binds specifically to the ISRE 
sequence present in the promoter of the chicken Mx1 gene, where it binds as a 




homodimer and activates transcription (Grant et al., 1995; Grant et al., 2000). 
Therefore, the chIRF7 protein contributes in both interferon signalling and 
production processes. To date, there has been no study of the interplay between any 
avian viral protein and the chicken IRF7 (chIRF7). This study identifies a protein 
encoded by an avian virus that negatively regulates the chIRF7 level and therefore 
negatively regulates type 1 interferon production.  
  
6.1.4 Aim 
Viruses have evolved different strategies to interfere with components of the host 
immune system. The work described here identifies the mechanism behind Meq 
down-regulation for chIFN-α and in particular the interplay between Meq and 
chIRF7. This was achieved through investigation of Meq over-expression on both the 
RNA and protein levels of chIRF7. In addition, the localisation pattern of the two 
proteins, when they were co-expressed together in the same cell, was investigated. 
 
6.2 Results 
6.2.1 Transient expression of Meq or LMeq has no effect on the 
endogenous chIRF7 mRNA level 
The luciferase reporter assays described in Chapter 5 outlined Meq and LMeq as 
antagonists of chIFN-α. In order to determine if this antagonism is due to a direct 
effect on chIRF7, the mRNA levels of chIRF7 in the presence or absence of Meq or 
LMeq were investigated. DF-1 cells grown o/n in 48 well plate were transfected with 
each Meq, LMeq or eGFP, six wells each. The transfection was done as described in 
Section 2.2.1. After 48 hr, three wells were treated with 1000U/well of chIFN-α or 
left untreated. After 15 hr, total RNA was extracted and quantitative real-time PCR 
was performed to measure the chIRF7 mRNA levels (see Section 2.9.4). A standard 
house keeping gene, β-actin, was used as an internal control for data normalisation. 
The quantitative real-time PCR showed a strong up-regulation of chIRF7 in the 
chIFN-α-treated samples compared with untreated samples (Figure 6.2.1). The 




presence of Meq or LMeq did not influence the levels of chIRF7 mRNA in the 
untreated or the chIFN-α treated samples, compared to the eGFP transfected cells.  







Figure 6.2.1: Meq and LMeq have no effect on chIRF7 mRNA level. DF-1 
cells were transfected with either Meq (a) or LMeq (b). Transfected Cells were 
grown for 48 hr prior to stimulation with 1000U of chIFN-α per well. After 15 
hr from chIFN-α treatment, total RNA was extracted and one-step quantitative 
real-time PCR was performed. All data were normalised to β-actin as an 
internal control, and values were expressed relative to the eGFP interferon-
treated samples values. Grey bars represent the eGFP transfected samples while 
black bars represent the Meq (a) or LMeq (b) transfected samples. 




6.2.2 Cloning and expression of chicken interferon regulatory factor 7 
(chIRF7) 
These data (Section 6.2.1) indicate that the transient expression of Meq or LMeq has 
no effect on chIRF7 mRNA level. To investigate the effect of Meq expression on 
chIRF7 protein level and due to the lack of commercially available specific antibody 
for the chIRF7 protein, it was necessary to clone a construct encoding the DNA 
sequences of the chIRF7 in a tagged vector. Three chicken cDNA clones 
(pgr1n.pk007.g20, C0000892J09_T7 and chEST39n20), encoding overlapping 
fragments of the chIRF7 DNA sequences, were obtained from Ark-Genomics 
laboratory (Roslin institute) to construct a full length cDNA. The three cDNA clones 
cover bases 1-671, 465-1145 and 907-1476, respectively. Semi-nested PCR was 
performed using the three cDNA clones as overlapping templates. Forward and 
reverse primers of the chIRF7 (see Appendix B) were designed based on published 
sequences of gallus gallus_IRF7 (accession number NM_205372.1). PCR conditions 
were as described in Section 2.5.3.  
 
The amplified fragment was cloned in pDONR 207 using Gateway® cloning 
technology, and the cloning was confirmed by BanII restriction digest and 
sequencing (Figure 6.2.2a,b). Sequencing was performed commercially using the 
forward and the reverse primers of pDONR 207 vector (GATC Biotech). The 
sequence of the cloned chIRF7 was correct for all three examined clones, with the 
exception of a single mutation present in all clones. This mutation was in the 254 aa, 
in which isoleucine has shifted to valine. As it was present in all three clones 
sequence, this consistent mutation is likely existed in the template used in the 
amplification process. Only one of the sequenced clones was subcloned into 
GATEWAY® compatible destination vectors, such HA-tagged pCR3 vector, Myc-
tagged pCR3 expression vector, pGBKT7 (bait vector) and pGADT7 (prey vector). 
Cloning was confirmed by restriction digestion using EcoRV (pCR3) or EcoRI & 
BamHI (pGBKT7and pGADT7).  
 




To test the expression of the cloned chIRF7, DF-1 cells were seeded in a 24 well 
plate at 1x105 cells per well. After 24 hr the cells were transfected with 500 ng of 
HA-tagged N-terminal chIRF7 (HA-chIRF7) expression plasmid. Forty eight hours 
later, total cell lysates were harvested and subjected to SDS-PAGE and 
immunoblotting using an anti-HA antibody followed by HRP-conjugated goat anti-
rat secondary antibody. As shown in Figure 6.2.2c, the chIRF7 is strongly expressed 




Figure 6.2.2a,b: Cloning of chIRF7 into the Gateway® system. Scanned 
images of ethidium bromide stained 1% TAE agarose gel which show: (a) PCR 
product of chIRF7; lane 1 contains 1 kbp DNA ladder (Fermentas), lane 2 and 3 
contain chIRF7 DNA, (b) BanII digests of chIRF7 clones in the entry vector 
pDONR 207; lane 1 contains 1 kbp DNA ladder (Fermentas), while lane 2-4 













Figure 6.2.2c: Expression of chIRF7 in the DF-1 chicken cell line. DF-1 
cells grown in 24 well plate were transfected with 500 ng DNA of HA-tagged 
N-terminal chIRF7 expression plasmid. After 48 hr, cells were harvested and 
lysed. The cell lysates were subjected to SDS-PAGE and immunoblotting using 
anti-HA primary antibody followed by HRP-conjugated goat anti-rat secondary 
antibody. 
 
6.2.3 Co-IP has not detect direct interaction between Meq and chIRF7 
The presence of direct protein-protein interaction between Meq and chIRF7 was 
investigated using a co-immunoprecipitation experiment. Meq_pGADT7 (prey) was 
transfected with empty pGBKT7 plasmid (negative control for the non-specific pull-
down) or chIRF7_pGBKT7 (bait) into QM7 cells. Also, chIRF7_pGBKT7 (bait 
vector) was transfected with empty pGADT7 plasmid (negative control for the non-
specific pull-down) into QM7 cells. The transfection was done using calcium 
phosphate transfection method (see Section 2.2.3). Simultaneously, cells were 
infected with recombinant vaccinia virus expressing T7 polymerase. Cell lysates 
were split into two parts and precipitated with either anti-c-Myc or anti-HA antibody 
(See section 2.3.3). Each precipitate was separated on two polyacrylamide gels. On 
the left side of the gel the precipitating proteins, whereas on the right side the co-
precipitating proteins. The precipitation was performed to control the expression 
levels and the correct size of the tested protein. Co-IP has not detected direct 
interaction between Meq and chIRF7. Hence, either Meq or chIRF7 failed to co-








Figure 6.2.3: No direct interaction between Meq and chIRF7 detected by 
Co-IP. QM7 cells were co-transfected with Meq_pGADT7 & 
chIRF7_pGBKT7, chIRF7_pGBKT7 & empty pGADT7 and Meq_pGADT7 & 
empty pGBKT7. The cells were simultaneously infected with recombinant 
vaccinia virus expressing T7 polymerase. Twenty four hours post transfection, 
cells were lysed and whole cell extracts were precipitated with either anti-c-
Myc or anti-HA antibody. Neither Meq nor chIRF7 were found to co-
precipitate. 




6.2.4 Meq down-regulates chIRF7 at the protein level 
In the Co-IP experiment, it was observed that while Meq and chIRF7 did not directly 
interact, the amount of the precipitated chIRF7 was lower in the presence of Meq 
(Figure 6.2.3). This observation led to an investigation of the effect of Meq 
expression on chIRF7 protein level. DF-1 cells were seeded into 6 well plate at a 
density 8x105 cells per well. After 24 hr, five wells were transfected with constant 
amount of HA-tagged N-terminal chIRF7 expression plasmid (HA-chIRF7) and 
increasing amounts of Myc-Meq. The transfection was done as described in Section 
2.2.2. The total amount of the transfected DNA was 2 µg per well (1 µg HA-tagged 
N-terminal chIRF7 expression plasmid and 0 ng, 250 ng, 500 ng, 750 ng or 1 µg of 
Myc-tagged Meq expression plasmid). eGFP control plasmid was used to fill up the 
total amount of DNA up to 2 µg. After 72 hr, the total cell lysates were harvested, 
and the total protein concentrations were measured. The total amount of the loaded 
protein was 10 µg of each sample, and it was loaded twice into two SDS gels. 
Thereafter, the samples were subjected to SDS-PAGE and immunoblotting. The 
immunoblotting was performed using either the anti-c-Myc or anti-HA antibodies 
followed by the HRP-conjugated goat anti-mouse or HRP-conjugated goat anti-rat 
secondary antibodies, respectively. Then, the membrane was stripped off and 
subjected to another immunoblotting, using the anti-β-actin antibody followed by the 
HRP-conjugated goat anti-rabbit secondary antibody. In this system, it was observed 
that there was a dose-dependent down-regulation of chIRF7 protein level coordinated 
with the increasing amount of Meq expression (Figure 6.2.4). These data suggest 















Figure 6.2.4: Dose-dependent down-regulation of chIRF7 by Meq. DF-1 
cells were transfected with an HA-tagged chIRF7 expression plasmid in 
combination with increasing amounts of a Myc-tag Meq expression plasmid (0- 
ng, 250 ng, 500 ng, 750 ng or 1 µg). After 72 hrs, cells were lysed and the 
lysates were analysed by immunoblotting with either an anti-HA primary 
antibody (chIRF7), an anti-c-Myc (Meq) or an anti-β-actin primary antibody 
followed by HRP-conjugated secondary antibodies. 
 
6.2.5 Meq affects chIRF7 protein stability 
To further study the effect of Meq on chIRF7, we aimed to determine if Meq 
influenced the half-life of chIRF7 protein turnover. Another transfection experiment 
was carried out, in which protein synthesis was blocked by treating cells with the 
protein synthesis blocker (cycloheximide). DF-1 cells were seeded in 6 well plates 
with 8x105 cells per well. After 24 hr, cells were transfected with 2 µg of total DNA 
in each well. The transfected DNA complex was composed of 1 µg of HA-tagged N-
terminal chIRF7 expression plasmid and either 1 µg of Myc-tagged N-terminal Meq 
expression plasmid or 1 µg of eGFP control plasmid (see Section 2.2.2). After 72 
hours, the cells were treated with 50 µg/ml cycloheximide. Thereafter, the cells were 
harvested at different time points. The protein concentrations of the cellular lysates 
were measured, and 10 µg of the total protein concentration from each sample was 
subjected to SDS-PAGE and immunoblotting. The immunoblotting was performed 
using the anti-HA antibody followed by the HRP-conjugated goat anti-rat secondary 
antibody. Then, the membrane was stripped off and subjected to another 
immunoblotting using the anti-β-actin antibody followed by the HRP-conjugated 




goat anti-rabbit secondary antibody. Western blot films were quantified by using 
Quantity One software (Bio-Rad, Richmond, CA). 
 
As shown in Figure 6.2.5, chIRF7 protein degraded gradually either in the presence 
or absence of Meq protein. In the presence of Meq, the half-life of the chIRF7 































Figure 6.2.5: Meq shortening chIRF7 protein half-life. DF-1 cells were 
transfected with an HA-chIRF7 expression plasmid in combination with a Myc-
Meq expression plasmid (+) or an eGFP control plasmid (-). After 72 hr, cells 
were treated with 50 µg/ml cycloheximide and harvested and lysed at different 
time points. The samples were analysed by immunoblotting using an anti-HA 
primary antibody (chIRF7) or an anti-β-actin primary antibody followed by 
HRP-conjugated secondary antibodies. Western blot films were quantified by 
using Quantity One software (Bio-Rad, Richmond, CA), and each sample was 
normalised using the actin signal. 




6.2.6 Meq degrades chIRF7 in a proteasome-dependent pathway 
To test if Meq-induced chIRF7 protein degradation is a proteasome-dependent, DF-1 
cells were seeded in 6 well plate at seeding density 8x105 cells per well. After 24 hr, 
cells were transfected with 2 µg of total DNA in each well (see Section 2.2.2). The 
transfected DNA complex was composed of 1 µg of HA-tagged N-terminal chIRF7 
expression plasmid and either 1 µg of Myc-tagged N-terminal Meq expression 
plasmid or 1 µg of eGFP control plasmid. After 72 hours, the cells were treated with 
50 µg/ml cycloheximide alone, 50 µg/ml cycloheximide and 100 μM MG132 or 
DMSO alone. Thereafter, the cells were harvested after 24 hr. The protein 
concentrations of the cellular lysates were measured and 15 µg of protein from each 
sample was subjected to SDS-PAGE and immunoblotting. The immunoblotting was 
performed using the anti-HA antibody followed by the HRP-conjugated goat anti-rat 
secondary antibody. Thereafter, the membrane was stripped off and subjected to 
another immunoblotting using the anti-β-actin antibody followed by the HRP-
conjugated goat anti-rabbit secondary antibody. This investigation showed that by 
inhibiting proteasome activity, the chIRF7 protein level was restored, and chIRF7 
degradation was inhibited inside the cells (Figure 6.2.6). This result suggested that 



















Figure 6.2.6: Proteasome-dependent reduction of chIRF7 protein stability 
by Meq. DF-1 cells were transfected with an HA-chIRF7 expression plasmid in 
combination with a Myc-Meq expression plasmid (+) or an eGFP control 
plasmid (-). After 72 hr, cells were treated with DMSO, 50 µg/ml 
cycloheximide or 50 µg/ml cycloheximide and 100 μM MG132. After 24 hr, 
cells were harvested, lysed and the samples were analysed by immunoblotting 
using an anti-HA primary antibody (chIRF7) or an anti-β-actin primary 
antibody followed by HRP-conjugated secondary antibodies. 
 
6.2.7 Meq auto-regulates its protein level in the presence of chIRF7 
The previous experiments indicated that Meq targets chIRF7 and consequently 
induces its degradation in a proteasome-dependent pathway. To investigate if the 
degradation of the both proteins is linked to each other, another transfection 
experiment was performed. In this experiment, DF-1 cells were seeded into 6 well 
plate with 8x105 cells per well. After 24 hr, five wells were transfected with 2 µg of 
total DNA each, and the DNA transfection complex was composed of 1 µg of N-
terminal Myc-tagged Meq expression plasmid (Myc-Meq) and increasing quantities 
of N-terminal HA-tagged chIRF7 expression plasmid (0 ng, 250 ng, 500 ng, 750 ng 
or 1 µg). eGFP control plasmid was used to fill up the total amount of DNA up to 2 
µg. Seventy two hours later, total cell lysates were harvested, and the total protein 
concentrations were measured. The total amount of the loaded protein was 10 µg of 
each sample, and the samples were subjected to SDS-PAGE and immunoblotting. 
The immunoblotting was performed using anti-HA, anti-c-Myc and anti-β-actin 




antibodies followed by HRP-conjugated goat anti-rat, HRP-conjugated goat anti-
mouse and HRP-conjugated goat anti-rabbit secondary antibodies, respectively. 
 
This experiment showed that there was a dose-dependent down-regulation in the 
Meq protein expression level coordinated with the increasing amount of chIRF7 
expression (Figure 6.2.7). Therefore, the over-expression of chIRF7 in turn led to 
increase Meq degradation, indicating that the degradation of both proteins is linked 
to each other. 
 
 
Figure 6.2.7: Meq auto-regulates itself in the presence of chIRF7. DF-1 cells 
were transfected with a Myc-Meq expression plasmid in combination with 
increasing amounts of an HA-chIRF7 expression plasmid (0 ng, 250 ng, 500 ng, 
750 ng or 1 µg). After 72 hrs, cells were lysed and the lysates were analysed by 
immunoblotting with either an anti-HA primary antibody (chIRF7), an anti-c-
Myc (Meq) or an anti-β-actin primary antibody followed by HRP-conjugated 
secondary antibodies. 
 
6.2.8 Over-expression of chIRF7 leads to a cytoplasmic accumulation of 
Meq 
Work described in the previous sections suggested that Meq-induced chIRF7 
degradation is proteasome-dependent degradation. In fact, Meq is detected in the 
nucleus, when it is expressed alone. IRF7 is detected at the cytoplasm while its 
phophorylated version is detected in the nucleus, when it is expressed alone. 
Therefore, it was of interest to investigate microscopically the localisation of the two 
proteins when they are over-expressed together in the same cell. DF-1 cells grown on 
chamber glass slide were transfecetd with an HA-tagged chIRF7 expression plasmid 




(HA-chIRF7), a Myc-tagged Meq expression plasmid (Myc-Meq) or both (see 
Section 2.2.1). After 72 hr from the transfection, cells were fixed and subjected to 
immunofluorescence staining (see Section 2.3.7). Cells were dually stained with anti-
c-Myc, mouse monoclonal and anti-HA high affinity, rat monoclonal antibodies. 
Then, the fluorescent signals were detected using Alexa fluor® 488 goat anti-mouse 
IgG (green) and Alexa fluor® 594 goat anti-rat IgG (red) conjugated antibodies. 
 
As presented in Figure 6.2.8, the upper panel of the images shows chIRF7 localised 
in the cytoplasm and nucleus. The middle panel of the images shows Meq localised 
in the nucleus only. If both proteins were coexpressed, the lower panel of the images, 
Meq could be detected both in the nucleus and in the cytoplasm, again suggesting 
that both proteins are targeted for proteasomal degradation if present simultaneously 
in the same cell.  






Figure 6.2.8: Over-expression of chIRF7 leads to a cytoplasmic 
accumulation of Meq. DF-1 cells were transfected with either an HA-tag 
chIRF7 expression plasmid (HA-chIRF7), a Myc-tag Meq expression plasmid 
(Myc-Meq) or both. After 72 hr, the slides were fixed and dually immuno-
stained with anti-HA and anti-c-Myc primary antibodies. Then, the fluorescent 
signals were detected using Alexa fluor® 488 goat anti-mouse IgG (green) and 
Alexa fluor® 594 goat anti-rat IgG (red) conjugated secondary antibodies. The 













This chapter has focused on study of the mechanism behind chIRF7 down-regulation 
by Meq. Meq is the main MDV oncoprotein, and it is highly expressed in MDV-
transformed T-cells (Ross et al., 1997; Liu et al., 1998). It can independently 
transform Rat-2, NIH3T3 and DF-1 cell lines (Liu et al., 1998; Levy et al., 2005; 
Ajithdoss et al., 2009). Recombinant virulent MDV lacking Meq (rMd5ΔMeq) 
provided the birds with higher protection than that provided by the Rispens strain 
(Lee et al., 2008). The mechanism by which Meq expressed inside the latently or 
transformed cells has remained uncertain yet. However, it is clearly that Meq owns a 
mechanism to evade the cellular and the innate immune response. Here it was 
demonstrated that Meq and its homologue in the vaccine strain LMeq were the most 
potent down- regulators for the interferon-alpha responsiveness of the chicken ISRE 
promoter (see Chapter 5). Meq immunosuppressive function is exerted via its 
interference with the chIRF7 at the proteomic level.  
 
6.3.1 Co-IP has not detected interaction between Meq and chIRF7 
Many viral proteins evade the innate immune response via binding with the 
interferon regulatory factors (IRFs). This binding leads to interruption of the IRFs 
dimerisation and consequently their DNA binding activity. This was the case of 
KSHV-vIRF3 protein and bICP0 proteins of BoHV-1 (Joo et al., 2007; Saira et al., 
2009). Co-IP was not able to detect any direct binding between Meq and chIRF7. 
This result could be attributed to many factors such as the follows. There is no 
existed interaction between Meq and chIRF7, or the interaction is existed but the 
buffering conditions of the experiment interfere with the interaction stability. 
However, it is also possible that the interaction occurs, and as a result of this 
interaction chIRF7 undergoes certain modifications. This modification leads to 
chIRF7 degradation and down-regulation. The latter case was reported before for 
bICP0 protein of bovine herpesvirus, as bICP0 degrades bovine IRF3 protein, and 
therefore the two proteins can not be co-precipitated together (Saira et al., 2007). The 




interesting observation from this experiment was that the precipitated chIRF7 in the 
case of Meq absence was more abundant, compared with Meq presence. 
 
6.3.2 Meq negatively regulates chIRF7 and its own protein stability  
One of the possible mechanisms to evade the innate immune response is targeting the 
innate immune system components for protein degradation. This mechanism has 
been used by the NDV V protein, the BoHV-1 bICP0 protein and the KSHV RTA 
protein. NDV V protein targets the degradation of the STAT1 protein, and mediates 
interruption for interferon-alpha pathway at the up-stream level of the ISRE 
transcriptional activity (Huang et al., 2003). On the other hand, bICP0 targets IRF3 
for a proteasome-dependent degradation, therefore it mediates down-stream effect 
(Saira et al., 2007). Moreover, KSHV RTA lytic protein encodes ubiquitin E3 ligase 
activity at its N-terminal, which targets IRF7 for degradation and down-regulation 
(Yu et al., 2005). The real-time PCR experiment showed that Meq and LMeq can not 
exert any down-regulation to the endogenous chIRF7 mRNA. The data presented 
here show that Meq down-regulates chIRF7 at the protein level and decreases its 
protein stability. Unlike the EBV LF2 protein, which is able to down-regulate IRF7 
at transcriptional level (Wu et al., 2009b), Meq targets chIRF7 for a protein 
degradation. Similar to KSHV RTA, Meq auto-regulates its own protein level in the 
presence of chIRF7, possibly by creating a multiprotein complex with chIRF7 which 
is degraded together.  
 
6.3.3 Meq enhances chIRF7 protein degradation via a proteasome-
dependent pathway 
Proteasome is cellular machinery that targets endogenous unneeded proteins for 
degradation. The targeted protein is mainly ligated with ubiquitin peptides via 
ubiquitin ligases and processed with the cellular proteasomes for degradation. Down-
regulation of mammalians IRF7 protein stability and enhancing its degradation 
process is mainly via ubiquitin-dependent proteasomal degradation (Yu et al., 2005; 
Prakash and Levy, 2006). This study presented the first evidence that the chIRF7 




protein undergoes proteasome-dependent degradation. It was demonstrated that the 
chIRF7 protein degradation was completely stopped after the cells were treated with 
the proteasomal-inhibitor drug MG132. This was the case in either the presence or 
absence of Meq. However, particularly in the presence of Meq, the high turnover of 
chIRF7 protein is totally reversed after inhibition of the cellular proteasomal activity. 
Therefore, during viral infection Meq may antagonise the interferon system via 
targeting chIRF7 for proteasome-dependent degradation. Meq may target chIRF7 
either directly or indirectly. The direct effect could be via forming polyubiquitinated 
complex with chIRF7, which undergoes proteasomal degradation. The evidence for 
the previous hypothesis is that Meq also degrades in a dosage-dependent manner in 
the presence of chIRF7. However, we were not able to detect any direct physical 
binding between Meq and chIRF7, so Meq may also act indirectly through other 
cellular proteins that cause chIRF7 proteasomal degradation. Meq N-terminal 
domain contains three lysine residues at the amino acids 45, 84 and 101, which are 
predicted to be ubiquitin substrate residues (Tung and Ho, 2008), and therefore Meq 
is predicted to be a substrate for the ubiquitin protein modification, although this is 
not confirmed yet. Interestingly, a proteomic analysis of MDV infected spleen CD4+ 
T-cells revealed that many proteins of the ubiquitin-proteasome protein degradation 
system were up- or down-regulated (Thanthrige-Don et al., 2009).  
 
6.3.4 Over-expression of chIRF7 leads to a cytoplasmic accumulation of 
Meq 
Most of viral proteins, which encode interferon antagonistic function, have nuclear 
localisation signals such as bICP0 of BoHV-1, ICP0 of HSV-1, LF2 of EBV and 
RTA of KSHV. Localisation of RTA protein inside the nucleus leads to IRF7 
retaining in the cytoplasm and inhibition of IRF7 entrance into the nucleus (Yu et al., 
2005). bICP0 interacts with IRF7 inside the nucleus, and interrupts IRF7 binding to 
the interferon-β promoter (Saira et al., 2009). On the other hand, LF2 expression 
inside the nucleus has no effect on IRF7 nuclear localisation. In our study, Meq 
presence inside the nucleus inhibits chIRF7 entrance to the nucleus. Furthermore, 
shift in Meq localisation to the cytoplasm was detected.   




Overall and from all the above mentioned results, a model for the interferon-alpha 
antagonistic function displayed by Meq can be hypothesised (Figure 6.3). We have 
concluded that the presence of Meq inside the nucleus inhibits chIRF7 entrance to 
the nucleus and initiating the transcriptional activitation for type 1 interferons 
inducible promoter. Moreover, Meq acts as a suicide gene that targets the chicken 
IRF7 directly or indirectly. As a result of this targeting which mainly happens at 
nuclear rim or cytoplasm, the proteasomal degradation of Meq and chIRF7 started. It 
is also very likely that Meq acts as ubiquitin source for chIRF7 degradation, although 
there is no evidence for that.  
 
From this study, it can be concluded that MDV utilises Meq, the main oncoprotein, 
to evade the host interferon-signalling. Thus, using of vaccine lacking Meq or LMeq 
will provide the birds with better immune response and better protection rate. Also, 
this study provides additional data for the role of the basic leucine zipper containing 
protein in the evading of interferon signalling. Thereby, Meq is considered as a very 
good hit for the drug designers to develop antiviral therapy. 







Figure 6.3: Model illustrating Meq mediated proteasomal 
degradation of chIRF7. Meq targets chIRF7 and itself for cytoplasmic 
proteasomal degradation. Therefore, it inhibits chIRF7 entrance to the 
nucleus, in order to initiate the transcriptional activity of type 1 interferon 
inducible promoters and type 1interferon promoters. 




Investigation of Meq-deletion MDV mutant sensitivity 
for chicken interferon-alpha treatment 
 
7.1 Introduction  
The cloning of RB-1B MDV as a bacterial artificial chromosome (pRB-1B5) has 
produced an extremely useful tool for the molecular analysis of the MDV genome 
(Petherbridge et al., 2004). In vitro and in vivo experiments revealed growth 
properties of pRB-1B5 which can cause visceral tumours similar to the wild-type 
RB-1B virus (Petherbridge et al., 2004). pRB-1B5 mutants have been generated to 
investigate the roles of various MDV genes such as UL13, RLORF4, RLORF5a and 
Meq genes (Jarosinski et al., 2005; Blondeau et al., 2007; Jarosinski et al., 2007b). 
The pRB-1B-D2 MDV mutant was engineered by Brown and colleagues by 
replacing the two copies of the Meq gene with a marker-less cassette (Brown et al., 
2006). This pRB-1B5 Meq knock-out mutant virus has been used to investigate the 
role of Meq in viral life cycle and in tumour formation. As an example, this mutant 
highlighted the importance of the physical interaction between Meq and CtBP for 
tumour formation (Brown et al., 2006). Furthermore, pRB-1B-D2 MDV was used to 
identify the contribution of Meq's leucine zipper domain in MDV latency and 
transformation properties (Brown et al., 2009).  
 
Work described here has used pRB-1B-D2 MDV to study the interplay between 
MDV infection and chIFN-α signalling pathway in CEF cells, particularly in the case 
of Meq absence. 
 
7.1.1 Aim  
To verify the role of Meq in the down-regulation of chIFN-α signalling in the context 
of MDV infection, the plaque formation efficiency of the wild-type pRB-1B5 and 
pRB-1B-D2 viruses were compared in the presence or absence of chIFN-α treatment. 




Levels of mRNA encoding endogenous chIRF7 were measured after infection with 
the two viruses in the presence or absence of chIFN-α treatment. 
 
7.2 Results 
7.2.1 Meq knock-out double deletion mutant is more sensitive to chIFN-
α treatment compared to the wild-type virus  
To study Meq’s role in antagonising chIFN-α in the virus context, the plaque 
formation efficiency of pRB-1B5 and pRB-1B-D2 viruses was compared in the 
presence and absence of chIFN-α treatment.  
 
Primary chicken embryo fibroblasts (CEF) cells were seeded into two 12 well plates, 
at a density of 4.1x105 cells per well. After cells settled down, half of the wells in the 
two plates were treated with 500 U of chIFN-α per well in reduced serum conditions 
and the other half were mock treated in the same reduced serum condition. Twenty 
four hours later, one plate was infected with 50 PFU of pRB-1B-D2 virus and the 
other plate was infected with pRB-1B5 virus in normal 5% serum growth medium. 
Interferon treatment was renewed at 3 days post infection only. After five days, three 
wells from each treatment of the infected cells were fixed and stained with HB3 Ab 
as described in Section 2.10, and the plaques were counted using the ordinary light 
microscope.  
 
As shown in Figure 7.2.1, both of pRB-1B-D2 and pRB-1B5 viruses were sensitive 
to chIFN-α treatment. Infection with 50 PFU of pRB-1B5 virus showed 10% 
reduction in the plaques number in case of chIFN-α treatment, compared to the 
untreated cells (Table 7.2.1). Whilst there was approximately a 40% reduction in the 
plaque number in case of infection with 50 PFU of pRB-1B-D2 and chIFN-α 
treatment, compared to the untreated cells (Table 7.2.1), the reduction in the plaques 
number was statistically significant only in the case of pRB-1B-D2 virus infection. 
 






Figure 7.2.1: Effect of chIFN-α treatment on the plaque formation 
efficiency of pRB-1B-D2 MDV and pRB-1B5 MDV. CEF cells were treated 
with 500U/ml of recombinant chIFN-α or kept untreated. Twenty four hours 
later, cells were infected with 50 PFU of wild-type pRB-1B5 MDV or pRB-1B-
D2 MDV. The effectiveness of chIFN-α treatment on virus plaque formation 
was measured by normalisation of the chIFN-α-treated samples to the untreated 
samples. The black bars represent the non-interferon-treated samples, while the 
white bars represent the interferon-treated samples. The statistical analysis was 
done using Welch’s T test (**P<0.01). 
 
Virus chIFN-α 
Average of plaque  
number 
Normalisation 
- 59.3 ±4.9 1.0 ±0.08 
pRB-1B5 
+ 51.7 ±8.5 0.9 ±0.14 
- 44.0 ±2.6 1.0 ±0.06 
pRB-1B-D2 
+ 25.7 ±3.1 0.6 ±0.07 




7.2.2 pRB-1B-D2 infected CEF cells have up-regulation of chIRF7 mRNA 
level 
As shown in Section 7.2.1, pRB-1B-D2 MDV plaque formation efficiency was more 
sensitive to chIFN-α treatment compared to the wild-type virus. In order to 
investigate the effect of MDV infection on the endogenous chIRF7 mRNA 
expression level, in particular in case of Meq absence, quantitative real-time PCR 
experiment was performed. 
 
In this experiment, chicken embryo fibroblasts (CEF) cells were seeded into two 12 
well plates, at a density of 4.1x105 cells per well. After the cells settling down, half 
of the wells in the two plates were treated with 500 U of chIFN-α per well in a 
reduced serum condition and the other half were mock treated under the same 
reduced serum conditions. Twenty four hours later, one plate was infected with 50 
PFU of pRB-1B-D2 virus and the other plate was infected with pRB-1B5 virus in 
normal 5% serum growth medium.  Interferon treatment was renewed 3 days post 
infection only. After five days, RNA was extracted from the infected cells, and real-
time PCR was performed. Differences in the mRNA expression levels of chIRF7 
were determined in the different samples, using β-actin as an internal control. 
 
As shown in Figure 7.2.2, CEF cells infected with either pRB-1B5 or pRB-1B-D2 
MDV showed significant up-regulation in chIRF7 mRNA expression level, 
compared to the mock treated cells infected with the same viruses. Particularly in 
case of pRB-1B-D2 MDV infection, the up-regulation of chIRF7 mRNA expression 
levels was more pronounced and highly significant in either interferon-treated or 












Figure 7.2.2: Infection with Meq knock-out mutant up-regulates IRF7 
mRNA after chIFN-α treatment. CEF cells were infected with 50 PFU of 
either wild-type pRB-1B5 or pRB-1B-D2 MDV. The mRNA was extracted at 
the 5th day post infection. All the samples were normalised according to the 
non-interferon-treated samples which infected with pRB-1B5 MDV. The 
interferon-treated cells and infected with pRB-1B5 or pRB-1B-D2 MDV 
showed significant up-regulation in chIRF7 mRNA level compared to the non-
treated cells infected with same viruses. The up-regulation was more significant 
in case of infection with pRB-1B-D2 MDV. The statistical analysis was done 
using Welch’s T test (**P<0.01) and (***P<0.001). 





MDV infection is associated with the development of the innate immune response 
(Abdul-Careem et al., 2009a), nevertheless MDV infections progress and virus's 
genome load increases in infected birds. Many studies suggest that MDV has evolved 
several mechanisms to evade the host immune response (Thanthrige-Don et al., 
2010). 
 
In this study, evidences are provided for Meq down-regulation of chIFN-α by 
inducing a proteasome-dependent degradation of chIRF7 protein. Although in our 
screen Meq was not the only MDV gene that restricts chIFN-α response, it was of 
curiosity to test the effect of Meq absence on virus growth, in the presence of chIFN-
α.  
 
7.3.1 Meq knock-out double deletion mutant is more sensitive to chIFN-
α treatment compared with the wild-type virus  
Viral mutagenesis is considered a beneficial tool for functional analysis of viral 
proteins. Indeed, genetic modification of the herpesvirus genome was the reason for 
discovering many of its interferon antagonistic encoded hits. By testing the growth of 
the deletion mutant compared with the wild type virus in the presence or absence of 
exogenous antiviral cytokines, the contribution of the deleted gene in the expression 
of innate immunity can be investigated. For instance, the growth of ICP0 knock-out 
HSV-1 was severely impaired in the presence of IFN-α compared with the wild type 
virus (Mossman et al., 2000). Another example, the growth of VZV mutant lacking 
ORF63 was severely impaired in the presence of IFN-α compared with its absence 
(Ambagala and Cohen, 2007).  
 
Since Meq is the main MDV oncogene, in recent years various Meq-deletion MDV 
mutants have been constructed and studied (Brown et al., 2006; Lee et al., 2008). 
These mutants were tested in vitro and in vivo for their ability to replicate and induce 
tumours. However, it was found that vaccination with rMd5V lacking Meq, provided 




birds with 100% protection against challenge with a very virulent plus MDV strain 
(Lee et al., 2008; Lee et al., 2010). Furthermore, the protection exerted by this 
mutant was superior to the protection exerted by the Rispens vaccine strain. Thus 
indicating that the lack of Meq correlates with improving the host immune response 
and that Meq may encode some immunomodulatory functions. The data presented 
here demonstrated that Meq expression correlates with the modulation of the 
chicken’s innate immune response during MDV infection. Although the Meq- 
deletion mutant was able to grow and form plaques in the presence of chIFN-α, there 
was a significant difference in the plaque formation efficiency of RB-1B-D2 MDV in 
the presence of chIFN-α, compared to the wild-type virus. This confirms the 
contribution of Meq in antagonising IFN-α signalling in the virus context.  
 
7.3.2 Analysis of chIRF7 mRNA levels following infection with pRB-1B5 
and pRB-1B-D2  
After virus infection, cells produced IFN-α and IFN-β which generate waves of 
signals to create an antiviral state inside the cells. These signals lead to secretion of 
group of antiviral cytokines and transcription factors such as Mx1 and IRF7, 
respectively (Muller-Doblies et al., 2002). The existence of the lytic infection of the 
gammaherpesvirus, EBV, is associated with marked down-regulation of IRF3 and 
IRF7 at both the RNA and protein levels (Bentz et al., 2010). MDV also induces lytic 
infection in CEF, but no previous studies have recorded the modulation of the 
chIRF7 during MDV infection. Furthermore, there is no commercially available 
antibody with specificity for chIRF7 protein, and therefore the estimation of the 
endogenous chIRF7 protein level seems to be impossible. The availability of the 
chIRF7 sequence makes it easier to analyse chIRF7 mRNA expression levels, using 
quantitative real-time PCR technology. This study quantified the change in the 
chIRF7 mRNA expression level after infection with either pRB-1B5 or pRB-1B-D2 
MDV, in the presence or absence of chIFN-α. There was no change in chIRF7 
mRNA level in Meq transfected cells (see Section 6.2.1), however this investigation 
aimed to detect the indirect effect which results from the positive feedback loop 




between chIFN-α and chIRF7. Both pRB-1B5 and pRB-1B-D2 MDV infected cells 
have up-regulation of the chIRF7 mRNA levels in case of IFN-α treatment. This up-
regulation was more pronounced and more significant in case of Meq-deletion MDV 
(pRB-1B-D2) compared with wild-type virus (pRB-1B5). This finding confirmed 
that the expression of Meq in the virus context counteracts chIRF7 level, 
subsequently negatively regulating chIFN-α levels and the innate immune response. 
As mentioned above, it is very likely that the difference in the mRNA level in the 
virus context is due to a positive feedback loop, especially since chIRF7 mRNA 
levels were measured at 5 dpi. Hence, the down-regulation of chIRF7 protein 
stability leads to decreased chIFN-α levels and subsequently decreases the 
transcriptional activity of the ISRE promoter including chIRF7 mRNA levels.  
 
The presence of Meq in the MDV genome has been confirmed and implicated in the 
down-regulation of chicken innate immune responses, namely chIFN-α signalling 
and production. Moreover, this role was clear in the virus context by modulation of 
chIRF7 levels during CEF lytic infection. Perhaps, the role of Meq becomes clearer 
during MDV latent infection and tumour formation, especially as recent findings 
suggested that IRF7 protein encodes anti-tumour activity (Solis et al., 2006; Goubau 
et al., 2009). 




Final discussion and future work 
 
Marek's disease virus was originally described in 1907, and since then the virus has 
developed a smart evolution strategy to replicate inside the host cells and increase its 
virulence. Moreover, MDV can exist and remain latent in chicken host cells masking 
itself from the chicken's immune response. MDV is also considered a virus of 
biomedical importance. It has a genomic structure similar to HSV-1 and VZV of 
Alphaherpesvirinae (Cebrian et al., 1982; Buckmaster et al., 1988; Osterrieder et al., 
2006), and it exerts biological properties similar to EBV of Gammaherpesvirinae. 
Using molecular approaches to understand the role played by each of the MDV 
genes, on a genome-wide scale, becomes necessary. Better understanding of MDV's 
molecular nature and composition will lead to the identification of essential 
components of the MDV genome required for viral replication and/or interaction 
with host cells. These components can be used by drug designers as targets to knock-
down virus replication or infection. Additionally, it can help to develop an innovative 
MDV vaccine that can overcome the disadvantages of the already existing MDV 
vaccine. As example, the deletion of either vIL8 or Meq gene from the MDV 
genome led to engineering of new vaccine constructs, which provide the birds with a 
protection similar to or sometimes better than established MDV vaccines (Cui et al., 
2005b; Lee et al., 2008; Lee et al., 2010).  
 
This study involved construction of the first genome-wide clone collection library for 
the MDV genome. The MDV ORFeome library was created in order to perform the 
first systematic functional analysis of MDV genes. By testing their interactions with 
themselves or the chicken interferon-alpha pathway, very useful information was 
obtained regarding the role played by each of the MDV genes. Recent studies 
suggested that the MDV genome encodes more than 400 ORFs (Spatz et al., 2007c), 
however not all of them are truly functional and are expressed during the course of 
MDV infection. Only the proteins which are more likely to be expressed during the 
viral infection have been studied (Lee et al., 2000a; Tulman et al., 2000). The MDV 




ORFeome library is composed of 149 MDV clone constructs. These clones represent 
114 functional genes cloned as full length, 4 functional genes cloned as fragments 
(10 fragments) and 25 extra and intra-cytoplasmic domains for the membrane-
associated proteins. Two MDV strains which are different in their virulence level 
were used to clone the different genes from the two genomes. This library was 
cloned into pDONR 207 using the Gateway® cloning system and confirmed by 
sequencing. The cloned library was later subcloned into different destination vectors 
to be used for different purposes (discussed in the previous chapters). 
 
Y2H assay is a technique used to analyse protein-protein interactions, especially on a 
genome-wide scale. It was used previously to investigate interactions between 
proteins encoded by many members of the Herpesviridae family (Calderwood et al., 
2007; Rozen et al., 2008; Fossum et al., 2009), and it led to the identification of 
many biological facts of herpesviridae. One example is the formation of the nuclear 
egress complex between UL31 and UL34 in many members of the herpesviridae 
(Fuchs et al., 2002c; Lake and Hutt-Fletcher, 2004). In this study, Y2H assay has 
been used to analyse the intraviral protein interactions of MDV (Chapter 4). The 
Y2H screen led to the identification of 435 interactions among the MDV proteins. 
Although the Y2H system is sometimes associated with some false positive and false 
negative interactions, The MDV interactome has remarkably good reliability, 
reaching 81%. This was enabled by confirmation of some of the identified 
interactions using biochemical assays (Co-IP and LUMIER). Interestingly, many of 
the identified interactions were found to represent the roles of these proteins in the 
different replication steps of MDV, including DNA replication, nucleic acid egress, 
nucleocapsid tegumentation, virus envelopment and finally virus release. A large 
number of interactions were reproducible and proved to have roles in the assembly 
and biology of other herpesviridae family members. For example, the screen 
identified the MDV large tegument protein, UL36, to be interacted with several 
proteins representing different parts of MDV virion. These interactions highlighted 
the central role of the MDV UL36 in virion assembly via interacting with various 
capsid, tegument and membrane-associated proteins. Additionally, four biologically 




important proteins form a dense network together (Meq, PP38, PP24 and vIL8), 
indicating a relationship between these proteins in the regulation of MDV infection. 
However, performing Y2H assay to study the interactions between MDV proteins 
and chicken proteins will provide more information regarding the roles of the 
mentioned genes in the regulation of MDV infection.  
 
MDV infection is characterised by immediate development of innate-immune 
responses. These immune responses are composed of activation of Macrophages and 
NK cells, which subsequently mediate the secretion of different antiviral cytokines 
(Garcia-Camacho et al., 2003; Abdul-Careem et al., 2008a; Abdul-Careem et al., 
2009a). Although MDV infection is associated with up-regulation of interferon-
gamma (Abdul-Careem et al., 2007; Heidari et al., 2008b), there is no evidence for 
up-regulation of interferon-alpha during MDV infection (Xing and Schat, 2000a; 
Heidari et al., 2008b). Furthermore, MDV was able to block interferon-alpha 
responses of chicken cells (Quere et al., 2005). The work presented in Chapter 5 
described the discovery of proteins encoded by MDV which are responsible for 
antagonising interferon-alpha response. The MDV library, cloned into the pCR3 
expression vector, was used to study the effect of MDV protein expression on 
chicken interferon-alpha signalling. The chicken Mx1 promoter contains an ISRE 
motif, which is induced by chIFN-α treatment (Schumacher et al., 1994). Therefore a 
luciferase reporter assay was designed that was based on using this ISRE motif 
upstream of Firefly luciferase as a reporter for chIFN-α secretion. Using a functional 
reporter assay, several viral proteins that can antagonise chIFN-α secretion were 
identified. These genes were identified as Meq, LMeq, UL50, UL26 and UL12, 
which encode MDV’s leucine zipper protein, dUTPase, capsid cleavage protein and 
DNase, respectively. Most of these genes proved to have an immunoregulatory 
function in other herpesviruses, particularly EBV (Hippenmeyer et al., 1997; Hahn et 
al., 2005; Wu et al., 2009b). Thus, EBV and MDV, which belong to two distinct 
herpesvirus subfamilies, use two structurally related proteins pairs, two bZIP-
containing proteins (BZLF-1 and Meq) and two dUTPase homologs (LF2 and 
UL50), to evade the innate immune response. In addition, these newly discovered 




antagonists have mainly immediate-early or early kinetics, as their early expression 
during the viral life cycle can facilitate the establishment of viral infection. 
 
Meq is a leucine zipper protein that has transcriptional activity similar to the cellular 
Jun/Fos family. Meq is the main MDV oncoprotein and its expression alone was 
enough to induce transformation in rat and chicken cell lines (Liu et al., 1998; Levy 
et al., 2005; Ajithdoss et al., 2009). Meq has an anti-apoptotic activity which is 
important for the protection of transformed cells from apoptosis (cell death) (Liu et 
al., 1998). It is expressed in both cytolytic and latent stages of MDV infection 
(Heidari et al., 2008a), and MDV transformed T lymphocytes are considered CD30+ 
CD4+ Meq+ cells (Gimeno et al., 2005). Indeed, Meq expression during latency and 
tumour formation is strategically good for these stages of infection; it is very likely 
that Meq expression exerts a certain immunomodulatory function. This function may 
allow the virus to exist latently inside the host cell without activation of the chicken 
immune response. Meq and LMeq were the only MDV proteins that robustly 
antagonise chIFN-α secretion in a dosage-dependent manner (Chapter 5). For the 
former, this study focused on the mechanism behind Meq's role in interferon-alpha 
down regulation. The N-terminal half of Meq encodes bZIP domain is required for 
both DNA binding and nuclear localisation (Qian et al., 1996; Liu et al., 1997; Lee et 
al., 2003; Ajithdoss et al., 2009). The C-terminal, proline-rich domain (129 to 339) 
has transactivating activity, particularly in the last 33 aminoacids (Qian et al., 1995). 
In this study, the sequence between aminoacids 25 to 151 was found to be essential 
for inhibiting chIFN-α signalling (Chapter 5), while the transregulatory C-terminal 
motif was not required, suggesting that the chIFN-α inhibitory function either 
requires nuclear localisation, DNA binding or, most likely dimerisation. This study 
indicates that both Meq, which is derived from the pathogenic RB1B strain, as well 
as its isoform LMeq derived from the CVI988 vaccine strain down-regulate the 
chIFN-α response for the chicken Mx1 promoter, indicating that the inhibition of 
chIFN-α signalling through Meq does not contribute to the difference in 
pathogenicity in these strains. Meq was not the only basic leucine zipper protein 
belonging to the herpesvirus involved in interferon-alpha down regulation, but also 




the EBV leucine zipper protein BZLF-1 has also been reported to down-regulate the 
interferon-alpha response (Hahn et al., 2005).  
 
Interferon regulatory factor 7 (IRF7) is a transcriptional factor and is responsible for 
type 1 interferon secretion after binding with their promoters. Chicken interferon 
regulatory factor 7 has the ability to bind efficiently to the ISRE motif in the chicken 
Mx1 promoter and acts as a transcriptional activator (Grant et al., 1995; Grant et al., 
2000). Thus, it is involved in the chIFN-α signalling process and plays a similar role 
to the mammalian ISGF3. Herpesviruses generally interfere with the production of 
type 1 interferon via modulation of IRF7 at different levels. Herpesviruses encoded 
interferon-antagonist proteins interfer with IRF7 at the transcriptional, translation or 
post-translational level. Work described in Chapter 6 showed that Meq inhibits 
chIFN-α through degradation of chIRF7. The over-expression of Meq protein alone 
did not affect chIRF7 mRNA level. On the other hand, it does affect chIRF7 at the 
protein level. Meq over-expression in chicken cells resulted in chIRF7 protein 
degradation in a dose-dependent manner. Meq negatively regulates chIRF7 protein 
stability and leads to shortening of its half-life. Moreover, this negative effect on 
chIRF7 protein stability is through proteasomal-dependent degradation, as chIRF7 
degradation by Meq was completely inhibited by inhibition of the proteasome. 
Similar to KSHV RTA (Yu et al., 2005), Meq auto-regulates its own protein stability 
in the presence of chIRF7, possibly by creating a multiprotein complex with IRF7 
then degraded together. Since the direct physical binding between Meq and IRF7 was 
not confirmed in Co-IP assay, Meq may act indirectly through other cellular proteins 
that cause proteasomal degradation. It became clear that Meq targets chIRF7 for 
proteasomal degradation, and probably acts as E3 ubiquitine ligase for chIRF7, 
although evidence for this is lacking. A proteomic analysis of MDV infected spleen 
cells revealed that many proteins of the ubiquitin-proteasome protein degradation 
system were up- or down-regulated (Thanthrige-Don et al., 2009). 
Immunofluorescent study revealed that Meq inhibits chIRF7 from entering into the 
nucleus by localising with it in the cytoplasm and targeting it for proteasomal 
degradation.  




Experiments described in Chapter 7 showed that the Meq-deletion RB-1B MDV 
strain is more sensitive for chIFN-α treatment at an infection dose of 50 PFU. The 
difference between Meq-deletion MDV and wild-type MDV is clearer at chIRF7 
mRNA expression level. DF-1 cells have a significantly higher level of chIRF7 
mRNA after infection with Meq-lacking MDV compared with Meq-encoding MDV. 
This up-regulation at the chIRF7 mRNA level is perhaps due to a positive feedback 
mechanism for the changes which occur earlier at the protein level. These findings 
confirm Meq's antagonisitic effect on chIFN-α response, and it can be concluded that 
MDV utilises Meq, the main oncoprotein, as a suicidal protein to evade the host 
interferon signalling cascade. Therefore, Meq expression by MDV negatively 
regulates the antiviral state induced by the interferon system. However, it is not clear 
from our study if this novel function displayed by Meq is important for establishing 
either the lytic or the latent stage of MDV infection.  
 
These observations lead to the recommendation that the use of a vaccine lacking Meq 
or LMeq will provide birds with a better immune response and protection. 




In this study, a new tool, the MDV gene library, to be used in MDV research was 
generated with a suitable flexible cloning system. MDV ORFeome was used in two 
functional assays Y2H assay and chIFN-α signalling reporter assay. Both the 
genome-wide interactome and the chIFN-α signalling investigation gave us useful 
novel data for the structurally and the regulatory essential MDV genes. Since the 
number of MDV intraviral interactome studies is very limited, MDV interactome 
data were mainly correlated to other studies of other herpesviruses. However, the 
presence of many conserved interactions with the other herpesviruses and the 
formation of Meq homodimers make it reasonable to expect that MDV interactome 
may present many other truly novel data. 
 




Genome-wide analysis of MDV proteins which inhibit chIFN-α signalling identified 
many chIFN-α antagonists encoded by the MDV genome. Meq is a potent interferon 
antagonist, according to the chIFN-α luciferase reporter assay. It negatively regulates 
chIFN-α signalling via inhibition of the chIRF7 protein entrance to the nucleus and 
by targeting it for proteasomal-dependent degradation. Meq deletion MDV was more 
sensitive for chIFN-α treatment. 
 
Future work 
Taking all the previous data together, it is therefore crucial to test the essential 
interactions via generation of mutant viruses which express tagged viral proteins 
using virus genomes cloned into BAC vectors. These mutants can be tested in vitro 
and in vivo for their ability to replicate and produce a disease.  
  
Furthermore, it is essential to undertake microarray analysis of cellular gene 
expression after infection with wild-type or Meq knock-out MDV. Performing such a 
comparison will be informative and will give more insight into the difference 
between the responses of interferon-related genes after infection with the two 
viruses. In addition, it is crucial to study the novel function displayed by Meq in vivo. 
Comparing the antiviral cytokine levels in birds after infection with either the Meq 
knock-out or the wild-type MDV in the future will help in understanding the 
importance of the immunosuppressive function displayed by Meq. Hopefully, this 










Table 1.9.2: Orthologues of MDV genes present in HSV-1, VZV, murine 
cytomegalovirus (mCMV), Epstein-Barr virus (EBV) and Kaposi’s sarcoma 
virus (KSHV)* 
α-Herpesvirus β–Herpesvirus ץ-Herpesvirus 
MDV HSV-1 VZV mCMV EBV KSHV 
Function in MDV 
UL1  UL1 ORF60 M115 BKRF2 ORF47 Glycoprotein L 
UL2  UL2 ORF59 M114 BKRF3 ORF46 
Uracil –DNA 
glycosylase 




UL4 UL4 ORF56 - - - Nuclear protein 




UL6  UL6 ORF54 M104 BBRF1 ORF43 Minor capsid protein 
UL7  UL7 ORF53 M103 BBRF2 ORF42 Capsid protein 
UL8  UL8 ORF52 M102 BBLF2 ORF40 
DNA helicase-primase 
associated protein 




α-Herpesvirus β–Herpesvirus ץ-Herpesvirus 
MDV HSV-1 VZV mCMV EBV KSHV 
Function in MDV 
UL10  UL10 ORF50 M100 BBRF3 ORF39 Glycoprotein M 
UL11  UL11 ORF49 M99 BBLF1 ORF38 
Myristylated tegument 
protein 
UL12 UL12 ORF48 M98 BGLF5 ORF37 DNase 
UL13 UL13 ORF47 M97 BGLF4 ORF36 
Serine/Threonine 
protein kinase 
UL14  UL14 ORF46 M95 BGLF3 ORF34 
Minor tegument 
protein 
UL15  UL15 ORF42 M89 BGRF1 ORF29a 
(DNA packaging 
protein) Terminase 
UL16  UL16 ORF44 M94 BGLF2 ORF33 Tegument protein 
UL17  UL17 ORF43 M93 BGLF1 ORF32 
Tegument protein, 
DNA packaging 
UL18 UL18 ORF41 M85 BDLF1 ORF26 Capsid protein 
UL19  UL19 ORF40 M86 BcLF1 ORF25 Major capsid protein 
UL20 UL20 ORF39 - - - 
Membrane protein, 
virus egress 
UL21 UL21 ORF38 M88 BTRF1 ORF23 Tegument protein 




α-Herpesvirus β–Herpesvirus ץ-Herpesvirus 
MDV HSV-1 VZV mCMV EBV KSHV 
Function in MDV 
Ul23  UL23 ORF36 - BXLF1 ORF21 Thymidine kinase 




UL25 UL25 ORF34 M77 BVRF1 ORF19 DNA packaging 
UL26  UL26 ORF33 M80 BVRF2 ORF17 Protease 
UL26.5  UL26.5 ORF33.5 M80.5 BdRF1 ORF17.5 
Minor capsid scaffold 
protein 
UL27  UL27 ORF31 M55 BALF4 ORF8 Glycoprotein B 
UL28  UL28 ORF30 M56 BALF3 ORF7 
DNA packaging 
protein 
UL 29  UL29 ORF29 M57 BALF2 ORF6 
Single stranded DNA 
binding protein 
UL30  UL30 ORF28 M54 BALF5 ORF9 DNA polymerase 
UL31  UL31 ORF27 M53 BFLF2 ORF69 
Nuclear 
phosphoprotein 
UL32  UL32 ORF26 M52 BFLF1 ORF68 
DNA packaging 
protein 






α-Herpesvirus β–Herpesvirus ץ-Herpesvirus 
MDV HSV-1 VZV mCMV EBV KSHV 
Function in MDV 
UL34  UL34 ORF24 M50 BFRF1 ORF67 
Membrane 
phosphoprotein 
UL35  UL35 ORF23 M48.2 BFRF3 ORF65 Capsid protein VP26 
UL36  UL36 ORF22 M48 BPLF1 ORF64 
Large tegument 
protein 
UL37  UL37 ORF21 M47 BOLF1 ORF63 Tegument protein 
UL38  UL38 ORF20 M46 BORF1 ORF62 Capsid protein 








UL41  UL41 ORF17 - - - 
Tegument, virion shut 
off protein 
UL42  UL42 ORF16  M44 BMRF1 ORF59  DNA polymerase 
UL43  UL43 ORF15 - - - 
Membrane-associated 
protein 
UL44  UL44 ORF14 - - - Glycoprotein C 






α-Herpesvirus β–Herpesvirus ץ-Herpesvirus 
MDV HSV-1 VZV mCMV EBV KSHV 
Function in MDV 
UL47 UL47 ORF11 - - - 
Tegument 
phosphoprotein 
UL48  UL48 ORF10 - - - 
Tegument immediate 
early protein 
UL49  UL49 ORF9 - - - 
Tegument 
phosphorprotein 
UL50  UL50 ORF8 M72 BLLF3 ORF54 dUTPase 
UL51  UL51 ORF7 M71 BSRF1 ORF55 Virion phosphoprotein 
UL52 UL52 ORF6 M70 BSLF1 ORF56 
DNA helicase primase 
associated protein 




ORF4 M69 BSLF2 ORF57 
Post translational gene 
regulation 
UL55  UL55 ORF3 - - - 
Nuclear matrix 
associated protein 
LORF10  ORF2     
US1 ICP22 ORF63 - - - 
Immediate- early 
protein 
ICP4 RS1 ORF62 - - - 
Immediate-early 
protein 




α-Herpesvirus β–Herpesvirus ץ-Herpesvirus 
MDV HSV-1 VZV mCMV EBV KSHV 
Function in MDV 
US3  US3 ORF66 - - - 
Serine/threonine 
protein kinase 
US6  US6     Glycoprotein D 
US7  US7 ORF67 - - - Glycoprotein I 
US8  US8 ORF68 - - - Glycoprotein E 
US10  US10 ORF64 - - -  















Table 2.5.1: The forward and the reverse primers used to amplify MDV genes 
and chicken interferon regulatory factor 7 (chIRF7) gene 
ORF FWD Primer Rev Primer Role 
RLORF1 
AAAAAGCAGGCTCCG
CC ATG ACC CGG GGG 
CAT CGC AC  
AGAAAGCTGGGTC 
CTA GCG AGG GGT 
CCT CTC GCC 
HSV-1 ICP0-like protein 
RLORF2 
AAAAAGCAGGCTCCG
CC ATG CAG GCG TTG 
TTG CTA GTA TTG 
AGAAAGCTGGGTC  
CTA AAG ACA GAT 
ATG GGA ACC AAT AG 




CC ATG GAG AGT CTC 
GCT GTC GAC AAG 
AGAAAGCTGGGTC  
CTA ATT GTG TTT TTT 




CC ATG ACA ACC CCA 
TAT TTT GGC C 
AGAAAGCTGGGTC 
CTA TAC TGA TGT 




CC ATG CCC AAG CCA 
GTA GGC CGA TTA G 
AGAAAGCTGGGTC 
CTA TAC TGA TGT 




CC ATG CGC CAG TTA 
TGC ATG ACG C 
AGAAAGCTGGGTC 
CTA  TAG CAT CGA 




CC ATG CGC CAG TTA 
TGC ATG ACG C 
AGAAAGCTGGGTC  
CTA TTT TGC AGT 




CC ATG AAG GGT CCT 
CAT AGT CTT GTG TTC 
AGAAAGCTGGGTC  
CTA TTT TGC AGT 




CC ATG CGC GTC ATG 
CAT AAC TGG CG 
AGAAAGCTGGGTC 
CTA ACG GTT CGT 




CC ATG CGC GTC ATG 
CAT AAC TGG CG 
 AGAAAGCTGGGTC  
CTA ACG GTT CGT 




CC ATG TCG ACA TTA 
ACG AAT ATA CAG GC 
AGAAAGCTGGGTC 
CTA CAC GTG GCA 
CTG CCG CGT AAA C 
Hypothetical protein, 




CC ATG TGG GGG AGA 
TGG GGT AAA AAG 
AGAAAGCTGGGTC 
CTA CCG GAT GAA 
CCT AAC GCT CC 
23kD nuclear protein, 




CC ATG TCT CAG GAG 
CCA GAG CCG 
AGAAAGCTGGGTC 
CTA GGG TCT CCC 





CC ATG AAC CTA ACG 
CTC CAC ATT G 
AGAAAGCTGGGTC 
CTA TAT ATA ACT 




CC ATG ACT ATC GTC 
TTT ATA TCA CCG  
AGAAAGCTGGGTC  
CTA AGT TGT ATG 
TAG TGT ATC GGT CTT 




CC ATG TGG AAC ACG 
ATT GGC CGT TG  
AGAAAGCTGGGTC 
CTA TCG ATA ATC 
GGC TCC GAT CCC 




ORF FWD Primer Rev Primer Role 
RLORF10 
AAAAAGCAGGCTCCG
CC ATG TGC AAA CAG 
CGA CTC ATT ATC 
AGAAAGCTGGGTC 
CTA CAG CTG TGA 
TAT CGT TGC AGA 




CC ATG CTC TCT CAG 
AAT GGC ACG 
AGAAAGCTGGGTC 
CTA GAG GGT CGA 
TTC CAC TTC TTT CTC 
14 kDa lytic protein A 
14KD B 
AAAAAGCAGGCTCCG
CC ATG ATA AAT ACT 
ACG GCA GAA AG 
AGAAAGCTGGGTC 
CTA GAG GGT CGA 
TTC CAC TTC TTT C 
14 kDa lytic protein B 
RLORF11 
AAAAAGCAGGCTCCG
CC ATG TTA CAT ATC 
TAT AAC TTG ATT 
AGAAAGCTGGGTC 
CTA TAC TTT ACC TGC 




CC ATG GCG ATT TTT 
TAT TTA CGG CGA 
AGAAAGCTGGGTC 
CTA GCC CAT CCT TTC 





CC ATG GCG ATT TTT 
TAT TTA CGG CGA 
AGAAAGCTGGGTC  
CTA GCT CAT CCC 




CC ATG TGT ATG CAA 
ATG AGC AGT GCG 
AGAAAGCTGGGTC 
CTA CTT ATT TGA TGA 
AGG GAG AAA TTC 





CC ATG TGT ATG CAA 
ATG AGC AGT GCG 
 AGAAAGCTGGGTC  
CTA TAC ACA AGA 
GCC GAG CCG CC 





CC ATG GTG AAT AGA 
CGC AAC TAT AAT 
AGAAAGCTGGGTC 
CTA TTG GTT CGC 




CC ATG GTG AAT AGA 
CGC AAC TAT AAT 
AGAAAGCTGGGTC  
CTA TCT GGC CTT TCT 




CC ATG TCC CGT TCA 
GCT TCG ACA AG 
AGAAAGCTGGGTC  
CTA TCT GGC CTT TCT 




CC  ATG ACC CAC AAC 
CGC GAT TTG 
AGAAAGCTGGGTC 
CTA TCC CCA TGG 
TCC CTC TGG 




CC ATG GAA TTC GAA 
GCA GAA CAC GAA G 
AGAAAGCTGGGTC 
CTA  AAC ATG TCG 





CC ATG TGG ACT GAT 
ATC AAT CCT CCA TC 
AGAAAGCTGGGTC 
CTA TAC CCG CGA 




CC ATG CCG AGT AAA 
AGT ATT GCG GAT C 
AGAAAGCTGGGTC 
CTA TAC CCG CGA 




CC ATG TTT ACC GGA 
GGA GGA ACT ATT GC 
AGAAAGCTGGGTC 
CTA  TTC ATC ATC 




CCATG AAA ATT TAT 
AGA GTA CTC GTG 
AGAAAGCTGGGTC 
CTA  GGC ATT GGC 





CC ATG CAA CCC GAT 
CCG CGA TTT C 
AGAAAGCTGGGTC 
CTA TAG AGT ACT 
CGT GCA TCT TTC CTT 





ORF FWD Primer Rev Primer Role 
LORF4 extra 
AAAAAGCAGGCTCCG
CC ATG CAA CCC GAT 
CCG CGA TTT C 
AGAAAGCTGGGTC  
CTA CGT TTT GAA 




CC ATG AGA ATG AAT 
TCG GGT ATG CTG 
AGAAAGCTGGGTC  
CTA CGT TTT GAA 




CC  ATG GCT CAA CTA 
GAC TTG ACA GG 
AGAAAGCTGGGTC 
CTA CGC GGT AAG 





CC ATG TAC AAA AGA 
CCG GGT CAC AAA C 
AGAAAGCTGGGTC 
CTA CGA ACC AGA 




CC ATG TTT GTA GTC 
TCC GCG TCT TTG 
AGAAAGCTGGGTC 
CTA TGT ACT AGC 
CGT TTT CGA AAT 




CC ATG GGA TCT ACC 
TTT ATC GCG TAT AC 
AGAAAGCTGGGTC 
CTA GGG ATA AAT 




CC ATG TCA CAG GAA 
TCG AAT GAC TTA TTT 
AGAAAGCTGGGTC 
CTA ATA GAC AAT 





CC ATG GAT GGC TAT 
GAT CGA AGA GCG 
AGAAAGCTGGGTC  
CTA ATC TCT CTG ACT 
TCC ATC ATC ATC CT 




CC ATG GAA GAA GAA 
ATG ACT TCC ATT CTC 
AGAAAGCTGGGTC 
CTA TTT TTG GTA TGT 
GTG AAA TAA ACA 




CC ATG CGT CAA ACC 
ATA TCA ACG ATG 
AGAAAGCTGGGTC 
CTA TTT ATT ATT AAT 





CC ATG TTT GCA TAC 
ATC AAG CCT ACG 
AGAAAGCTGGGTC 
CTA TAA ACG ATG 
AAA ATC TAC AGC 
Origin binding protein 
UL9 
AAAAAGCAGGCTCCG
CC ATG ATA GAC TAT 
GCA TCC AGC GCC 
AGAAAGCTGGGTC 
CTA TAA ACG ATG 
AAA ATC TAC AGC 
 Origin binding protein 
UL10 
AAAAAGCAGGCTCCG
CC ATG GCC AGT CGA 
GCA CGA ATG G 
AGAAAGCTGGGTC 
CTA ATC ATC CCA TTC 





CC ATG GCC AGT CGA 
GCA CGA ATG G 
AGAAAGCTGGGTC  
CTA CCA CAT CTT TTT 




CC ATG CGG GCC AGT 
TTA TAT CAT CGT CG 
AGAAAGCTGGGTC  
CTA CCA CAT CTT TTT 




CC ATG GGC CAA GCA 
GTG TCG TAT TTA  
AGAAAGCTGGGTC  
CTA TTC TTT ATT AAA 





CC ATG GAA CTA GGA 
ACC AAG TTT CCA C 
AGAAAGCTGGGTC 
CTA AAT ACG ACA 




CC ATG GAT ACT GAA 
TCA AAA AAC AAA 
AGAAAGCTGGGTC 
CTA GTT CCA TAA 






ORF FWD Primer Rev Primer Role 
UL13A(R) 
AAAAAGCAGGCTCCG
CC ATG GAT ACT GAA 
TCA AAA AAC AAA 
AGAAAGCTGGGTC 
CTA AAA CAT TCC 




CC ATG ACA TTG ATA 
GCC GGT GAA TGT G 
AGAAAGCTGGGTC 
CTA GTT CCA TAA 




CC ATG TTT GCA GTG 
AGC GCA ATG CG 
AGAAAGCTGGGTC 
CTA TAC ACA GCT 
GTC TGA GAC ATC G 
Minor tegument protein 
UL15(Fr)1 
AAAAAGCAGGCTCCG
CC ATG TTT GGT GGT 
TTA CTT GGC GAA G 
TCC ACG AAT GCT 
GTT CGT GTT ATG GCT 
AGA TGC 
DNA packaging protein 
(terminase) 
UL15(Fr)2 
TAA CAC GAA CAG 
CAT TCG TGG ACA 
AGA TTT C 
AGAAAGCTGGGTC 
CTA TAC TCT AAT 
GGG GGC AAA TGC 




CC ATG ACT ACG CAG 
AGA CTG AAG ATA CC 
AGAAAGCTGGGTC 
CTA TAC GAC GTT 




CC ATG GAG GCG CAT 
ATA GAA AGC G 
AGAAAGCTGGGTC 
CTA CAT ATA CAC 
CTC TGA AAC GTA 




CC ATG AGT ACT TCC 
AAC GGC ACG ATA G 
AGAAAGCTGGGTC  
CTA ATA CCA GTT 




CC ATG GCC GGA TGC 
CAT TGT CCC 
AGAAAGCTGGGTC 
CTA GCA TAT GGG 
CAA ACA TCC ACC AA 
Major capsid protein 
UL20 
AAAAAGCAGGCTCCG
CC ATG TCG AAG CAT 
GGA TTT GGA TAC 
AGAAAGCTGGGTC 
CTA GAA TGG CAC 
ACA CGA TTT AAG 




CC ATG TCG AAG CAT 
GGA TTT GGA TAC 
AGAAAGCTGGGTC  
CTA AAC ATA CCG 




CC ATG GAT ATT AAA 
TAC GAA CAT GTT 
AGAAAGCTGGGTC 
CTA AGA ACA TAT 




CC ATG GGT CTT CCC 
GGT AGT ATA G 
AGAAAGCTGGGTC 
CTA  AAG ATC GTC 




CC ATG GGT CTT CCC 
GGT AGT ATA G 
AGAAAGCTGGGTC  
CTA AGT AGG GTT 




CC ATG TCG GAG CCA 
CAA TCG TGG TC 
AGAAAGCTGGGTC 
CTA CAT AGC CAT 




CC ATG TCA TCT GAG 
ATG CCA TTA CCG 
AGAAAGCTGGGTC 
CTA CGG TCT CTG 





CC  ATG GCA AAC TTT 
ATT TGG GAC GCG 
AGAAAGCTGGGTC  
CTA CAA CGT AGA 




CC ATG AAT CCG GCC 
GAC CAT CCA TC 
AGAAAGCTGGGTC 
CTA TTG ATG CGC 
CAT CAT TTG ATT AAT 





ORF FWD Primer Rev Primer Role 
UL26.5 
AAAAAGCAGGCTCCG
CC ATG AAC ACT CAA 
TCT TCT CGC CC 
AGAAAGCTGGGTC  
CTA TTG ATG CGC 
CAT CAT TTG ATT AAT 




CC ATG AGT AAA CCA 
TAT CAT GCT CTA TGC 
AGAAAGCTGGGTC  
CTA TCC TAT GAC 
AAC AGA AGT GCT 
 Hypothetical protein 
UL27 
AAAAAGCAGGCTCCG
CC ATG CAC TAT TTT 
AGG CGG AAT TGC 
AGAAAGCTGGGTC  
CTA CAC AGC ATC 





CC ATG AAC AAG CTT 
AAA AGC AAT CCA 
AGAAAGCTGGGTC  
CTA CAC AGC ATC 




CC ATG AAC AAG CTT 
AAA AGC AAT CCA 
AGAAAGCTGGGTC  
CTA GGA TTT GAC 




CC ATG TTG GGA ATG 
TCT CAT AAC CGG 
AGAAAGCTGGGTC  
CTA GAT GGG GGC 
GTG GCT GTT G 
DNA packaging protein 
UL29(Fr)1 
AAAAAGCAGGCTCCG
CC  ATG GAT GGT GTA 
GGA AAA AGC GTG 
AGAAAGCTGGGTC  
CTA TGA TCG CTT 





CC  ATG GAA GGC 
GAG GCA AGC CGT 
AGAAAGCTGGGTC  
CTA CAA CAT ATC 





CC ATG TCA GTA GAC 
GGA ACT AAA ACA 
AGAAAGCTGGGTC 
CTA ATA TCG ATG 




CC ATG ACT GGT CAT 
ACC TTA GTG AGA C 
AGAAAGCTGGGTC  
CTA ACG AGG AGG 




CC ATG GCC AAC CGC 
CCT ACA GAG 
AGAAAGCTGGGTC  
CTA CAC GTA GAC 




CC ATG GCC GGT GAA 
AAT ACC TCT CG 
AGAAAGCTGGGTC  
CTA ACA GTC TTT 




CC ATG GAA GTC ATT 
CCG AAC ATA AAT 
AGAAAGCTGGGTC  
CTA AGA GTA CAA 





CC ATG GAA GTC ATT 
CCG AAC ATA AAT 
AGAAAGCTGGGTC  
CTA GCG CGG TAT 




CC ATG TCT CGT GCA 
TCA TCC CAA CAG 
AGAAAGCTGGGTC  
CTA TGA CGT CGA 
TAT ATC ATC ATC 
Capsid protein, VP26 
UL36(Fr)1 
AAAAAGCAGGCTCCG
CC ATG ACA GAT TCT 
ACT GAC AGC AGA 
AGAAAGCTGGGTC 
CTA CCT TTC TAT AAG 
GTC TAT AGA TTC AG 
Large tegument protein 
UL36(Fr)2 
AAAAAGCAGGCTCCG
CC ATG GTT CTT GCG 
GAG AAT TCC AAG 
AGAAAGCTGGGTC  
CTA TTT TGA AAG TTC 
AGC TAT CTT GCG 
Large tegument protein 
UL36(Fr)3 
AAAAAGCAGGCTCCG
CC ATG CTA ATA AGG 
TCT GCA AAT CAG 
AGAAAGCTGGGTC 
CTA AAC CGT TCG 
AAA ACA GAG AGA 




ORF FWD Primer Rev Primer Role 
UL36(Fr)4 
AAAAAGCAGGCTCCG
CC ATG GGG GAA AAA 
TTA GCT GCT TGT TTG 
AGAAAGCTGGGTC 
CTA TCC AGT CAG 
GAT CAT TTT AAT TTT 
Large tegument protein 
LORF6 
AAAAAGCAGGCTCCG
CC ATG ACT GTA TCT 
AAT CCA TAC GCA 
AGAAAGCTGGGTC  
CTA AAT ATC CGA 




CC ATG ACT GTA TCT 
AAT CCA TAC GCA 
AGAAAGCTGGGTC  
CTA GGA CCT AAG 




CC ATG  CAT TCA TCT 
AGA ATT ACC TCA GG 
AGAAAGCTGGGTC  
CTA TTC AAG AAC 




CC ATG ATT GAA AAT 
ATG CGT CGA AAC 
AGAAAGCTGGGTC  
CTA TTC AAG AAC 




CC  ATG TCT GCC GTA 
ACG ACC GAT G                
AGAAAGCTGGGTC  
CTA TGC ATT ATC 
ACC GTT TGC CCT CC  




ATG TCT GTC GTA 
AGAAAGCTGGGTC  
CTA TGC ATT ATC 
ACC GTT TGC CCT CC  
Small tegument protein 
LORF7 
AAAAAGCAGGCTCCG
CC  ATG CGC CAG AGA 
ATT AAA CCG ACG          
AGAAAGCTGGGTC  
CTA CAT TTT ATA GAT 




CC  ATG AAA CCA CTC 
TTA CGA TCG C  
AGAAAGCTGGGTC  
CTA ATA ACA TTC 




CCATG GAC CAT TCA 
GAT GTC TAC GAA C 
AGAAAGCTGGGTC  
CTA CAA GAC GCA 





CC  ATG AGC GGC CCT 
CCG TCA CAT 
AGAAAGCTGGGTC  
CTA AAG ATC GTT 





CC ATG GGA GTA TAT 
GGA TGT ATG AAT 
AGAAAGCTGGGTC  
CTA GTC ATT AGA 
TCG TGT TGT CTT TAA 




CC ATG GCA GGA ATA 
ACT ATG GGC AG 
AGAAAGCTGGGTC  
CTA TTG GTT GAT 
AAC TTT GGC AAG 




CC ATG GAT TCT GTC 
AAC AAC TCA TCA 
AGAAAGCTGGGTC  
CTA AGA TAG CGC 





CC ATG GAT TCT GTC 
AAC AAC TCA TCA 
AGAAAGCTGGGTC  
CTA CAT GGT TAC 




CC ATG CTC ACG CCG 
CGT GTG TTA C 
AGAAAGCTGGGTC  
CTA TAA TCG AAT 




CC ATG CTC ACG CCG 
CGT GTG TTA C 
AGAAAGCTGGGTC  
CTA CGT AAT AAC 




CC ATG CTC ACG CCG 
CGT GTG TTA C 
AGAAAGCTGGGTC  
CTA  AGG CTG GCT 





ORF FWD Primer Rev Primer Role 
UL44B(R) 
AAAAAGCAGGCTCCG
CC ATG GGC GTG GAA 
ATT AGA AAT GTA G 
AGAAAGCTGGGTC  
CTA TAA TCG AAT 




CC ATG GGC GTG GAA 
ATT AGA AAT GTA G 
AGAAAGCTGGGTC  
CTA CGT AAT AAC 




CC ATG ATC GTG CCA 
GTC ACC AC  
AGAAAGCTGGGTC  
CTA TAC AAT CAG 




CC ATG ATC GTG TCA 
GTC ACC ACA ATA 
AGAAAGCTGGGTC  
CTA TAC AAT CAG 




CC ATG GTG GGT AGT 
ATA CAG GTA G 
AGAAAGCTGGGTC  
CTA TGA CAA AAG 
AGT TGC ACG GAT CC 
23 kDa protein 
UL45 
AAAAAGCAGGCTCCG
CC ATG ATG TCG CCT 
ACA CCC GAG G 
AGAAAGCTGGGTC  
CTA TTT CAT AAT TGC 
GTT CGA GAG AAT 




CC ATG AAG CGG CTC 
AGC TCT TCT G 
AGAAAGCTGGGTC  
CTA ATC GGT AGC 





CC ATG CAA ATG CCT 
TCT ATG CAT CGG 
AGAAAGCTGGGTC  
CTA ATT CGC CCG 





CC ATG GAG GCA AAT 
ATG AG 
AGAAAGCTGGGTC  
CTA TAA AGT ACT 
GAT AGT AG 
VP16, tegument protein 
UL49 
AAAAAGCAGGCTCCG
CC ATG GGG GAT TCT 
GAA AGG CGG 
 AGAAAGCTGGGTC  
CTA  TTC GCT ATC 
ACT GCT ACG ATA 
 VP22, tegument protein 
UL49.5 
AAAAAGCAGGCTCCG
CC ATG GGA CTC ATG 
GAC ATC CAT AAT G 
AGAAAGCTGGGTC  
CTA CCA CTC CTC TTT 




CC ATG GGA CTC ATG 
GAC ATT CAT AAT GC 
AGAAAGCTGGGTC  
CTA CCA CTC CTC TTT 
AAA CAT ATC TGC 
 Glycoprotein N 
UL50 
AAAAAGCAGGCTCCG
CC ATG GAT GTC CAT 
GAG TCC CAT CCT C 
AGAAAGCTGGGTC  
CTA TAT ACC GGT 




CC ATG AAT GTC CAT 
GAG TCC CAT CCT 
AGAAAGCTGGGTC  
CTA TAT ACC GGT 




CC ATG CAA ACC AGC 
TCA AGA ACA TAC G  
AGAAAGCTGGGTC  
CTA TAA TTC GGT 






CC ATG GCG AGA TTT 
TCG TCT ATA TCC G 
AGAAAGCTGGGTC  
CTA TTG ATG TTC TAA 





CC ATG TCG ATT AGA 
ACA TCA ATA GCT 
AGAAAGCTGGGTC  
CTA AGG CAA ATA 




CC ATG TCT GTA GAT 
GCA TTC TCT CGC 
AGAAAGCTGGGTC  
CTA CAT ACC AAA 





ORF FWD Primer Rev Primer Role 
LORF9 
AAAAAGCAGGCTCCG
CC ATG TCT GCT AAC 
GGT ACA GAC C 
AGAAAGCTGGGTC  
CTA TAT ATC ACC 




CC ATG GCA GCA GGG 
GCG ATG TC 
AGAAAGCTGGGTC  
CTA ATG ACA GTA 





CC ATG GGC ATT ATT 
TTT TCC AAC CCC 
AGAAAGCTGGGTC  
CTA ATC TAC TGT TGT 
TGG  TCC AAA C 
 Similar to VZV ORF2 




CC ATG TCT TGC TTC 
GCT TCT TCT ATA 
AGAAAGCTGGGTC  
CTA ATT GTA AAT 




CC ATG GAA AAT GGA 
CAG CTG CAG C 
AGAAAGCTGGGTC  
CTA TGT TTC TGT GAT 
AAT AGT TAC AAG 
 Hypothetical protein 
LORF12-cyt 
AAAAAGCAGGCTCCG
CC ATG GAA AAT GGA 
CAG CTG CAG C 
AGAAAGCTGGGTC  
CTA ATC ATG TCG 




CC ATG GAA TTC GAA 
GCA GAA CAC GAA GG 
AGAAAGCTGGGTC  
CTA ATT TGA TTC 
AGA TTT TGT TTC TCC 




CC ATG ACC CAC AAC 
CGC GAT TTG TTT TTC 
AGAAAGCTGGGTC  
CTA CCC TTT ATT GGA 
ATA GCC CCC 




CC ATG ATG AAG CGG 
TTC GTC GGT CAG 
AGAAAGCTGGGTC  
CTA GCC CAT CCT TTC 





CC ATG CGC GTC ATG 
CAT AAC TGG CG 
 AGAAAGCTGGGTC  
CTA AAA ACT AAC 




CC ATG TCG GGA ATA 
TCC CTT ACT CC 
AGAAAGCTGGGTC  
CTA CTG TGT TCT CGG 
TCC GGA GAT C 
Hypothetical protein  
ANTISENSE 
AAAAAGCAGGCTCCG
CC ATG TAC CCG ATT 
GTC CGG CTA GC 
AGAAAGCTGGGTC  
CTA GCA CAT CGA 
AAT TTC CGC ACT TG 
Antisense RNA protein 
ICP4(Fr)1 
AAAAAGCAGGCTCCG
CC ATG GAC AAC CCG 
CCT GAT TTC GAC 
AGAAAGCTGGGTC  
CTA TAT AAT ATA 




CC ATG TCA GCT TTT 
CTT CGA TTT CTG GG  
AGAAAGCTGGGTC  
CTA ACG GCA TTT 




CC ATG ATT CTC CTC 
GTC TCC TGG TAC 
AGAAAGCTGGGTC  
CTA GTC TGT AAA 




CC ATG CAT ATG TCG 
CAA CAT CAA TAT 
AGAAAGCTGGGTC  
CTA AAC TGA CAC 




CC ATG CAT ATG TCG 
CAA CAT CAA TAT 
AGAAAGCTGGGTC  
CTA GGG GAT ATG 




CC ATG CAG CGC CAA 
ACC GGA CAT ATG 
AGAAAGCTGGGTC  
CTA ATG TAC TAC 
TTG CTC TAT ATA TTC 





ORF FWD Primer Rev Primer Role 
US1 
AAAAAGCAGGCTCCG
CC ATG AGT CGT GAT 
CGA GAT CGA GCC 
AGAAAGCTGGGTC  
CTA ATG CAA TTT 






CC ATG GCC ATG TGG 
TCT CTA CGG C 
AGAAAGCTGGGTC  
CTA TAA GTA GGA 
TTC CCC GTC TCC TG 
Virion protein binds to 
stem cell antigen 25 
lymphocyte antigen 6 
SORF3 
AAAAAGCAGGCTCCG
CC ATG AGC AGA GTC 
AAT GCT ACA ATG 
AGAAAGCTGGGTC  
CTA TAT GGG GTA 




CC ATG GCA CCT TCG 
GGA CCT ACG 
AGAAAGCTGGGTC  
CTA GAA AAA TGA 




CC ATG GGT GTG TCC 
ATG ATA ACT ATA 
GTC
AGAAAGCTGGGTC  
CTA  ATG ACT ACC 





CC ATG TCT TCG AGT 
CCG GAG GCA G 
AGAAAGCTGGGTC  
CTA CAT ATG AGC 
GGC AGT TAT CGT 




CC ATG AAT AGA TAC 
AGA TAT GAA AGT 
AGAAAGCTGGGTC  
CTA TAG GCG GGA 




CC ATG GGA CTT AAG 
AAA GAC AAT TCT 
AGAAAGCTGGGTC  
CTA TTG CGT TCG 




CC ATG TAT CTA CTA 
CAA TTA TTA TTT TGG 
AGAAAGCTGGGTC  
CTA TAC ACA TTC TTC 




CC ATG TAT CTA CTA 
CAA TTA TTA TTT TGG 
AGAAAGCTGGGTC  
CTA CCT TGG AAG 




CC ATG TGT GAA AGG 
TGC CGC TCT CC 
AGAAAGCTGGGTC  
CTA TAC ACA TTC TTC 




CC ATG TGT GTT TTC 
CAA ATC CTG ATA 
AGAAAGCTGGGTC  
CTA GTG GTA TAA 




CC ATG TGT GTT TTC 
CAA ATC CTG ATA 
AGAAAGCTGGGTC  
CTA TAA AAT ATC 




CC ATG AGG CGT AGG 
AGA CGA CGT CG 
AGAAAGCTGGGTC  
CTA GTG GTA TAA 




CC ATG AAT GAC CGC 
GGA GTT CCA A 
AGAAAGCTGGGTC  
CTA CTC ACA GAG 





CC ATG GCA GCG CTG 
GAC AGC G 
AGAAAGCTGGGTC  
CTA GTC TGT CTG CAT 
GTG GTA TTG CTC 
Chicken interferon 
regulatory factor 7 









Table 3.2: The amplified and cloned ORFs of the MDV library 




1 RLORF1 MDV 002 CVI988-RB-1B - - - 
2 RLORF2* MDV 003 RB-1B RNA + + + 
3 RLORF3* MDV 003.2 RB-1B BAC + + + 
4 RLORF4* MDV 003.4 CVI988 BAC + + + 
5 RLORF5 MDV 003.6 CVI988 BAC + + + 
6 RLORF5b MDV 003.6 RB-1B BAC + + + 
7 L1 MDV 003.8 CVI988 BAC + + + 
8 23KDa MDV 004 CVI988 BAC + + + 
9 23KDa MDV 004 RB-1B BAC + + + 
10 RLORF7 MDV 005 CVI988 BAC + + + 
11 RLORF7 MDV 005 RB-1B BAC + + + 
12 RLORF6 MDV005.1 CVI988 BAC + + + 
13 RLORF6 MDV005.1 RB-1B BAC + + + 
14 RLORF8 MDV 005.4 RB-1B BAC + + + 
15 RLORF9 MDV 005.7 RB-1B BAC + + + 
16 RLORF10 MDV 005.8 CVI988 BAC + + + 
17 14KDA MDV 006 RB-1B RNA + + + 
18 14KDB MDV 006.1 RB-1B RNA + + + 
19 RLORF11 MDV 006.4 CVI988 BAC + + + 
20 B68b* MDV 006.6 CVI988 BAC + + + 
21 RLORF12 MDV 007 CVI988 BAC + + + 
22 LORF1* MDV 009 CVI988-RB-1B - - - 
23 RLORF13b MDV 009.5 RB-1B BAC + + + 
24 RLORF14b MDV 008 CVI988 BAC + + + 
25 LORF2 MDV 008.4 CVI988 BAC + + + 
26 Lipase MDV 010 





27 LORF3 MDV 012 CVI988 BAC + + + 
28 UL1 MDV 013 RB-1B BAC + + + 
29 LORF4* MDV 013.5 CVI988 BAC + + + 
30 UL2 MDV 014 CVI988 BAC + + + 








32 UL3.5 MDV 015.5 CVI988 BAC + + + 
33 UL4 MDV 016 CVI988 BAC + + + 
34 UL5 MDV 017 RB-1B BAC + + + 
35 UL6 MDV 018 CVI988 BAC + + + 
36 UL7 MDV 019 CVI988 BAC + + + 
37 UL8 MDV 020 CVI988 BAC + + + 
38 UL8.5 MDV 020.5 CVI988 BAC + + + 
39 UL9 MDV 021 RB-1B BAC + + + 
40 UL10* MDV 022 CVI988 BAC + + + 
41 UL11 MDV 023 CVI988 BAC + + + 
42 UL12 MDV 024 RB-1B BAC + + + 
43 U13 MDV 025 CVI988 BAC + + + 
44 U13B MDV 025.2 RB-1B BAC + + + 
45 U13A MDV 025.1 RB-1B BAC + + + 
46 UL14 MDV 026 CVI988 BAC + + + 
47 UL15 MDV 027 RB-1B BAC + + + 
48 UL16 MDV 028 CVI988 BAC + + + 
49 UL17 MDV 029 RB-1B BAC + + + 
50 UL18 MDV 030 CVI988 BAC + + + 
51 UL19 MDV 031 RB-1B BAC + + + 
52 UL20* MDV 032 CVI988 BAC + + + 
53 UL21 MDV 033 CVI988 BAC + + + 
54 UL22* MDV 034 CVI988 BAC + + + 
55 UL23 MDV 036 CVI988 BAC + + + 
56 UL24 MDV 035 CVI988 BAC + + + 
57 UL25 MDV 037 CVI988 BAC + + + 
58 UL26 MDV 038 RB-1B BAC + + + 
59 UL26.5 MDV 039 CVI988 BAC + + + 
60 LORF5 MDV 039.5 CVI988 BAC + + + 
61 UL27* MDV 040 CVI988 BAC + + + 
62 UL28 MDV 041 RB-1B BAC + - - 
63 UL29 MDV 042 RB-1B BAC 
   + 2 
fragments 
+ + 
64 UL30 MDV 043 CVI988 BAC + + + 
65 UL31 MDV 044 CVI988 BAC + + + 








67 UL33 MDV 045 CVI988 BAC + + + 
68 UL34* MDV 047 CVI988 BAC + + + 
69 UL35 MDV 048 CVI988 BAC + + + 
70 UL36 MDV 049 RB-1B BAC 
   + 4 
fragments 
+ + 
71 LORF6* MDV 049.5 CVI988 BAC + + + 
72 UL37 MDV 050 CVI988 BAC + + + 
73 UL37 MDV 050 RB-1B BAC + + + 
74 LORF7 MDV 050.5 CVI988 BAC + + + 
75 UL38 MDV 051 CVI988 BAC + + + 
76 UL39 MDV 052 RB-1B BAC + - - 
77 UL40 MDV 053 RB-1B BAC + + + 
78 UL41 MDV 054 RB-1B BAC + + + 
79 UL42 MDV 055 CVI988 BAC + + + 
80 UL43* MDV 056 CVI988 BAC + + + 
81 UL44* MDV 057 CVI988 BAC + + + 
82 UL44a MDV 057 RB-1B BAC + + + 
83 UL44b MDV 057.1 RB-1B BAC + + + 
84 MDV57.4 MDV 057.4 CVI988 BAC + + + 
85 MDV57.4 MDV 057.4 RB-1B BAC + + + 
86 LORF8 MDV 057.8 CVI988 BAC + + + 
87 UL45 MDV 058 CVI988 BAC + + + 
88 UL46 MDV 059 CVI988 BAC + + + 
89 UL47 MDV 060 RB-1B BAC + + + 
90 UL48 MDV 061 RB-1B BAC + + + 
91 UL49 MDV 062 RB-1B BAC + + + 
92 UL49.5 MDV 064 CVI988 BAC + + + 
93 UL49.5 MDV 064 RB-1B BAC + + + 
94 UL50 MDV 063 CVI988 BAC + + + 
95 UL50 MDV 063 RB-1B BAC + + + 
96 UL51 MDV 065 CVI988 BAC + + + 
97 UL52 MDV 066 CVI988 BAC + + + 
98 UL53* MDV 067 CVI988 BAC + + + 
99 UL54 MDV 068 CVI988 BAC + + + 








101 UL55 MDV 070 CVI988 BAC + + + 
102 LORF10 MDV 071 CVI988 BAC + + + 
103 LORF11 MDV 072 RB-1B BAC + - - 
104 LORF12 MDV072.8 CVI988BAC + + + 
105 RLORF14a MDV 073 RB-1B BAC + + + 
106 RLORF13a MDV 073.4 RB-1B BAC + + + 
107 RLORF12 MDV 074 RB-1B BAC + + + 
108 B68a* MDV 075.1 RB-1B BAC + + + 
109 RLORF5a MDV 078.2 RB-1B BAC + + + 
110 RSORF1 MDV 082 CVI988 BAC + + + 
111 Antisense MDV 083 CVI988 BAC + + + 
112 ICP4 MDV 084 RB-1B BAC 
   + 2 
fragments 
+ + 
113 SORF1 MDV 086.6 CVI988 BAC + + + 
114 SORF1 MDV 086.6 RB-1B BAC + + + 
115 SORF2 MDV 087 RB-1B BAC + + + 
116 US1 MDV 088 CVI988 BAC + + + 
117 US10 MDV 089 CVI988 BAC + + + 
118 SORF3 MDV 090 RB-1B BAC + + + 
119 US2 MDV 091 RB-1B cDNA Library + + + 
120 US3 MDV 092 RB-1B BAC + + + 
121 SORF4 MDV 093 RB-1B BAC + + + 
122 US6* MDV 094 RB-1B BAC + + + 
123 US7* MDV 095 RB-1B BAC 
   + 2 
fragments 
+ + 
124 US8* MDV 096 RB-1B BAC + + + 
125 vTR MDV001a RB-1B BAC - - - 
* Represent the proteins which have transmembrane domain(s), and 










Table 4.2.1: Identification of Marek’s disease virus protein-protein interaction 
using Yeast two-hybrid (Y2H) 
Interaction Interaction Interaction 
Bait Prey Bait Prey Bait Prey 
vIL8 Meq RLORF5bRB-1B UL20 LMeq SORF2 
vIL8 UL27 L1 LORF4 LMeq UL51 
vIL8 UL8.5 23KDaCVI RLORF13a LMeq UL36 
RLORF3 Md57.4CVI 23KDaCVI RLORF13b LMeq UL36 
RLORF3 RLORF12aCVI 23KDaCVI UL25 LMeq US10 
RLORF3 LORF6 23KDaRB-1B 14KDb RLORF6CVI Md57.4CVI 
RLORF3 RLORF5bRB-1B 23KDaRB-1B B68b RLORF6CVI RLORF12aCVI 
RLORF3 UL27 23KDaRB-1B Md57.4CVI RLORF6RB-1B 14KDb 
RLORF3 UL36 23KDaRB-1B Md57.4RB-1B RLORF8 UL27 
RLORF3 US6 23KDaRB-1B RLORF12aCVI RLORF9 Md57.4CVI 
RLORF3 vIL8 23KDaRB-1B SORF1CVI RLORF9 PP24 
RLORF4 RLORF13a 23KDaRB-1B UL3.5 RLORF9 RLORF13a 
RLORF4 RLORF13b 23KDaRB-1B US7 RLORF9 RLORF13b 
RLORF4 Md57.4CVI 23KDaRB-1B US8 RLORF9 UL27 
RLORF4 RLORF11 23KDaRB-1B vIL8 RLORF10 UL27 
RLORF5CVI UL27 Meq Meq RLORF11 LORF5 
RLORF5CVI UL32 Meq PP24 RLORF11 US3 
RLORF5ARB-1B UL25 Meq UL20 RLORF12aCVI PP38 
RLORF5bRB-1B Meq LMeq LORF10 RLORF12aCVI vIL8 
RLORF12RB-1B 14KDb 14KDb vIL8 LORF4 UL13 




Interaction Interaction Interaction 
Bait Prey Bait Prey Bait Prey 
RLORF12RB-1B Md57.4CVI B68a PP24 LORF4 UL10 
RLORF12RB-1B Md57.4RB-1B B68a UL20 LORF4 UL2 
RLORF12RB-1B PP38 B68a UL30 LORF4 UL3.5 
RLORF12RB-1B RLORF12aCVI PP24 Md57.4CVI LORF4 UL36 
RLORF12RB-1B SORF1CVI 
PP24 
Meq LORF4 UL36 
RLORF12RB-1B UL3.5 
PP24 
PP24 LORF4 UL44CVI 
RLORF12RB-1B US8 
PP24 
PP38 LORF4 UL5 
RLORF12RB-1B vIL8 
PP24 
UL20 LORF4 UL52 
RLORF13a RLORF13b 
PP24 
US8 LORF4 US10 
RLORF13a UL47 
PP24 
vIL8 LORF4 UL27 
RLORF13b 14KDb PP38 Meq UL2 SORF3 
RLORF13b Md57.4CVI PP38 PP24 UL2 UL30 
RLORF13b RLORF13a PP38 UL20 UL3.5 UL48 
RLORF13b RLORF13b UL1 UL27 UL4 SORF3 
14KDa Meq LORF4 UL50RB-1B UL4 UL51 
14KDa PP24 LORF4 14KDb UL4 UL27 
14KDa UL20 LORF4 B68a UL4 US10 
14KDb Meq LORF4 Md57.4CVI UL4 US8 
14KDb PP24 LORF4 Md57.4RB-1B UL5 UL52 
14KDb PP38 LORF4 Meq UL5 US10 
14KDb UL20 LORF4 RLORF12aCVI UL6 B68b 
14KDb UL22 LORF4 SORF1CVI UL6 LORF7 
UL6 UL29 UL10 B68b UL12 UL50CVI 




Interaction Interaction Interaction 
Bait Prey Bait Prey Bait Prey 
UL6 UL51 UL10 vIL8 UL12 UL20 
UL6 UL9 UL10 Md57.4CVI UL12 UL36 
UL6 UL3.5 UL10 Md57.4RB-1B UL12 UL40 
UL6 UL4 UL10 RLORF12aCVI UL12 UL55 
UL6 UL45 UL10 SORF1CVI UL12 US1 
UL6 UL52 UL10 23KDaCVI UL12 US10 
UL6 UL6 UL10 UL14 UL12 US7 
UL7 UL51 UL10 UL54 UL13 UL55 
UL8 LORF10 UL10 UL22 UL13ARB-1B UL25 
UL8 SORF2 UL11 UL16 UL13ARB-1B UL27 
UL8 UL51 UL11 UL8.5 UL13ARB-1B UL37CVI 
UL8 UL36 UL11 vIL8 UL13ARB-1B UL37RB-1B 
UL8 UL48 UL12 PP24 UL13ARB-1B SORF4 
UL8 UL52 UL12 RLORF12aCVI UL13ARB-1B B68a 
UL8 UL55 UL12 RLORF13a UL13BRB-1B UL27 
UL8 US10 UL12 RLORF13b UL14 LORF5 
UL8.5 UL6 UL12 SORF2 UL14 UL51 
UL9 UL27 UL12 SORF3 UL14 US10 
UL9 UL34 UL12 UL14 UL15 Md57.4CVI 
UL9 UL36 UL12 UL20 UL16 Md57.4CVI 
UL9 UL9 UL12 UL25 UL17 SORF3 
UL9 US10 UL12 UL42 UL17 UL25 
UL17 US10 UL26 B68b UL30 UL42 




Interaction Interaction Interaction 
Bait Prey Bait Prey Bait Prey 
UL20 Meq UL26 Md57.4RB-1B UL32 RLORF5bRB-1B 
UL20 PP24 UL26 PP38 UL32 RLORF5CVI 
UL20 UL20 UL26 RLORF12aCVI UL32 UL14 
UL20 UL41 UL26 SORF1CVI UL32 UL32 
UL20 LORF12 UL26 UL3.5 UL32 UL34 
UL20 UL32 UL26 UL48 UL32 US6 
UL20 vIL8 UL26 US8 UL33 Meq 
UL22 UL27 UL26 vIL8 UL33 UL16 
UL22 UL36 LORF5 SORF1CVI UL33 UL26 
UL22 23KDaRB-1B UL27 as UL33 UL31 
UL22 RLORF13a UL27 LORF1 UL33 vIL8 
UL22 UL27 UL27 UL32 UL34 SORF1CVI 





UL27 PP24 UL34 14KDb 
UL25 UL25 UL27 SORF3 UL34 Md57.4CVI 
UL25 UL29 UL27 UL27 UL34 Md57.4RB-1B 
UL25 UL54 UL29 UL27 UL34 PP38 
UL25 UL9 UL30 Md57.4CVI UL34 RLORF12aCVI 
UL25 UL10 UL30 RLORF12aCVI UL34 SORF1CVI 
UL25 UL36 UL30 UL20 UL34 UL3.5 
UL25 UL44CVI UL30 UL26 UL34 US8 
UL26 14KDb UL30 UL27 UL34 vIL8 
UL35 Md57.4CVI LORF6 UL3.5 UL44CVI PP38 




Interaction Interaction Interaction 
Bait Prey Bait Prey Bait Prey 
UL36 LORF10 LORF6 vIL8 UL44CVI RLORF5CVI 
UL36 Md57.4CVI LORF6 UL32 UL44CVI UL51 
UL36 RLORF12aCVI UL38 UL36 UL44CVI UL40 
UL36 SORF2 UL40 UL40 UL44CVI US7 
UL36 SORF3 UL40 US10 UL44ARB-1B UL27 
UL36 UL25 UL42 Meq UL44ARB-1B PP24 
UL36 UL51 UL42 PP24 UL44BRB-1B UL27 
UL36 UL36 UL42 UL42 UL44BRB-1B PP24 
UL36 UL36 UL43 PP24 Md57.4CVI 14KDb 
UL36 US10 UL43 14KDb Md57.4CVI Md57.4CVI 
UL37CVI UL25 UL43 B68b Md57.4CVI RLORF13a 
UL37CVI UL51 UL43 Md57.4CVI Md57.4CVI RLORF13b 
UL37CVI UL36 UL43 Md57.4RB-1B Md57.4CVI UL41 
UL37CVI US10 UL43 PP38 Md57.4RB-1B Md57.4CVI 
UL37RB-1B UL25 UL43 RLORF12aCVI LORF8 UL4 
UL37RB-1B UL26 UL43 RLORF4 LORF8 23KDaRB-1B 
UL37RB-1B UL27 UL43 SORF1CVI LORF8 LORF6 
UL37RB-1B UL51 UL43 UL3.5 LORF8 RLORF12aCVI 
UL37RB-1B UL54 UL43 UL36 LORF8 RLORF5bRB-1B 
UL37RB-1B US10 UL43 US8 LORF8 UL14 
LORF6 14KDb UL43 vIL8 LORF8 UL27 
LORF6 PP38 UL44CVI Md57.4CVI LORF8 UL36 
UL45 Meq UL49.5CVI Meq UL53 Meq 




Interaction Interaction Interaction 
Bait Prey Bait Prey Bait Prey 
UL45 UL48 UL49.5CVI UL20 UL53 UL18 
UL46 RLORF13b UL49.5RB-1B PP24 UL53 UL20 
UL46 UL47 UL49.5RB-1B UL20 UL53 UL26 
UL47 14KDa UL50CVI UL50CVI UL53 UL26.5 
UL47 RLORF13a UL50RB-1B Md57.4CVI UL53 UL29 
UL47 RLORF13b UL50RB-1B UL50CVI UL53 UL45 
UL47 UL5 UL51 UL51 UL54 UL14 
UL47 US2 UL51 UL5 UL54 UL54 
UL45 Meq UL51 UL7 UL54 US8 
UL45 PP24 UL52 14KDb LORF9 RLORF11 
UL45 UL48 UL52 ICP4 LORF9 RLORF12aCVI 
UL46 RLORF13b UL52 LORF6 LORF9 RLORF13a 
UL46 UL47 UL52 RLORF3 LORF9 UL27 
UL47 14KDa UL52 UL22 LORF9 UL4 
UL47 RLORF13a UL52 UL8 LORF9 US2 
UL47 RLORF13b UL52 UL10 UL55 14KDb 
UL47 UL5 UL52 UL36 UL55 Md57.4CVI 
UL47 US2 UL52 UL4 UL55 PP38 
UL49 PP38 UL52 UL43 UL55 RLORF12aCVI 
UL49 SORF1CVI UL52 UL5 UL55 UL3.5 
UL49 UL48 UL52 US10 UL55 UL55 
UL49.5RB-1B Meq UL53 B68b UL55 US8 
UL55 vIL8 RSORF1 US8 US7 vIL8 




Interaction Interaction Interaction 
Bait Prey Bait Prey Bait Prey 
LORF10 Md57.4CVI as Md57.4CVI US8 US8 
LORF10 SORF2 as RLORF12aCVI   
LORF10 UL11 as SORF1CVI   
LORF10 UL25 as UL27   
LORF10 UL8 ICP4 14KDb   
LORF10 UL9 ICP4 Md57.4CVI   
LORF10 UL10 ICP4 ICP4   
LORF10 UL36 SORF1CVI B68b   
LORF10 UL43 SORF1CVI Md57.4CVI   
LORF10 US10 US1 UL13   
LORF10 US2 US1 UL51   
LORF12 RLORF12aCVI US1 UL36   
LORF12 RLORF5CVI US1 UL40   
LORF12 UL26 US1 US10   
LORF12 UL13 US1 US8   
LORF12 UL4 US10 SORF2   
RSORF1 14KDb US10 UL13   
RSORF1 Md57.4CVI US10 UL51   
RSORF1 Md57.4RB-1B US10 UL36   
RSORF1 RLORF12aCVI US10 UL40   
RSORF1 SORF1CVI US10 US10   








Table 5.2.2: The numerical values of the effect of MDV proteins on the 










eGFP+IFN 1.0 0.16534 eGFP 0.069823 0.062675 
vIL8+IFN 1.49209 0.262507 vIL8 0.041966 0.004871 
RLORF3+IFN 1.328954 0.487856 RLORF3 0.237044 0.017722 
RLORF4+IFN 1.037674 0.334241 RLORF4 0.011612 0.003654 
RLORF5RB-1B+IFN 1.808734 0.704699 RLORF5bRB-1B 0.068819 0.027594 
RLORF5CVI+IFN 1.765183 0.293051 RLORF5CVI 0.063423 0.033825 
L1+IFN 1.25489 0.126396 L1 0.056665 0.010278 
23kda_CVI+IFN 1.162766 0.202582 23KDaCVI 0.072864 0.03851 
23kda_RB-1B+IFN 1.069637 0.184628 23KDaRB-1B 0.078587 0.0358 
LMeq+IFN 0.31064 0.026773 LMeq 0.024027 0.008082 
Meq+IFN 0.449744 0.114416 Meq 0.015069 0.012314 
RLORF6CVI+IFN 1.445779 0.166815 RLORF6CVI 0.087652 0.00747 
RLORF6RB-1B+IFN 2.1089 0.886282 RLORF6RB-1B 0.110289 0.080382 
RLORF8+IFN 1.329707 0.215092 RLORF8 0.084709 0.048104 
RLORF9+IFN 1.35835 0.140026 RLORF9 0.054757 0.022971 
RLORF10+IFN 1.58485 0.447502 RLORF10 0.10022 0.065212 
14KDa+IFN 1.237381 0.088084 14KDa 0.046228 0.00709 
14KDb+IFN 0.994252 0.094758 14KDb 0.045296 0.026059 
RLORF11+IFN 0.522039 0.052994 RLORF11 0.020802 0.007716 
B68b+IFN 1.116021 0.121436 B68b 0.029428 0.002101 
RLORF12bCVI+IFN 0.832019 0.130909 RLORF12bCVI 0.016175 0.00413 
RLORF13b+IFN 0.942246 0.201298 RLORF13b 0.037771 0.012397 
PP24+IFN 1.341103 0.335274 PP24 0.049424 0.033697 
LORF2+IFN 1.682861 0.108702 LORF2 0.049625 0.006588 
LORF3+IFN 0.723325 0.136411 LORF3 0.032662 0.006508 
UL1+IFN 1.499119 0.348279 UL1 0.081774 0.072394 
LORF4+IFN 1.183722 0.095527 LORF4 0.045067 0.01455 
UL2+IFN 1.196484 0.262369 UL2 0.316391 0.252665 
UL3+IFN 1.26982 0.137849 UL3 0.085913 0.016591 
UL3.5+IFN 1.734225 0.841201 UL3.5 0.508306 0.24926 
UL4+IFN 0.594858 0.210887 UL4 0.090546 0.017355 
UL5+IFN 1.909871 0.062944 UL5 0.255532 0.033011 
UL6+IFN 1.988312 0.902447 UL6 0.107 0.046826 
UL7+IFN 0.919352 0.283584 UL7 0.058762 0.003335 
UL8+IFN 1.257369 0.760573 UL8 0.186898 0.0968 
UL9+IFN 1.040604 0.111186 UL9 0.069287 0.025947 
UL10+IFN 1.682967 0.934403 UL10 0.121739 0.002928 
UL11+IFN 0.916876 0.293177 UL11 0.045984 0.008159 













UL13+IFN 1.596626 0.183903 UL13 0.149715 0.047171 
UL13A+IFN 0.87577 0.365039 UL13aRB-1B 0.24768 0.118737 
UL13b+IFN 1.511026 0.264313 UL13bRB-1B 0.079071 0.008417 
UL14+IFN 1.235135 0.116192 UL14 0.056171 0.001616 
UL15+IFN 1.038761 0.018748 UL15 0.018748 0.003049 
UL16+IFN 1.187254 0.28919 UL16 0.085952 0.016884 
UL17+IFN 1.718816 0.412036 UL17 0.066694 0.016937 
UL18+IFN 1.112079 0.149059 UL18 0.600161 0.139604 
UL19+IFN 1.694555 0.200181 UL19 0.466247 0.051126 
UL20+IFN 0.695007 0.135863 UL20 0.423045 0.214537 
UL21+IFN 1.068993 0.101595 UL21 0.062631 0.034783 
UL22+IFN 0.66958 0.07006 UL22 0.012675 0.000623 
UL23+IFN 1.12328 0.029275 UL23 0.038805 0.016874 
UL24+IFN 1.091794 0.120934 UL24 0.016113 0.00532 
UL25+IFN 0.888225 0.129982 UL25 0.014994 0.002952 
UL26+IFN 0.412425 0.08982 UL26 0.015136 0.002819 
UL26.5+IFN 0.551151 0.032191 UL26.5 0.016616 0.003921 
LORF5+IFN 1.661143 0.065003 LORF5 0.075038 0.045707 
UL27+IFN 1.444679 0.245428 UL27 0.045212 0.02314 
UL30+IFN 0.627062 0.017542 UL30 0.014746 0.001789 
UL31+IFN 1.169132 0.287987 UL31 0.050541 0.000178 
UL32+IFN 0.583084 0.070248 UL32 0.010007 0.001644 
UL33+IFN 0.793754 0.065273 UL33 0.023201 0.007881 
UL34+IFN 1.619251 0.308477 UL34 0.030592 0.031362 
UL35+IFN 1.455501 0.240831 UL35 0.035731 0.000717 
LORF6+IFN 1.265154 0.133452 LORF6 0.024812 0.006617 
UL37_CVI+IFN 0.865137 0.044159 UL37CVI 0.118946 0.044562 
UL37_RB-1B+IFN 1.128124 0.104866 UL37RB-1B 0.420194 0.156932 
LORF7+IFN 0.634582 0.366021 LORF7 0.035517 0.000621 
UL38+IFN 1.805827 0.12199 UL38 0.086299 0.020257 
UL40+IFN 2.673375 1.090528 UL40 0.099089 0.008966 
UL41+IFN 0.898225 0.006341 UL41 0.139678 0.028961 
UL42+IFN 0.660176 0.062826 UL42 0.040624 0.005444 
UL43+IFN 1.219835 0.255028 UL43 0.246007 0.023494 
UL44CVI+IFN 1.166072 0.462613 UL44CVI 0.040617 0.037494 
UL44a+IFN 1.028272 0.09567 UL44aRB-1B 0.035279 0.003596 
UL44b+IFN 0.821422 0.233449 UL44bRB-1B 0.022262 0.009716 
MD57.4CVI+IFN 1.799864 0.528962 MD57.4 0.065463 0.045611 
LORF8+IFN 0.883265 0.077757 LORF8 0.03832 0.017787 
UL45+IFN 0.929565 0.169686 UL45 0.102615 0.028908 
UL46+IFN 0.663386 0.125843 UL46 0.106084 0.101098 
UL48+IFN 1.302712 0.07279 UL48 0.095594 0.010654 
UL49.5_CVI+IFN 1.447516 0.102125 UL49.5CVI 0.091263 0.007836 













UL50CVI+IFN 0.455546 0.053802 UL50CVI 0.006681 0.011572 
UL50RB-1B+IFN 0.450693 0.140661 UL50RB-1B 0.032085 0.008965 
UL51+IFN 1.028272 0.09567 UL51 0.035279 0.003596 
UL52+IFN 1.718816 0.412036 UL52 0.066694 0.016937 
UL53+IFN 1.431731 0.052063 UL53 0.082695 0.011428 
UL54+IFN 0.698898 0.1102 UL54 0.044294 0.022974 
LORF9+IFN 0.97934 0.095722 LORF9 0.024011 0.003606 
UL55+IFN 0.904668 0.143916 UL55 0.546908 0.300884 
LORF10+IFN 1.788456 0.134222 LORF10 0.035228 0.004813 
LORF12+IFN 1.093384 0.095898 LORF12 0.039548 0.018336 
PP38+IFN 1.141776 0.065059 PP38 0.209004 0.064627 
RLORF13a+IFN 0.791402 0.196789 RLORF13a 0.021756 0.005287 
RLORF12a+IFN 1.040934 0.207575 RLORF12a 0.049289 0.018054 
B68a+IFN 1.008997 0.071038 B68a 0.027764 0.004686 
RSORF1+IFN 1.306082 0.295115 RSORF1 0.04113 0.013423 
AS+IFN 1.15371 0.210209 AS 0.032659 0.006458 
SORF1CVI+IFN 0.850416 0.144585 SORF1CVI 0.03617 0.01415 
SORF1RB-1B+IFN 1.264532 0.184965 SORF1RB-1B 0.042009 0.003105 
SORF2+IFN 1.660094 0.529852 SORF2 0.059386 0.016165 
US1+iIFN 0.69414 0.051642 US1 0.031017 0.013478 
US10+IFN 1.046616 0.395184 US10 0.052247 0.014336 
SORF3+IFN 0.883528 0.041291 SORF3 0.050312 0.014624 
US2+IFN 1.293782 0.186567 US2 0.039032 0.013763 
US3+IFN 0.77547 0.158048 US3 0.178141 0.02916 
SORF4+IFN 1.431731 0.052063 SORF4 0.082695 0.011428 
US6+IFN 1.348856 0.511236 US6 0.051167 0.002772 
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